



US007033590B1

(12) **United States Patent**
Scheiflinger et al.

(10) **Patent No.:** **US 7,033,590 B1**
(45) **Date of Patent:** **Apr. 25, 2006**

(54) **FACTOR IX/FACTOR IXA ACTIVATING ANTIBODIES AND ANTIBODY DERIVATIVES**

(75) Inventors: **Friedrich Scheiflinger**, Vienna (AT); **Randolf Kerschbaumer**, Vienna (AT); **Falko-Guenter Falkner**, Orth/Donau (AT); **Friedrich Dorner**, Vienna (AT); **Hans-Peter Schwarz**, Vienna (AT)

(73) Assignee: **Baxter Aktiengesellschaft**, Vienna (AT)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 462 days.

(21) Appl. No.: **09/661,992**

(22) Filed: **Sep. 14, 2000**

(30) **Foreign Application Priority Data**

Sep. 14, 1999 (AT) 1576/99

(51) **Int. Cl.**

A61K 39/395 (2006.01)
A61K 38/04 (2006.01)
C12N 5/20 (2006.01)
C07K 16/00 (2006.01)
C07K 16/34 (2006.01)

(52) **U.S. Cl.** **424/145.1**; 435/326; 530/388.25; 530/387.1; 530/327; 530/328; 530/389.3

(58) **Field of Classification Search** 530/387.3, 530/388.25, 389.3, 327, 328; 424/133.1, 424/145.1; 435/326

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,395,396 A 7/1983 Eibl et al.
4,873,316 A 10/1989 Meade et al.
5,932,706 A 8/1999 Mertens et al.
6,391,299 B1 * 5/2002 Blackburn et al.
6,632,927 B1 * 10/2003 Adair et al.

FOREIGN PATENT DOCUMENTS

WO WO95/13300 5/1995
WO WO97/26010 7/1997
WO WO99/01476 1/1999

OTHER PUBLICATIONS

Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. *Proc Natl Acad Sci U S A.* 85(9):3080-3084, 1988.*

Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. *Proc Natl Acad Sci U S A.* 79(6):1979-1983, 1982.*

Ames, R.S. et al., *Conversion of Murina Fabs Isolated From a Combinatorial Phage Display Library to Full Length Immunoglobulins*, *J. Immunol. Methods*, pp. 177-186 (1995).

Bajaj, S.P. et al., *A Monoclonal Antibody to Factor IX That Inhibits the Factor VIII:Ca Potentiation of Factor X Activation*, *The Journal of Biological Chemistry*, 260(21), pp. 11574-11580 (1985).

Bessos, H., et al., *The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX*, *Thrombosis Research*, 40, pp. 863-867 (1985).

Cao, Y. et al., *Bispecific Antibodies as Novel Bioconjugates*, *Bioconjugate Chemistry*, 9(6); pp. 635-644 (1998).

Cohen, F.E., et al., *The Combinatorial Approach, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 9, pp. 207-227 (1996).

Engelhardt, O., et al., *Two Step Cloning of Antibody Variable Domains in a Phage Display Vector*, *Biotechniques*, 17, p. 44-46 (1994).

Esser, C., et al., *Immunoglobulin Class Switching: Molecular and Cellular Analysis*, *Annu. Rev. Immunol.*, 8, p. 717-735 (1990).

Evan, G.I., et al., *Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product*, *Mol. Cell. Biol.*, 5(12), p. 3610-3616 (1985).

Fay, P.J., et al., *Factor VIII A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site*, *Journal of Biological Chemistry*, 269(32), p. 20522-20527 (1994).

Frazier, D., et al., *Mapping of Monoclonal Antibodies to Human Factor IX*, *Blood*, 74(3), p. 971-977 (1989).

Gao, C., et al., *Making Artificial Antibodies: A Format for Phage Display of Combinatorial Heterodimeric Arrays*, *Proc. Natl. Acad. Sci.*, 96, p. 6025-6030 (1999).

Grassy, G., et al., *Computer-Assisted Rational Design of Immunosuppressive Compounds*, *Nature Biotechnology*, 16, p. 748-752 (1998).

Greer, J., et al., *Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design*, *Journal of Medicinal Chemistry*, 37(8), p. 1035-1054 (1994).

Harlow, E., et al., 2. *Antibody Molecules, Antibodies—A Laboratory Manual*; pp. 7-22 (1988).

Harlow, E., et al., 3. *Antibody-Antigen Interactions, Antibodies—A Laboratory Manual*; p. 23-35 (1988).

Harlow, E., et al., 6. *Monoclonal Antibodies, Antibodies—A Laboratory Manual*; p. 139-243 (1988).

Hochuli, E., et al., *Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent*, *Biotechnology*, 6, p. 1321-1325 (1988).

Huston, J.S., et al., *Medical Applications of Single-Chain Antibodies*, *Intern. Rev. Immunol.*, 10, p. 195-217 (1993).

(Continued)

Primary Examiner—Christina Chan
Assistant Examiner—Maher Haddad

(74) Attorney, Agent, or Firm—Townsend and Townsend and Crew LLP


(57) **ABSTRACT**

An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.

OTHER PUBLICATIONS


- Jones, D.T., et al., *Protein Folds and Their Recognition from Sequence, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 8, p. 174–206 (1996).
- Jones, P.T., et al., *Replacing the Complementarity—Determining Regions in a Human Antibody with Those from a Mouse*, *Nature*, 321, p. 522–525 (1986).
- Jorquera, J.I., et al., *Synthetic Peptides Derived from Residues 698 to 710 of Factor VIII Inhibit Factor IXa Activity*, *Circulation*, 86, Abstract No. 2725, p. 1–685 (1992).
- Karpen, M.E., et al., *Modelling Protein Conformation by Molecular Mechanics and Dynamics, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 10, p. 229–261 (1996).
- Kemp, D.S., *Peptidomimetics and the Template Approach to Nucleation of β -sheets and α -helices in Peptides*, *TIBTECH8*, p. 249–255 (1990).
- Kerschbaumer, R.J., et al., *pDAP2: A Vector for Construction of Alkaline Phosphatase Fusion—Proteins*, *Immunotechnology*, 2, p. 145–150 (1996).
- Kerschbaumer, R.J. et al., *Single—Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme—Linked Immunosorbent Assay*, *Analytical Biochemistry*, 249, p. 219–227 (1997).
- Lane, R.D., *A Short—Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody—Secreting Hybridomas*, *Journal of Immunological Methods*, 81, p. 223–227 (1985).
- Lenting, P.J., et al., *The Sequence Glu¹⁸¹¹—Lys¹⁸¹⁸ of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX*, *Journal of Biological Chemistry*, 271(4), p. 1935–1940 (1996).
- Liles, D.K., et al, *The Factor VIII Peptide Consisting of Amino Acids 698 to 712 Enhances Factor IXa Cleavage of Factor X*, *Blood*, 90(1), Abstract No. 2054, p. 463a (1997).
- Lin, H-F., et al, *A Coagulation Factor IX—Deficient Mouse Model for Human Hemophilia B*, *Blood*, 90(10), p. 3962–3966 (1997).
- Malik, P., et al., *Multiple Display of Foreign Peptide Epitopes on Filamentous Bacteriophage Virions, Phage Display of Peptides and Proteins* (Ed. B. K. Kay et al.), Academic Press, p. 127–139 (1996).
- Mann, K.G., et al., *Surface—Dependent Reactions of the Vitamin K—Dependent Enzyme Complexes*, *Blood*, 76(1), p. 1–16 (1990).
- Mikaelsson, M., et al., *Standardization of VIII:C Assays: A Manufacturer's View*, *Scandinavian Journal of Haematology* (Ed. Nilsson et al.), 33, p. 79–86 (1984).
- Nilsson, I.M. et al., *Induction of Split Tolerance and Clinical Cure in High—Responding Hemophiliacs with Factor IX Antibodies*, *Proc. Natl. Acad. Sci. USA*, 83, p. 9169–9173 (1986).
- Persic, L., et al., *An Integrated Vector System For The Eukaryotic Expression of Antibodies of Their Fragments After Selection From Phase Display Libraries*, *Genes*, p. 9–18 (1997).
- Pluckthun, A., et al., *New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments*, *Immunotechnology*, 3, p. 83–105 (1997).
- Raag, R., et al., *Single—Chain Fvs*, *FASEB Journal*, 9(1), pp. 73–80 (1995).
- Rees, A.R., et al., *Antibody Combining Sites: Structure and Prediction, Protein Structure Prediction—A Practical Approach* (Ed. M.J.E. Sternberg), Oxford University Press, Ch. 7, p. 141–172 (1996).
- Roitt, I.M., et al., *Molecules which Recognize Antigen, Immunology*, 2nd Edition, p. 5.1–5.11 (1989).
- Sadler, J.E., et al., *Hemophila A, Hemophilia B, and von Willebrand's Disease, The Molecular Basis of Blood Diseases* (Ed. G. Stamatoyannopoulos et al.), p. 575–630 (1987).
- Vaughan, T.J., et al., *Human Antibodies By Design*, *Nature Biotechnology*, p. 535–539 (1998).
- Winter, G., et al., *Making Antibodies by Phage Display Technology*, *Annu. Rev. Immunol.*, 12, p. 433–455 (1994).
- Zhong, D., et al., *Some Human Inhibitor Antibodies Inter-face with Factor VIII Binding to Factor IX*, *Blood*, 92(1), p. 136–142 (1998).

* cited by examiner



clone #

FIG. 1



Well number

FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7A





FIG. 7B



Scan number
FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9




FIG. 10A




FIG. 10B




FIG. 11

Mouse V_H back primers (containing SfiI-site):

VH1BACK-SfiI	5' C ATG CCA TGA CTC GCG GCC CAG CCG GCC ATG GCC SAG GTS MAR CTG CAG SAG TCW GG 3' (SEQ.ID.NO. 50)
VH1BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTG CAG CTT CAG GAG TCA GG 3' (SEQ.ID.NO. 51)
VH2BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAT GTG CAG CTT CAG GAG TCR GG 3' (SEQ.ID.NO. 52)
VH3BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTG CAG CTG AAG SAG TCA GG 3' (SEQ.ID.NO. 53)
VH4/6BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTY CAG CTG CAR CAR TCT GG 3' (SEQ.ID.NO. 54)
VH5/9BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG GTY CAR CTG CAG CAG YCT GG 3' (SEQ.ID.NO. 55)
VH7BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAR GTG AAG CTG GTG GAR TCT GG 3' (SEQ.ID.NO. 56)
VH8BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAG GTT CAG CTT CAG CAG TCT GG 3' (SEQ.ID.NO. 57)
VH10BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC GAA GTG CAG CTG KTG GAG WCT GG 3' (SEQ.ID.NO. 58)
VH11BACKSfi	5' GTC CTC GCA ACT GCG GCC CAG CCG GCC ATG GCC CAG ATC CAG TTG CTG CAG TCT GG 3' (SEQ.ID.NO. 59)

FIG. 12-1

Mouse J_H forward primers (containing 1/2 linker-sequence and AscI-site):

VH1FOR2LiASC 5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT
GAC CGT GGT CCC TTG GCC CC 3' (SEQ.ID.NO. 60)

JH1FORLiASC 5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT
GAC CGT GGT CCC 3' (SEQ.ID.NO. 61)

JH2FORLiASC 5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC TGT
GAG AGT GGT GCC 3' (SEQ.ID.NO. 62)

JH3FORLiASC 5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGC AGA GAC AGT
GAC CAG AGT CCC 3' (SEQ.ID.NO. 63)

JH4FORLiASC 5' ACC GCC AGA GGC GCG CCC ACC TGA ACC GCC TCC ACC TGA GGA GAC GGT
GAC TGA GGT TCC 3' (SEQ.ID.NO. 64)

IUPAC-Code: M=A/C, W=A/T, R=A/G, Y=C/T, S=C/G, K=G/T, H=A/C/T, D=A/G/T, V=A/C/G, B=T/C/G.

FIG. 12-2

Primers for cloning mouse V_K genes**Mouse V_K back primers (containing AscI-site and 1/2 linker-sequence):**

VK2BACKLi AscI 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GAG
 CTC ACC CAG TCT CCA 3' (SEQ.ID.NO. 65)

VK1BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG
 ATG WCA CAG TCT CC 3' (SEQ.ID.NO. 66)

VK2BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT GTT KTG
 ATG ACC CAA ACT CC 3' (SEQ.ID.NO. 67)

VK3BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT ATT GTG
 ATR ACB CAG GCW GC 3' (SEQ.ID.NO. 68)

VK4BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG
 CTG ACM CAR TCT GC 3' (SEQ.ID.NO. 69)

VK5BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG SAA AWT GTK
 CTC ACC CAG TCT CC 3' (SEQ.ID.NO. 70)

VK6BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAY ATY VMG
 ATG ACM CAG WCT CC 3' (SEQ.ID.NO. 71)

VK7BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG CAA ATT GTT
 CTC ACC CAG TCT CC 3' (SEQ.ID.NO. 72)

VK8BACKLi Asc 5' GGT TCA GAT GGG CGC GCC TCT GGC GGT GGC GGA TCG TCA TTA TTG
 CAG GTG CTT GTG GG 3' (SEQ.ID.NO. 73)

FIG. 13-1

Mouse J_k forward primers (containing NotI-site):

JK1NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT GAT TTC CAG CTT GGT GCC 3'
(SEQ.ID.NO. 74)

JK2NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAG CTT GGT CCC 3'
(SEQ.ID.NO. 75)

JK3NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAG TCT GGT CCC 3'
(SEQ.ID.NO. 76)

JK4NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT TAT TTC CAA CTT TGT CCC 3'
(SEQ.ID.NO. 77)

JK5NOT10 5' GAG TCA TTC TGC GGC CGC CCG TTT CAG CTC CAG CTT GGT CCC 3'
(SEQ.ID.NO. 78)

IUPAC-Code: K=G/T, M=A/C, W=A/T, R=A/G, Y=C/T, S=C/G, H=A/C/T, D=A/G/T, V=A/C/G, B=T/C/G.

FIG. 13-2

VH

+1 E V K L V E S G P E L K K P G
 1 GAG GTG AAG CTG GTG GAG TCT GGA CCT GAG CTG AAG AAG CCT GGA

+1 E T V K I S C K A S G Y I F T
 46 GAG ACA GTC AAG ATC TCC TGC AAG GCT TCT GGG TAT ATC TTC ACA

+1 N Y G M N W V K Q A P G K G L
 91 AAC TAT GGA ATG AAC TGG GTG AAG CAG GCT CCA GGA AAG GGT TTA

+1 K W M G W I N T Y T G E P T Y
 136 AAG TGG ATG GGC TGG ATA AAC ACC TAC ACT GGA GAG CCA ACA TAT

+1 A D D F K G R F A F S L E T S
 181 GCT GAT GAC TTC AAG GGA CGG TTT GCC TTC TCT TTG GAA ACC TCT

+1 A S T A Y L Q I N N L K N E D
 226 GCC AGC ACT GCC TAT TTG CAG ATC AAC AAC CTC AAA AAT GAG GAC

+1 T A T Y F C A L Y G N S P K G
 271 ACG GCT ACA TAT TTC TGT GCA TTA TAT GGT AAC TCC CCT AAG GGG

linker

+1 F A Y W G Q G T L V T V S A G
 316 TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA GGT

VL

+1 G G G S G G R A S G G G G S D
 361 GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC GGA TCG GAT

+1 I Q M T Q S P K F L L V S A G
 406 ATT CAG ATG ACA CAG TCT CCC AAA TTC CTG CTT GTA TCA GCA GGA

FIG. 14-1

+1 D R V T I T C K A S Q S V S N
451 GAC AGG GTT ACC ATA ACC TGC AAG GCC AGT CAG AGT GTG AGT AAT

+1 D V A W Y Q Q K P G Q S P K L
496 GAT GTA GCT TGG TAC CAA CAG AAG CCG GGG CAG TCT CCT AAA CTA

+1 L M Y Y A S N R Y T G V P D R
541 CTG ATG TAC TAT GCA TCC AAT CGC TAC ACT GGA GTC CCT GAT CGC

+1 F T G S G Y G T D F T F T I S
586 TTC ACT GGC AGT GGA TAT GGG ACG GAT TTC ACT TTC ACC ATC AGC

+1 T V Q A E D L A V Y F C Q Q D
631 ACT GTG CAG GCT GAA GAC CTG GCA GTT TAT TTC TGT CAG CAG GAT

+1 Y G S P P T F G G G T K L E I
676 TAT GGC TCT CCT CCC ACG TTC GGA GGG GGC ACC AAG CTG GAA ATT

+1 K R
721 AAA CGG

FIG. 14-2

VH

+1 E V Q L V E S G G G L V K P G
1 GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC CTA GTG AAG CCT GGA

+1 G S L K L S C A A S G F T F S
46 GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT

+1 T Y T M S W V R Q T P E K R L
91 ACC TAT ACC ATG TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG

+1 E W V A T I S S G G S Y T Y Y
136 GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT TAC ACC TAC TAT

+1 P D S V R G R F T I S R D N A
181 CCA GAC AGT GTG AGG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC

+1 K N T L Y L Q M S S L K S E D
226 AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AAG TCT GAG GAC

+1 T A M Y Y C T R D G G H G Y G
271 ACA GCC ATG TAT TAC TGT ACA AGA **GAT GGG GGA CAC GGG TAC GGT**

+1 S S F D Y W G Q G T T L T V S
316 **AGT AGC TTT GAC TAC** TGG GGC CAA GGC ACC ACT CTC ACA GTC TCC

linker

+1 S G G G S G G R A S G G G G
361 TCA GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC GGA

VL

+1 S Q I V L T Q S P L S L P V S
406 TCG CAA ATT GTG CTC ACC CAG TCT CCA CTC TCC CTG CCT GTC AGT

FIG. 15-1

+1 L G D Q A S I S C R S S Q S I
451 CTT GGA GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC ATT

+1 V H S N G N T Y L E W Y L Q K
496 GTA CAT AGT AAT GGA AAC ACC TAT TTA GAA TGG TAC CTG CAG AAA

+1 P G Q S P K L L I Y K V S N R
541 CCA GGC CAG TCT CCA AAG CTC CTG ATC TAC AAA GTT TCC AAC CGA

+1 F S G V P D K F S G S G S G T
586 TTT TCT GGG GTC CCA GAC AAA TTC AGT GGC AGT GGA TCA GGG ACA

+1 D F T L K I S R V E A E D L G
631 GAT TTC ACA CTC AAG ATC AGC AGA GTG GAG GCT GAG GAT CTG GGA

+1 V Y Y C F Q G S H V P W T F G
676 GTT TAT TAC TGC TTT CAA GGT TCA CAT GTT CCG TGG ACG TTC GGT

+1 G G T K L E I K R
721 GGA GGC ACC AAG CTG GAA ATC AAA CGG

FIG. 15-2

+1 E V Q L Q E S G G G L V K P G
1 GAG GTG CAG CTT CAG GAG TCA GGG GGA GGC TTA GTG AAG CCT GGA

+1 G S L K L S C A A S G F T F S
46 GGG TCC CTG AAA CTC TCC TGT GCA GCC TCT GGA TTC ACT TTC AGT

+1 S Y T M S W V R Q T P E K R L
91 AGC TAT ACC ATG TCT TGG GTT CGC CAG ACT CCG GAG AAG AGG CTG

+1 E W V A T I S S G G S S T Y Y
136 GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT TCC ACC TAC TAT

+1 P D S V K G R F T I S R D N A
181 CCA GAC AGT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC

+1 K N T L Y L Q M S S L R S E D
226 AAG AAC ACC CTG TAC CTG CAA ATG AGC AGT CTG AGG TCT GAG GAC

+1 T A M Y Y C T R E G G G F T V
271 ACA GCC ATG TAT TAC TGT ACA AGA **GAG GGG GGT GGT TTC ACC GTC**

+1 N W Y F D V W G A G T L V T V
316 **AAC TGG TAC TTC GAT GTC** TGG GGC GCA GGG ACT CTG GTC ACT GTC

linker

+1 S A G G G G S G G R A S G G G
361 TCT GCA GGT GGA GGC GGT TCA GGT GGG CGC GCC TCT GGC GGT GGC

VL

+1 G S E N V L T Q S P A S L A V
406 GGA TCG GAA AAT GTG CTC ACC CAG TCT CCA GCT TCT TTG GCT GTG

FIG. 16-1

+1 S L G Q R A T I S C R A S E S
451 TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC AGA GCC AGT GAA AGT

+1 V D S Y G Y N F M H W Y Q Q I
496 GTT GAT AGT TAT GGC TAT AAT TTT ATG CAC TGG TAT CAG CAG ATA

+1 P G Q P P K L L I Y R A S N L
541 CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CGT GCA TCC AAC CTA

+1 E S G I P A R F S G S G S R T
586 GAG TCT GGG ATC CCT GCC AGG TTC AGT GGC AGT GGG TCT AGG ACA

+1 D F T L T I N P V E A D D V A
631 GAC TTC ACC CTC ACC ATT AAT CCT GTG GAG GCT GAT GAT GTT GCA

+1 T Y Y C Q Q S N E D P L T F G
676 ACC TAT TAC TGT CAG CAA AGT AAT GAG GAT CCG CTC ACG TTC GGT

+1 T G T R L E I K R
721 ACT GGG ACC AGA CTG GAA ATA AAA CGG

FIG. 16-2

```

+1  E V Q L Q E S G G G L V K P G G S L K L
1   GAG GTG CAG CTT CAG GAG TCA GGG GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC
   CTC CAC GTC GAA GTC CTC AGT CCC CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG

+1  S C A A S G F I F S S Y T M S W V R Q T
61  TCC TGT GCA GCC TCT GGA TTC ATT TTT AGT AGT TAT ACC ATG TCT TGG GTT CGC CAG ACT
   AGG ACA CGT CGG AGA CCT AAG TAA AAA TCA TCA ATA TGG TAC AGA ACC CAA GCG GTC TGA

+1  P E K R L E W V A T I S S G G S S T Y Y
121 CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT GGT GGT AGT TCC ACC TAC TAT
   GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAG AGG TCT CTG TTA CGG TTC TTG TGG GAC ATG

+1  P D S V K G R F T I S R D N A K N T L Y
181 CCA GAC AGT GTG AAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC
   GGT CTG TCA CAC TCC CCG GCT AAG TGG TAG AGG TCT CTG TTA CGG TTC TTG TGG GAC ATG

+1  L Q M S S L K S E D T A M Y H C T R E G
241 CTG CAA ATG AGC AGT CTG AAG TCT GAG GAC ACA GCC ATG TAT CAC TGT ACA AGA GAG GGG
   GAC GTT TAC TCG TCA GAC TTC AGA CTC CTG TGT CGG TAC ATA GTG ACA TGT TCT CTC CCC

+1  G G Y Y V N W Y F D V W G A G T T L T V
301 GGT GGT TAT TAC GTC AAC TGG TAC TTC GAT GTC TGG GGC GCA GGC ACC ACT CTC ACA GTC
   CCA CCA ATA ATG CAG TTG ACC ATG AAG CTA CAG ACC CCG CGT CCG TGG TGA GAG TGT CAG

+1  S S G G G S G G R A S G G G S D I E
361 TCC TCA GGT GGA GGC GGT TCA GGT GGC CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GAG
   AGG AGT CCA CCT CCG CCA AGT CCA CCC GCG CGG AGA CCG CCA CCG CCT AGC CTG TAA CTC

+1  L T Q S P A S L A V S L G Q R A T I S C
421 CTC ACN CAG TCT CCA GCT TCT TTG GCT GTG TCT CTA GGG CAG AGG GCC ACC ATA TCC TGC
   GAG TGN GTC AGA GGT CGA AGA AAC CGA CAC AGA GAT CCC GTC TCC CGG TGG TAT AGG ACC

```

FIG. 17-1

```

+1   R   A   S   E   S   V   D   S   Y   G   K   S   F   M   H   W   Y   Q   Q   K
481  AGA GCC AGT GAA AGT GTT GAT AGT TAT GGC AAG AGT TTT ATG CAC TGG TAC CAG CAG AAA
    TCT CGG TCA CTT TCA CAA CTA TCA ATA CCG TTC TCA AAA TAC GTG ACC ATG GTC GTC TTT

+1   P   G   Q   P   P   K   L   L   I   Y   R   A   S   N   L   E   S   G   I   P
541  CCA GGG CAG CCA CCC AAA CTC CTC ATC TAT CGT GCA TCC AAC CTA GAA TCT GGG ATC CCT
    GGT CCC GTC GGT GGG TTT GAG GAG TAG ATA GCA CGT AGG TTG GAT CTT AGA CCC TAG GGA

+1   A   R   F   S   G   S   G   S   R   T   D   F   T   L   T   I   N   P   V   E
601  GCC AGG TTC AGT GGC AGT GGG TCT AGG ACA GAC TTC ACC CTC ACC ATT AAT CCT GTG GAG
    CGG TCC AAG TCA CCG TCA CCC AGA TCC TGT CTG AAG TGG GAG TGG TAA TTA GGA CAC CTC

+1   A   D   D   V   A   T   Y   Y   C   Q   Q   S   N   E   D   P   L   T   F   G
661  GCT GAT GAT GTT GCN ACC TAT TAC TGT CAG CAA AGT AAT GAG GAT CCC CTC ACG TTC GGT
    CGA CTA CTA CAA CGN TGG ATA ATG ACA GTC GTT TCA TTA CTC CTA GGG GAG TGC AAG CCA

+1   A   G   T   R   L   E   I   K   R
721  GCT GGG ACC AGA CTG GAA ATA AAA CGG
    CGA CCC TGG TCT GAC CTT TAT TTT GCC
    
```

FIG. 17-2




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24A




FIG. 24B




FIG. 25




FIG. 26-1




FIG. 26-2

+1	L	L	I	G	D	G	M	G	D	S	E	I	T	A
463	TTG	CTG	ATT	GGC	GAT	GGG	ATG	GGG	GAC	TCG	GAA	ATT	ACT	GCC
	AAC	GAC	TAA	CCG	CTA	CCC	TAC	CCC	CTG	AGC	CTT	TAA	TGA	CGG
+1	A	R	N	Y	A	E	G	A	G	G	F	F	K	G
505	GCA	CGT	AAT	TAT	GCC	GAA	GGT	GCG	GGC	GGC	TTT	TTT	AAA	GGT
	CGT	GCA	TTA	ATA	CGG	CTT	CCA	CGC	CCG	CCG	AAA	AAA	TTT	CCA
+1	I	D	A	L	P	L	T	G	Q	Y	T	H	Y	A
1051	ATA	GAT	GCC	TTA	CCG	CTT	ACC	GGG	CAA	TAC	ACT	CAC	TAT	GCG
	TAT	CTA	CGG	AAT	GGC	GAA	TGG	CCC	GTT	ATG	TGA	GTG	ATA	CGC
+1	L	N	K	K	T	G	K	P	D	Y	V	T	D	S
1093	CTG	AAT	AAA	AAA	ACC	GGC	AAA	CCG	GAC	TAC	GTC	ACC	GAC	TCG
	GAC	TTA	TTT	TTT	TGG	CCG	TTT	GGC	CTG	ATG	CAG	TGG	CTG	AGC
+1	A	A	S	A	T	A	W	S	T	G	V	K	T	Y
1135	GCT	GCA	TCA	GCA	ACC	GCC	TGG	TCA	ACC	GGT	GTC	AAA	ACC	TAT
	CGA	CGT	AGT	CGT	TGG	CGG	ACC	AGT	TGG	CCA	CAG	TTT	TGG	ATA
+1	N	G	A	L	G	V	D	I	H	E	K	D	H	P
1177	AAC	GGC	GCG	CTG	GGC	GTC	GAT	ATT	CAC	GAA	AAA	GAT	CAC	CCA
	TTG	CCG	CGC	GAC	CCG	CAG	CTA	TAA	GTG	CTT	TTT	CTA	GTG	GGT
+1	T	I	L	E	M	A	K	A	A	G	L	A	T	G
1219	ACG	ATT	CTG	GAA	ATG	GCA	AAA	GCC	GCA	GGT	CTG	GCG	ACC	GGT
	TGC	TAA	GAC	CTT	TAC	CGT	TTT	CGG	CGT	CCA	GAC	CGC	TGG	CCA
+1	N	V	S	T	A	E	L	Q	D	A	T	P	A	A
1261	AAC	GTT	TCT	ACC	GCA	GAG	TTG	CAG	GAT	GCC	ACG	CCC	GCT	GCG
	TTG	CAA	AGA	TGG	CGT	CTC	AAC	GTC	CTA	CGG	TGC	GGG	CGA	CGC
+1	L	V	A	H	V	T	S	R	K	C	Y	G	P	S
1303	CTG	GTG	GCA	CAT	GTG	ACC	TCG	CGC	AAA	TGC	TAC	GGT	CCG	AGC
	GAC	CAC	CGT	GTA	CAC	TGG	AGC	GCG	TTT	ACG	ATG	CCA	GGC	TCG
+1	A	T	S	E	K	C	P	G	N	A	L	E	K	G
1345	GCG	ACC	AGT	GAA	AAA	TGT	CCG	GGT	AAC	GCT	CTG	GAA	AAA	GGC
	CGC	TGG	TCA	CTT	TTT	ACA	GGC	CCA	TTG	CGA	GAC	CTT	TTT	CCG
+1	G	K	G	S	I	T	E	Q	L	L	N	A	R	A
1387	GGA	AAA	GGA	TCG	ATT	ACC	GAA	CAG	CTG	CTT	AAC	GCT	CGT	GCC
	CCT	TTT	CCT	AGC	TAA	TGG	CTT	GTC	GAC	GAA	TTG	CGA	GCA	CGG
+1	D	V	T	L	G	G	G	A	K	T	F	A	E	T
1429	GAC	GTT	ACG	CTT	GGC	GGC	GGC	GCA	AAA	ACC	TTT	GCT	GAA	ACG
	CTG	CAA	TGC	GAA	CCG	CCG	CCG	CGT	TTT	TGG	AAA	CGA	CTT	TGC

FIG. 26-3

+1	A	T	A	G	E	W	Q	G	K	T	L	R	E	Q
1471	GCA	ACC	GCT	GGT	GAA	TGG	CAG	GGA	AAA	ACG	CTG	CGT	GAA	CAG
	CGT	TGG	CGA	CCA	CTT	ACC	GTC	CCT	TTT	TGC	GAC	GCA	CTT	GTC
+1	A	Q	A	R	G	Y	Q	L	V	S	D	A	A	S
1513	GCA	CAG	GCG	CGT	GGT	TAT	CAG	TTG	GTG	AGC	GAT	GCT	GCC	TCA
	CGT	GTC	CGC	GCA	CCA	ATA	GTC	AAC	CAC	TCG	CTA	CGA	CGG	AGT
+1	L	N	S	V	T	E	A	N	Q	Q	K	P	L	L
1555	CTG	AAT	TCG	GTG	ACG	GAA	GCG	AAT	CAG	CAA	AAA	CCC	CTG	CTT
	GAC	TTA	AGC	CAC	TGC	CTT	CGC	TTA	GTC	GTT	TTT	GGG	GAC	GAA
+1	G	L	F	A	D	G	N	M	P	V	R	W	L	G
1177	GGC	CTG	TTT	GCT	GAC	GGC	AAT	ATG	CCA	GTG	CGC	TGG	CTA	GGA
	CCG	GAC	AAA	CGA	CTG	CCG	TTA	TAC	GGT	CAC	GCG	ACC	GAT	CCT
+1	P	K	A	T	Y	H	G	N	I	D	K	P	A	V
1639	CCG	AAA	GCA	ACG	TAC	CAT	GGC	AAT	ATC	GAT	AAG	CCC	GCA	GTC
	GGC	TTT	CGT	TGC	ATG	GTA	CCG	TTA	TAG	CTA	TTC	GGG	CGT	CAG
+1	T	C	T	P	N	P	Q	R	N	D	S	V	P	T
1681	ACC	TGT	ACG	CCA	AAT	CCG	CAA	CGT	AAT	GAC	AGT	GTA	CCA	ACC
	TGG	ACA	TGC	GGT	TTA	GGC	GTT	GCA	TTA	CTG	TCA	CAT	GGT	TGG
+1	L	A	Q	M	T	D	K	A	I	E	L	L	S	K
1723	CTG	GCG	CAG	ATG	ACC	GAC	AAA	GCC	ATT	GAA	TTG	TTG	AGT	AAA
	GAC	CGC	GTC	TAC	TGG	CTG	TTT	CGG	TAA	CTT	AAC	AAC	TCA	TTT
+1	N	E	K	G	F	F	L	Q	V	E	G	A	S	I
1765	AAT	GAG	AAA	GGC	TTT	TTC	CTG	CAA	GTT	GAA	GGT	GCG	TCA	ATC
	TTA	CTC	TTT	CCG	AAA	AAG	GAC	GTT	CAA	CTT	CCA	CGC	AGT	TAG
+1	D	K	Q	D	H	A	A	N	P	C	G	Q	I	G
1807	GAT	AAA	CAG	GAT	CAT	GCT	GCG	AAT	CCT	TGT	GGG	CAA	ATT	GGC
	CTA	TTT	GTC	CTA	GTA	CGA	CGC	TTA	GGA	ACA	CCC	GTT	TAA	CCG
+1	E	T	V	D	L	D	E	A	V	Q	R	A	L	E
1849	GAG	ACG	GTC	GAT	CTC	GAT	GAA	GCC	GTA	CAA	CGG	GCG	CTG	GAA
	CTC	TGC	CAG	CTA	GAG	CTA	CTT	CGG	CAT	GTT	GCC	CGC	GAC	CTT
+1	F	A	K	K	E	G	N	T	L	V	I	V	T	A
1891	TTC	GCT	AAA	AAG	GAG	GGT	AAC	ACG	CTG	GTC	ATA	GTC	ACC	GCT
	AAG	CGA	TTT	TTC	CTC	CCA	TTG	TGC	GAC	CAG	TAT	CAG	TGG	CGA
+1	D	H	A	H	A	S	Q	I	V	A	P	D	T	K
1933	GAT	CAC	GCC	CAC	GCC	AGC	CAG	ATT	GTT	GCG	CCG	GAT	ACC	AAA
	CTA	GTG	CGG	GTG	CGG	TCG	GTC	TAA	CAA	CGC	GGC	CTA	TGG	TTT
+1	A	P	G	L	T	Q	A	L	N	T	K	D	G	A
1975	GCT	CCG	GGC	CTC	ACC	CAG	GCG	CTA	AAT	ACC	AAA	GAT	GGC	GCA
	CGA	GGC	CCG	GAG	TGG	GTC	CGC	GAT	TTA	TGG	TTT	CTA	CCG	CGT

FIG. 26-4

	+1	V	M	V	M	S	Y	G	N	S	E	E	D	S	Q
2017		GTG	ATG	GTG	ATG	AGT	TAC	GGG	AAC	TCC	GAA	GAG	GAT	TCA	CAA
		CAC	TAC	CAC	TAC	TCA	ATG	CCC	TTG	AGG	CTT	CTC	CTA	AGT	GTT
	+1	E	H	T	G	S	Q	L	R	I	A	A	Y	G	P
2059		GAA	CAT	ACC	GGC	AGT	CAG	TTG	CGT	ATT	GCG	GCG	TAT	GGC	CCG
		CTT	GTA	TGG	CCG	TCA	GTC	AAC	GCA	TAA	CGC	CGC	ATA	CCG	GGC
	+1	H	A	A	N	V	V	G	L	T	D	Q	T	D	L
2101		CAT	GCC	GCC	AAT	GTT	GTT	GGA	CTG	ACC	GAC	CAG	ACC	GAT	CTC
		GTA	CGG	CGG	TTA	CAA	CAA	CCT	GAC	TGG	CTG	GTC	TGG	CTA	GAG
	+1	F	Y	T	M	K	A	A	L	G	D	I	His tag		
2143		TTC	TAC	ACC	ATG	AAA	GCC	GCT	CTG	GGG	GAT	ATC	GCA	CAC	CAT
		AAG	ATG	TGG	TAC	TTT	CGG	CGA	GAC	CCC	CTA	TAG	CGT	GTG	GTA
	+1	H	H	H	H	*									
2185		CAC	CAT	CAC	CAT	TAA									
		GTG	GTA	GTG	GTA	ATT									

FIG. 26-5




FIG. 27

PelB-Leader

```

+1 M K Y L L P T A A A G L L L L
1  ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
   TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

+1 A A Q P A M A E V K L V E S G
46  GCG GCC CAG CCG GCC ATG GCG GAG GTG AAG CTG GTG GAG TCT GGG
   CGC CGG GTC GGC CGG TAC CGC CTC CAC TTC GAC CAC CTC AGA CCC

+1 G G L V K P G G S L K L S C A
91  GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA
   CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG AGG ACA CGT

+1 A S G F T F S S Y T M S W V R
136 GGC TCT GGA TTC ACT TTC AGT AGC TAT ACC ATG TCT TGG GTT CGC
   CGG AGA CCT AAG TGA AAG TCA TCG ATA TGG TAC AGA ACC CAA GCG

+1 Q T P E K R L E W V A T I S S
181 CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT
   GTC TGA GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAA TCA TCA

+1 G G S S T Y Y P D S V K G R F
226 GGN GGT AGT TCC ACC TAC TAT CCA GAC AGT GTG AAG GGC CGA TTC
   CCN CCA TCA AGG TGG ATG ATA GGT CTG TCA CAC TTC CCG GCT AAG

+1 T I S R D N A K N T L Y L Q M
271 ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC CTG CAA ATG
   TGG TAG AGG TCT CTG TTA CGG TTC TTG TGG GAC ATG GAC GTT TAC

+1 S S L R S E D T A M Y Y C T R
316 AGC AGT CTG AGG TCT GAG GAC ACA GCC ATG TAT TAC TGT ACA AGA
   TCG TCA GAC TCC AGA CTC CTG TGT CGG TAC ATA ATG ACA TGT TCT

+1 E G G G F T V N W Y F D V W G
361 GAG GGG GGT GGT TTC ACC GTC AAC TGG TAC TTC GAT GTC TGG GGC
   CTC CCC CCA CCA AAG TGG CAG TTG ACC ATG AAG CTA CAG ACC CCG
  
```

Linker

```

+1 A G T S V T V S S G G G G S G
406 GCA GGA ACC TCA GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGT
   CGT CCT TGG AGT CAG TGG CAG AGG AGT CCA CCT CCG CCA AGT CCA
  
```

VL

```

+1 G R A S G G G S D I V L T Q
451 GGG CGC GCC TCT GGC GGT GGC GGA TCG GAC ATT GTG CTG ACA CAG
   CCC GCG CGG AGA CCG CCA CCG CCT AGC CTG TAA CAC GAC TGT GTC
  
```

FIG. 28-1

```

+1 X P A S L A V S L G Q R A T I
496 TNT CCA GCT TCT TTG GCT GTG TCT CTA GGG CAG AGG GCC ACC ATA
ANA GGT CGA AGA AAC CGA CAC AGA GAT CCC GTC TCC CGG TGG TAT

+1 S C R A S E S V D S Y G Y N F
541 TCN TGC AGA GCC AGT GAA AGT GTT GAT AGT TAT GGC TAT AAT TTT
AGN ACG TCT CGG TCA CTT TCA CAA CTA TCA ATA CCG ATA TTA AAA

+1 M H W Y Q Q I P G Q P P K L L
586 ATG CAC TGG TAT CAG CAG ATA CCA GGA CAG CCA CCC AAA CTC CTC
TAC GTG ACC ATA GTC GTC TAT GGT CCT GTC GGT GGG TTT GAG GAG

+1 I Y R A S N L E S G I P A R F
631 ATC TAT CGT GCA TCC AAC CTA GAG TCT GGG ATC CCT GCC AGG TTC
TAG ATA GCA CGT AGG TTG GAT CTC AGA CCC TAG GGA CGG TCC AAG

+1 S G S G S R T D F T L T I N P
676 AGT GGC AGT GGG TCT AGG ACA GAC TTC ACC CTC ACC ATT AAT CCT
TCA CCG TCA CCC AGA TCC TGT CTG AAG TGG GAG TGG TAA TTA GGA

+1 V E A D D V A T Y Y C Q Q S N
721 GTG GAG GCT GAT GAT GTT GCA ACC TAT TAC TGT CAG CAA AGT AAT
CAC CTC CGA CTA CTA CAA CGT TGG ATA ATG ACA GTC GTT TCA TTA

+1 E D P L T F G T G T R L E I K
766 GAG GAT CCG CTC ACG TTC GGT ACT GGG ACC AGA CTG GAA ATA AAA
CTC CTA GGC GAG TGC AAG CCA TGA CCC TGG TCT GAC CTT TAT TTT

Spacer Hinge Helix

+1 R A A A P K P S T P P G S S R
811 CGG GCG GCC GCA CCG AAG CCT TCC ACT CCG CCC GGG TCT TCC CGT
GCC CGC CGG CGT GGC TTC GGA AGG TGA GGC GGG CCC AGA AGG GCA

+1 M K Q L E D K V E E L L S K N
856 ATG AAA CAG CTG GAA GAC AAA GTA GAG GAG CTC CTT AGC AAG AAC
TAC TTT GTC GAC CTT CTG TTT CAT CTC CTC GAG GAA TCG TTC TTG

+1 Y H L E N E V A R L K K L V G
901 TAC CAT CTA GAA AAC GAG GTA GCT CGT CTG AAA AAG CTT GTT GGT
ATG GTA GAT CTT TTG CTC CAT CGA GCA GAC TTT TTC GAA CAA CCA

Spacer His-tag
+1 E R G G H H H H H *
946 GAA CGT GGT GGT CAC CAT CAC CAT CAC CAT TAA
CTT GCA CCA CCA GTG GTA GTG GTA GTG GTA ATT
    
```

FIG. 28-2




FIG. 29-1


```

+1 V S L G Q R A T I S C R A S
505 GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TGC AGG GCC AGC
    CAT AGA GAC CCC GTC TCC CGG TGG TAG AGT ACG TCC CGG TCG

+1 K S V S T S G Y S Y M H W Y
547 AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG TAC
    TTT TCA CAG TCA TGT AGA CCG ATA TCA ATA TAC GTG ACC ATG

+1 Q Q K P G Q P P K L L I Y L
589 CAA CAG AAA CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CTT
    GTT GTC TTT GGT CCT GTC GGT GGG TTT GAG GAG TAG ATA GAA

+1 A S N L E S G V P A R F S G
631 GCA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC
    CGT AGG TTG GAT CTT AGA CCC CAG GGA CGG TCC AAG TCA CCG

+1 S G S G T D F T L N I H P V
679 AGT GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG
    TCA CCC AGA CCC TGT CTG AAG TGG GAG TTG TAG GTA GGA CAC

+1 E E E D A A T Y Y C Q H S R
715 GAG GAG GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC AGT AGG
    CTC CTC CTC CTA CGA CGT TGG ATA ATG ACA GTC GTG TCA TCC

+1 E L P R T F G G G T K L E I
757 GAG CTT CCT CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC
    CTC GAA GGA GCC TGC AAG CCA CCT CCG TGG TTC GAC CTT TAG

+1 K R | Spacer | Alkaline phosphatase
799 AAA CGG | GCG GCC GCA GCC | R A P E M P V L
    TTT GCC | CGC CGG CGT CGG | GCC CGT GGT CTT TAC GGA CAA GAC

+1 E N R A A Q G D I T A P G G
841 GAA AAC CGG GCT GCT CAG GGC GAT ATT ACT GCA CCC GGC GGT
    CTT TTG GCC CGA CGA GTC CCG CTA TAA TGA CGT GGG CCG CCA

+1 A R R L T G D Q T A A L R D
883 GCT CGC CGT TTA ACG GGT GAT CAG ACT GCC GCT CTG CGT GAT
    CGA GCG GCA AAT TGC CCA CTA GTC TGA CGG CGA GAC GCA CTA

+1 S L S D K P A K N I I L L I
925 TCT CTT AGC GAT AAA CCT GCA AAA AAT ATT ATT TTG CTG ATT
    AGA GAA TCG CTA TTT GGA CGT TTT TTA TAA TAA AAC GAC TAA

+1 G D G M G D S E I T A A R N
967 GGC GAT GGG ATG GGG GAC TCG GAA ATT ACT GCC GCA CGT AAT
    CCG CTA CCC TAC CCC CTG AGC CTT TAA TGA CGG CGT GCA TTA
    
```

FIG. 29-2

+1	Y	A	E	G	A	G	G	F	F	K	G	I	D	A
1009	TAT	GCC	GAA	GGT	GCG	GGC	GGC	TTT	TTT	AAA	GGT	ATA	GAT	GCC
	ATA	CGG	CTT	CCA	CGC	CCG	CCG	AAA	AAA	TTT	CCA	TAT	CTA	CGG
+1	L	P	L	T	G	Q	Y	T	H	Y	A	L	N	K
1051	TTA	CCG	CTT	ACC	GGG	CAA	TAC	ACT	CAC	TAT	GCG	CTG	AAT	AAA
	AAT	GGC	GAA	TGG	CCC	GTT	ATG	TGA	GTG	ATA	CGC	GAC	TTA	TTT
+1	K	T	G	K	P	D	Y	V	T	D	S	A	A	S
1093	AAA	ACC	GGC	AAA	CCG	GAC	TAC	GTC	ACC	GAC	TCG	GCT	GCA	TCA
	TTT	TGG	CCG	TTT	GGC	CTG	ATG	CAG	TGG	CTG	AGC	CGA	CGT	AGT
+1	A	T	A	W	S	T	G	V	K	T	Y	N	G	A
1135	GCA	ACC	GCC	TGG	TCA	ACC	GGT	GTC	AAA	ACC	TAT	AAC	GGC	GCG
	CGT	TGG	CCG	ACC	AGT	TGG	CCA	CAG	TTT	TGG	ATA	TTG	CCG	CGC
+1	L	G	V	D	I	H	E	K	D	H	P	T	I	L
1177	CTG	GCC	GTC	GAT	ATT	CAC	GAA	AAA	GAT	CAC	CCA	ACG	ATT	CTG
	GAC	CCG	CAG	CTA	TAA	GTG	CTT	TTT	CTA	GTG	GGT	TGC	TAA	GAC
+1	E	M	A	K	A	A	G	L	A	T	G	N	V	S
1219	GAA	ATG	GCA	AAA	GCC	GCA	GGT	CTG	GCG	ACC	GGT	AAC	GTT	TCT
	CTT	TAC	CGT	TTT	CGG	CGT	CCA	GAC	CGC	TGG	CCA	TTG	CAA	AGA
+1	T	A	E	L	Q	D	A	T	P	A	A	L	V	A
1261	ACC	GCA	GAG	TTG	CAG	GAT	GCC	ACG	CCC	GCT	GCG	CTG	GTG	GCA
	TGG	CGT	CTC	AAC	GTC	CTA	CGG	TGC	GGG	CGA	CGC	GAC	CAC	CGT
+1	H	V	T	S	R	K	C	Y	G	P	S	A	T	S
1303	CAT	GTG	ACC	TCG	CGC	AAA	TGC	TAC	GGT	CCG	AGC	GCG	ACC	AGT
	GTA	CAC	TGG	AGC	GCG	TTT	ACG	ATG	CCA	GGC	TCG	CGC	TGG	TCA
+1	E	K	C	P	G	N	A	L	E	K	G	G	K	G
1345	GAA	AAA	TGT	CCG	GGT	AAC	GCT	CTG	GAA	AAA	GGC	GGA	AAA	GGA
	CTT	TTT	ACA	GGC	CCA	TTG	CGA	GAC	CTT	TTT	CCG	CCT	TTT	CCT
+1	S	I	T	E	Q	L	L	N	A	R	A	D	V	T
1387	TCG	ATT	ACC	GAA	CAG	CTG	CTT	AAC	GCT	CGT	GCC	GAC	GTT	ACG
	AGC	TAA	TGG	CTT	GTC	GAC	GAA	TTG	CGA	GCA	CGG	CTG	CAA	TGC
+1	L	G	G	G	A	K	T	F	A	E	T	A	T	A
1429	CTT	GGC	GGC	GGC	GCA	AAA	ACC	TTT	GCT	GAA	ACG	GCA	ACC	GCT
	GAA	CCG	CCG	CCG	CGT	TTT	TGG	AAA	CGA	CTT	TGC	CGT	TGG	CGA
+1	G	E	W	Q	G	K	T	L	R	E	Q	A	Q	A
1471	GGT	GAA	TGG	CAG	GGA	AAA	ACG	CTG	CGT	GAA	CAG	GCA	CAG	GCG
	CCA	CTT	ACC	GTC	CCT	TTT	TGC	GAC	GCA	CTT	GTC	CGT	GTC	CGC

FIG. 29-3

```

+1 R G Y Q L V S D A A S L N S
1513 CGT GGT TAT CAG TTG GTG AGC GAT GCT GCC TCA CTG AAT TCG
    GCA CCA ATA GTC AAC CAC TCG CTA CGA CGG AGT GAC TTA AGC

+1 V T E A N Q Q K P L L G L F
1555 GTG ACG GAA GCG AAT CAG CAA AAA CCC CTG CTT GGC CTG TTT
    CAC TGC CTT CGC TTA GTC GTT TTT GGG GAC GAA CCG GAC AAA

+1 A D G N M P V R W L G P K A
1597 GCT GAC GGC AAT ATG CCA GTG CGC TGG CTA GGA CCG AAA GCA
    CGA CTG CCG TTA TAC GGT CAC GCG ACC GAT CCT GGC TTT CGT

+1 T Y H G N I D K P A V T C T
1639 ACG TAC CAT GGC AAT ATC GAT AAG CCC GCA GTC ACC TGT ACG
    TGC ATG GTA CCG TTA TAG CTA TTC GGG CGT CAG TGG ACA TGC

+1 P N P Q R N D S V P T L A Q
1681 CCA AAT CCG CAA CGT AAT GAC AGT GTA CCA ACC CTG GCG CAG
    GGT TTA GGC GTT GCA TTA CTG TCA CAT GGT TGG GAC CGC GTC

+1 M T D K A I E L L S K N E K
1723 ATG ACC GAC AAA GCC AAT GAA TTG TTG AGT AAA AAT GAG AAA
    TAC TGG CTG TTT CGG TAA CTT AAC AAC TCA TTT TTA CTC TTT

+1 G F F L Q V E G A S I D K Q
1765 GGC TTT TTC CTG CAA GTT GAA GGT GCG TCA ATC GAT AAA CAG
    CCG AAA AAG GAC GTT CAA CTT CCA CGC AGT TAG CTA TTT GTC

+1 D H A A N P C G Q I G E T V
1807 GAT CAT GCT GCG AAT CCT TGT GGG CAA ATT GGC GAG ACG GTC
    CTA GTA CGA CGC TTA GGA ACA CCC GTT TAA CCG CTC TGC CAG

+1 D L D E A V Q R A L E F A K
1849 GAT CTC GAT GAA GCC GTA CAA CGG GCG CTG GAA TTC GCT AAA
    CTA GAG CTA CTT CGG CAT GTT GCC CGC GAC CTT AAG CGA TTT

+1 K E G N T L V I V T A D H A
1891 AAG GAG GGT AAC ACG CTG GTC ATA GTC ACC GCT GAT CAC GCC
    TTC CTC CCA TTG TGC GAC CAG TAT CAG TGG CGA CTA GTG CGG

+1 H A S Q I V A P D T K A P G
1933 CAC GCC AGC CAG AAT GTT GCG CCG GAT ACC AAA GCT CCG GGC
    GTG CGG TCG GTC TAA CAA CGC GGC CTA TGG TTT CGA GGC CCG

+1 L T Q A L N T K D G A V M V
1975 CTC ACC CAG GCG CTA AAT ACC AAA GAT GGC GCA GTG ATG GTG
    GAG TGG GTC CGC GAT TTA TGG TTT CTA CCG CGT CAC TAC CAC

```

FIG. 29-4

```
+1 M S Y G N S E E D S Q E H T
2017 ATG AGT TAC GGG AAC TCC GAA GAG GAT TCA CAA GAA CAT ACC
      TAC TCA ATG CCC TTG AGG CTT CTC CTA AGT GTT CTT GTA TGG

+1 G S Q L R I A A Y G P H A A
2059 GGC AGT CAG TTG CGT ATT GCG GCG TAT GGC CCG CAT GCC GCC
      CCG TCA GTC AAC GCA TAA CGC CGC ATA CCG GGC GTA CGG CGG

+1 N V V G L T D Q T D L F Y T
2101 AAT GTT GTT GGA CTG ACC GAC CAG ACC GAT CTC TTC TAC ACC
      TTA CAA CAA CCT GAC TGG CTG GTC TGG CTA GAG AAG ATG TGG

+1 M K A A L G D I A | His tag
2143 ATG AAA GCC GCT CTG GGG GAT ATC GCA | H H H H H
      TAC TTT CGG CGA GAC CCC CTA TAG CGT | GTG GTA GTG GTA GTG

+1 H *
2185 CAT TAA
      GTA ATT
```

FIG. 29-5

PelB-Leader

```

+1 M K Y L L P T A A A G L L L L
1  ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
   TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

```

VH

```

+1 A A Q P A M A | E V Q L Q Q S G
46 GCG GCC CAG CCG GCC ATG GCG | GAG GTT CAG CTT CAG CAG TCT GGA
   CGC CGG GTC GGC CGG TAC CGC | CTC CAA GTC GAA GTC GTC AGA CCT

```

```

+1 P E L V K P G A S V K I S C K
91 CCT GAG CTG GTG AAG CCC GGG GCC TCA GTG AAG ATT TCC TGC AAA
   GGA CTC GAC CAC TTC GGG CCC CGG AGT CAC TTC TAA AGG ACG TTT

```

```

+1 A S G Y A F S S S W M N W V K
136 GCT TCT GGC TAC GCA TTC AGT AGC TCT TGG ATG AAC TGG GTG AAG
   CGA AGA CCG ATG CGT AAG TCA TCG AGA ACC TAC TTG ACC CAC TTC

```

```

+1 Q R P G Q G L E W I G R I Y P
181 CAG AGG CCT GGA CAG GGT CTT GAG TGG ATT GGA CGG ATT TAT CCT
   GTC TCC GGA CCT GTC CCA GAA CTC ACC TAA CCT GCC TAA ATA GGA

```

```

+1 G N G D T N Y N G K F K G K A
226 GGA AAT GGA GAT ACT AAC TAC AAT GGG AAG TTC AAG GGC AAG GCC
   CCT TTA CCT CTA TGA TTG ATG TTA CCC TTC AAG TTC CCG TTC CGG

```

```

+1 T L T A D K S S S T A Y M Q L
271 ACA CTG ACT GCA GAC AAA TCC TCC AGC ACA GCC TAC ATG CAG CTC
   TGT GAC TGA CGT CTG TTT AGG AGG TCG TGT CGG ATG TAC GTC GAG

```

```

+1 S S L T S V D S A V Y F C A D
316 AGC AGC CTG ACC TCT GTG GAC TCT GCG GTC TAT TTC TGT GCA GAT
   TCG TCG GAC TGG AGA CAC CTG AGA CGC CAG ATA AAG ACA CGT CTA

```

```

+1 G N V Y Y Y A M D Y W G Q G T
361 GGT AAC GTA TAT TAC TAT GCT ATG GAC TAC TGG GGT CAA GGA ACC
   CCA TTG CAT ATA ATG ATA CGA TAC CTG ATG ACC CCA GTT CCT TGG

```

Linker

```

+1 S V T V S S | G G G G S G G R A
406 TCA GTC ACC GTC TCC TCA | GGT GGA GGC GGT TCA GGT GGG CGC GCC
   AGT CAG TGG CAG AGG AGT | CCA CCT CCG CCA AGT CCA CCC GCG CGG

```

FIG. 30-1

Spacer		His-tag						
+1	G	H	H	H	H	H	*	
946	GGT	CAC	CAT	CAC	CAT	CAC	CAT TAA	
	CCA	GTG	GTA	GTG	GTA	GTG	GTA ATT	

FIG. 30-3




FIG. 31




FIG. 32

HindIII

2206 CAG GAA ACA GCT ATG ACC ATG ATT ACG CCA[~]AGC[~]TTT CAT GAA AAT
 GTC CTT TGT CGA TAC TGG TAC TAA TGC GGT TCG AAG GTA CTT TTA

PelB-Leader

M K Y L L P T

2251 TCT ATT TCA AGG AGA CAG TCA TAA TGA AAT ACC TAT TGC CTA CGG
 AGA TAA AGT TCC TCT GTC AGT ATT ACT TTA TGG ATA ACG GAT GCC

A A A G L L L L A A Q P A M A

SfiI

2296 CAG CCG CTG GAT TGT TAT TAC TCG CGG[~]CCC[~]AGC[~]CGG[~]CCA TGG CCC
 GTC GGC GAC CTA ACA ATA ATG AGC GCC GGG TCG GCC GGT ACC GGG

Polylinker

Q V Q L Q A R L Q V D L E I K

AscI

2341 AGG TGC AGC TGC AGG[~]CGC[~]GCC[~]TGC AGG TCG ACC TCG AGA TCA AAC
 TCC ACG TCG ACG TCC GCG CGG ACG TCC AGC TGG AGC TCT AGT TTG

	Spacer	Myc-tag
	R A A A	E Q K L I S E E D L N
	NotI	

2386 GGG[~]CGG[~]CCG[~]CAG AAC AAA AAC TCA TCT CAG AAG AGG ATC TGA ATG
 CCC GCC GGC GTC TTG TTT TTG AGT AGA GTC TTC TCC TAG ACT TAC

	Spacer	His tag
	G A A	H H H H H H * *
		EcoRI

2431 GGG CGG CAC ATC ACC ATC ACC ATC ACT AAT AAG AAT TCA CTG GCC
 CCC GCC GTG TAG TGG TAG TGG TAG TGA TTA TTC TTA AGT GAC CGG

FIG. 33

PelB-leader

```

+1  M  K  Y  L  L  P  T  A  A  A  G  L  L  L  L
1   ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC
    TAC TTT ATG GAT AAC GGA TGC CGT CGG CGA CCT AAC AAT AAT GAG

+1  A  A  Q  P  A  M  A  |  VH
46  GCG GCC CAG CCG GCC ATG GCC | GAG GTG AAG CTG GTG GAG TCT GGG
    CGC CGG GTC GGC CGG TAC CGG | CTC CAC TTC GAC CAC CTC AGA CCC

+1  G  G  L  V  K  P  G  G  S  L  K  L  S  C  A
91  GGA GGC TTA GTG AAG CCT GGA GGG TCC CTG AAA CTC TCC TGT GCA
    CCT CCG AAT CAC TTC GGA CCT CCC AGG GAC TTT GAG AGG ACA CGT

+1  A  S  G  F  T  F  S  S  Y  T  M  S  W  V  R
136 GCC TCT GGA TTC ACT TTC AGT AGC TAT ACC ATG TCT TGG GTT CGC
    CGG AGA CCT AAG TGA AAG TCA TCG ATA TGG TAC AGA ACC CAA GCG

+1  Q  T  P  E  K  R  L  E  W  V  A  T  I  S  S
181 CAG ACT CCG GAG AAG AGG CTG GAG TGG GTC GCA ACC ATT AGT AGT
    GTC TGA GGC CTC TTC TCC GAC CTC ACC CAG CGT TGG TAA TCA TCA

+1  G  G  S  S  T  Y  Y  P  D  S  V  K  G  R  F
226 GGN GGT AGT TCC ACC TAC TAT CCA GAC AGT GTG AAG GGC CGA TTC
    CCN CCA TCA AGG TGG ATG ATA GGT CTG TCA CAC TTC CCG GCT AAG

+1  T  I  S  R  D  N  A  K  N  T  L  Y  L  Q  M
271 ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTG TAC CTG CAA ATG
    TGG TAG AGG TCT | CTG TTA CGG TTC TTG TGG GAC ATG GAC GTT TAC

+1  S  |  S  L  R  |  S  E  D  T  A  M  Y  Y  C  T  R
316 AGC AGT CTG AGG TCT GAG GAC ACA GCC ATG TAT TAC TGT ACA AGA
    TCG TCA GAC TCC AGA CTC CTG TGT CGG TAC ATA ATG ACA TGT TCT

+1  E  G  G  G  F  T  V  N  W  Y  F  D  V  W  G
361 GAG GGG GGT GGT TTC ACC GTC AAC TGG TAC TTC GAT GTC TGG GGC
    CTC CCC CCA CCA AAG TGG CAG TTG ACC ATG AAG CTA CAG ACC CCG

+1  A  G  T  S  V  T  V  S  S  |  Leader
406 GCA GGA ACC TCA GTC ACC GTC TCC TCA | GGT GGA GGC GGT TCA GGT
    CGT CCT TGG AGT CAG TGG CAG AGG AGT | CCA CCT CCG CCA AGT CCA

```

FIG. 34-1




FIG. 34-2




FIG. 35-1

```

+1 S L A V S L G Q R A T I S C R
496 TCC TTA GCT GTA TCT CTG GGG CAG AGG GCC ACC ATC TCA TGC AGG
    AGG AAT CGA CAT AGA GAC CCC GTC TCC CGG TGG TAG AGT ACG TCC

+1 A S K S V S T S G Y S Y M H W
541 GCC AGC AAA AGT GTC AGT ACA TCT GGC TAT AGT TAT ATG CAC TGG
    CCG TCG TTT TCA CAG TCA TGT AGA CCG ATA TCA ATA TAC GTG ACC

+1 Y Q Q K P G Q P P K L L I Y L
586 TAC CAA CAG AAA CCA GGA CAG CCA CCC AAA CTC CTC ATC TAT CTT
    ATG GTT GTC TTT GGT CCT GTC GGT GGG TTT GAG GAG TAG ATA GAA

+1 A S N L E S G V P A R F S G S
631 GCA TCC AAC CTA GAA TCT GGG GTC CCT GCC AGG TTC AGT GGC AGT
    CGT AGG TTG GAT CTT AGA CCC CAG GGA CGG TCC AAG TCA CCG TCA

+1 G S G T D F T L N I H P V E E
676 GGG TCT GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG
    CCC AGA CCC TGT CTG AAG TGG GAG TTG TAG GTA GGA CAC CTC CTC

+1 E D A A T Y Y C Q H S R E L P
721 GAG GAT GCT GCA ACC TAT TAC TGT CAG CAC AGT AGG GAG CTT CCT
    CTC CTA CGA CGT TGG ATA ATG ACA GTC GTG TCA TCC CTC GAA GGA

+1 R T F G G G T K L E I K R | Spacer
766 CGG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC AAA CGG | GGG GCC
    GCC TGC AAG CCA CCT CCG TGG TTC GAC CTT TAG TTT GCC | CGC CGG

+1 A | Myc-tag | Spacer
811 GCA | E Q K L I S E E D L N G | A A |
    CGT | CTT GTT TTT GAG TAG AGT CTT CTC CTA GAC TTA CCC | CGC CGT |

His tag
+1 H H H H H H *
856 CAT CAC CAT CAC CAT CAC TAA
    GTA GTG GTA GTG GTA GTG ATT

```

FIG. 35-2




FIG. 36

**FACTOR IX/FACTOR IXA ACTIVATING
ANTIBODIES AND ANTIBODY
DERIVATIVES**

The present invention relates to actor IX/factor IXa-antibodies and antibody derivatives.

Blood clots (thrombi) are formed by a series of zymogen activations referred to as the coagulation cascade. In the course of this enzymatic cascade, the activated form of each of such zymogens (referred to as factors) catalyzes the activation of the next one. Thrombi are deposits of blood components on the surface of a blood vessel wall and mainly consist of aggregated blood platelets and insoluble, cross-linked fibrin. Fibrin formation is effected by means of thrombin by limited proteolysis of fibrinogen. Thrombin is the final product of the coagulation cascade, (K. G. Mann, Blood, 1990, Vol. 76, pp. 1-16).

Activation of factor x by the complex of activated factor IX (FIXa) and activated factor VIII (FVIIIa) is a key step in coagulation. The absence of the components of this complex or a disturbance of their function is associated with the blood coagulation disorder called hemophilia (J. E. Sadler & E. W. Davie: Hemophilia A, Hemophilia B and von Willebrand's disease, in G. Stamatoyannopoulos et al. (Eds.): The molecular basis of blood diseases. W. B. Saunders Co., Philadelphia, 1987, pp. 576-602). Hemophilia A denotes a (functional) absence of factor VIII activity, while Hemophilia B is characterized by the absence of factor IX activity. At present, treatment of Hemophilia A is effected via a substitution therapy by administering factor VIII concentrates. However, approximately 20-30% of Hemophilia A patients develop factor VIII inhibitors (i.e. antibodies against factor VIII), whereby the effect of administered factor VIII preparations is inhibited. Treatment of factor VIII inhibitor patients is very difficult and involves risks, and so far there exist only a limited number of treatments for these patients.

In the case of patients having a low FVIII inhibitor level, it is possible, though expensive, to administer high doses of factor VIII to such patients and thus to neutralize the antibodies against factor VIII. The amount of factor VIII beyond that needed to neutralize the inhibitor antibodies then has hemostatic action. In many cases, desensitization can be effected, whereupon it is then possible again to apply standard factor VIII treatments. Such high dose factor VIII treatments require, however, large amounts of factor VIII, are time-consuming and may involve severe anaphylactic side reactions. Alternatively, the treatment may be carried out with porcine factor VIII molecules.

A further high-cost method involves removing factor VIII inhibitors through extra corporeal immunoadsorption on lectins which bind to immunoglobulins (protein A, protein G) or to immobilized factor VIII. Since the patient must be connected to an apheresis machine during this treatment, the treatment also constitutes a great burden on the patient. It is also not possible to treat an acute hemorrhage in this way.

At present, the therapy of choice is to administer activated prothrombin complex concentrates (APCC), such as FEIBA® and AUTOPLEX®, which are suitable for the treatment of acute hemorrhages even in patients having a high inhibitor titer (DE 31 27 318).

In the intravascular system of blood coagulation, the last step is the activation of factor X. This reaction is stimulated by the binding of factor VIIIa to factor IXa and the formation of a "tenase"-complex consisting of the factors IXa, VIIIa, X and phospholipid. Without the binding of FVIIIa, FIXa exhibits no or only a very slight enzymatic activity relative to FX.

Over the last several years, a number of possible binding sites for factor VIIIa to factor IXa have been characterized, and it has been shown that antibodies or peptides which bind to these regions inhibit the activity of FIXa (Fay et al., J. Biol. Chem., 1994, Vol. 269, pp. 20522-20527, Lenting et al., J. Biol. Chem., 1996, Vol. 271, pp. 1935-1940, Jorquera et al., Circulation, 1992, Vol. 86, Abstract 2725). The inhibition of coagulation factors, such as factor IX, has also been achieved through the use of monoclonal antibodies with the aim of preventing thrombosis formation (WO 97/26010).

The opposite effect, i.e. an increase in the factor IXa mediated activation of factor X, has been described by Liles D. K. et al., (Blood, 1997, Vol. 90, suppl. 1, 2054) through the binding of a factor VIII peptide (amino acids 698-712) to factor IX. Yet, this effect only occurs in the absence of factor VIIIa, while in the presence of factor VIIIa the factor IXa/factor VIIIa-mediated cleavage of factor X is inhibited by this peptide.

SUMMARY OF THE INVENTION

With a view to the possible risks and side effects which may occur in the treatment of hemophilia patients, there is a need for a therapy which allows for the effective treatment of FVIII inhibitor patients. Therefore, it is an object of the present invention to provide a preparation for the treatment of blood coagulation disorders which has particular advantages for factor VIII inhibitor patients.

According to the present invention, this object is achieved through the use of antibodies or antibody derivatives against factor IX/factor IXa which have factor VIIIa-cofactor activity or factor IXa-activating activity and lead to an increase in the procoagulant activity of factor IXa. Surprisingly, the action of these inventive factor IX/factor IXa-activating antibodies and antibody derivatives is not negatively affected by the presence of inhibitors, such as inhibitors against factor VIII/factor VIIIa, but instead the procoagulant activity of factor IXa in this case also is increased.

A further advantage of this invention is that the administration of the preparation according to the invention allows for rapid blood coagulation even in the absence of factor VIII or factor VIIIa, even in the case of FVIII inhibitor patients. Surprisingly, these agents are also effective in the presence of factor VIIIa.

The antibodies and antibody derivatives according to the present invention thus have a FVIII-cofactor-like activity which, in a FVIII assay (e.g. a COATEST® assay or Immunochrom test) after 2 hours of incubation exhibits a ratio of background (basic noise) to measured value of at least 3. Calculation of this ratio may, e.g., be effected according to the following scheme:

$$\frac{\text{Antibody measurement (OD 405) - blank value from reagent}}{\text{Mouse-IgG-measurement (OD 405) - blank value from reagent}} \geq 3$$

after two hours of incubation.

The antibodies according to the invention preferably have an in vivo half life of at least 5 days, more preferably at least 10 days, though it is more preferred to have a half life of at least 20 days.

A further aspect of this invention is a preparation comprising antibodies and/or antibody derivatives against factor IX/factor IXa and a pharmaceutically acceptable carrier substance. Furthermore, the preparation according to the invention may additionally comprise factor IX and/or factor IXa.

A further aspect of the invention is the use of the antibodies or antibody derivatives to increase the amidolytic activity of factor IXa.

FIG. 1 shows the results of a screening of supernatants from hybridoma cell cultures for FVIII-like activity. Pre-selected clones from fusion experiments, #193, #195 and #196, were tested in a chromogenic assay.

FIG. 2 shows the results of screening for IgG-mediated factor VIII-like activity in supernatants of a hybridoma cell culture of a master plate.

FIG. 3 shows the subcloning of clone 193/C0, namely the results of the first cloning round.

FIG. 4 shows a comparison of the chromogenic FVIII-like activity and factor IX-ELISA-reactivity of hybridoma cultures derived from the starting clone 193/C0.

FIG. 5 shows the results of the measurement of the chromogenic activity of some master clones and sub-clones.

FIG. 6A shows the FVIII-like activity of the anti-FIX/FIXa-antibodies 193/AD3 and 196/AF2 compared to human FVIII, TBS buffer and cell culture medium. After a lag phase, both antibodies gave rise to chromogenic substrate cleavage, as judged by the increasing optical density.

FIG. 6B shows a comparison of the chromogenic activity of factor VIII, 196/AF1, 198/AC1/1 and mouse-IgG.

FIG. 7A shows a comparison of the kinetics of Factor Xa generation by Factor VIII and 196/AF2 with and without the addition of a Factor Xa specific inhibitor.

FIG. 7B shows a comparison of the kinetics of the Factor Xa generation by Factor VIII, mouse-IgG and anti-factor IX/IXa-antibody 198/AM1 with and without the addition of a factor Xa-specific inhibitor, Pefabloc Xa®.

FIG. 8A shows a measurement of the dependence of the factor VIII-like activity of purified anti-factor IX/IXa-antibody 198/AC1/1 in the presence and absence of phospholipids, FIXa/FX and calcium ions.

FIG. 8B shows a measurement of the dependence of FXa generation by anti-FIXa-antibody 196/AF1 in the presence of phospholipids, Ca²⁺ in FIXa/FX.

FIG. 8C shows the generation of FXa by unspecific mouse IgG antibody.

FIG. 9 is a graphical representation of the coagulation times of Factor VIII-deficient plasma in an APTT assay by using various concentrations of anti-factor IX/IXa-antibody 193/AD3.

FIG. 10A shows that in the presence of Factor IXa, antibody 193/AD3 leads to a reduction in the coagulation time of factor VIII-deficient plasma.

FIG. 10B shows a dose-dependent reduction of the clotting time by antibody 193/AD3 in the presence of factor IXa- and factor VIII-inhibitors.

FIG. 11 shows the chromogenic activity of antibodies 198/A1, 198/B1 and 198/AP1 in the presence and absence of human FIXaβ.

FIG. 12 shows the primer sequences (SEQ ID NOS:50-61) for the amplification of the genes of the variable heavy chain of mouse antibody.

FIG. 13 shows the primer sequences (SEQ ID NOS:65-78) for the amplification of the genes of the variable light (kappa) chain of the mouse antibody.

FIG. 14 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 193/AD3 (SEQ.ID.NOS. 81 and 82).

FIG. 15 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 193/K2 (SEQ.ID.NOS. 83 and 84).

FIG. 16 shows the DNA and derived protein sequence of the scFv from hybridoma cell line 198/AB2 (subclone of 198/B1) (SEQ.ID.NOS. 85 and 86).

FIG. 17 shows the DNA and deduced protein sequence of scFv derived from the cell line 198/A1 (SEQ.ID.NOS. 87 and 88).

FIG. 18 demonstrates the chromogenic FVIII-like activity of peptide A1/3 in the presence of 2.9 nM human FIXa. The scrambled version of peptide A1/3, peptide A1/5 does not give rise to any FXa generation.

FIG. 19 demonstrates the dependence of the chromogenic FVIII-like activity of peptide A1/3 on the presence of human FIXa. In the absence of human FIXa, peptide A1/3 does not give rise to any FXa generation. The buffer control, plain imidazole buffer is designated IZ.

FIG. 20 shows that the chirality of Arg-residues does not play a significant role for the chromogenic activity of peptides A1/3-rd and A1/3-Rd-srmb.

FIG. 21 shows that the addition of 2.4 μM peptide B1/7 to the reaction mixture led to a measureable generation of FXa.

FIG. 22 shows that the addition of a FX-specific inhibitor results in a significant reduction in the reaction. If there was no FIXa and FX is added to the reaction mixture, no FXa was synthesized.

FIG. 23 shows vector pBax-IgG1.

FIG. 24 shows the increase of the amidolytic activity of FIXa in the presence of antibody 198/B1 (FIG. 24A) and IgM antibody 198/AF1 (FIG. 24B).

FIG. 25 demonstrates the chromogenic FVIII-like activity of the antibody 198/A1 Fab fragment in the presence of 2.3 nM human FIXa. As a positive control the intact antibody 198/A1 was used as well as 7.5 pM FVIII. The buffer control (IZ) was used as a negative control.

FIG. 26 shows the nucleotide and amino acid sequence of the 198AB2 scFv-alkaline phosphatase fusion protein (ORF of the expression vector pDAP2-198AB2#100, (SEQ.ID.NOS. 89 and 90).

The genes for the VL and the VH domains of antibody 198/AB2 (198/AB2 is an identical subclone of 198/B1) were derived from the corresponding hybridoma cells as described in example 10. The PCR product of the VH-gene was digested SfiI-AscI and the PCR-product of the VL-gene was digested AscI and NotI. VH and VL genes were linked via the AscI site and inserted into SfiI-NotI digested vector pDAP2 (Kerschbaumer R. J. et al, Immuno-technology 2, 145-150, 1996; GeneBank accession No.:U35316). PelB leader: leader sequence of *Erwinia carotovora* Pectate Lyase B, His tag, Histidine tag for metal ion chromatography.

FIG. 27 demonstrates the chromogenic FVIII-like activity of two antibody 198/B1 (subclone AB2) scFv fragment-alkaline phosphatase fusion proteins (198AB2#1 and 198AB2#100) in the presence of 2.3 nM human FIXa. As a positive control 7.5 pM FVIII was used.

FIG. 28 shows the amino acid and nucleotide sequence of pZip198AB2#102 (SEQ.ID.NOS. 91 and 92).

FIG. 29 shows the nucleotide and amino acid sequence of the mAB#8860 scFv-alkaline phosphatase fusion protein (vector pDAP2-8860scFv#11, (SEQ.ID.NOS. 93 and 94). The genes for the VT and the VH domains of antibody #8860 were derived from the corresponding hybridoma cells as described in example 10. The PCR product of the VH-gene was digested SfiI-AscI and the PCR-product of the VL-gene was digested AscI and NotI. VH and VL genes were linked via the AscI site and inserted into SfiI-NotI digested vector pDAP2 (Kerschbaumer R. J. et al, Immuno-technology 2, 145-150, 1996; GeneBank accession No.:U35316).

FIG. 30 shows the nucleotide and amino acid sequence of the mAB #8860 scFv-leucine zipper fusion protein

5

(miniantibody; vector p8860-Zip#1.2, (SEQ.ID.NOs. 95 and 96). The gene of the scFv fragment was derived from mAB #8860 and was swapped from vector pDAP2-8860scFv#11 into SfiI-NotI digested plasmid pZip1 (Kerschbaumer R. J. et al., *Analytical Biochemistry* 249, 219–227, 1997; GeneBank accession No.: U94951)

FIG. 31 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) miniantibody 198AB-Zip#102 in the presence of 2.3 nM human FIXa. As a positive control 4.5 pM FVIII was used whereas a unrelated miniantibody (8860-Zip#1.2) and plain reaction buffer (IZ) served as negative controls.

FIG. 32 shows a schematic representation of the plasmid pMycHis6 (SEQ ID NOS:107–110).

FIG. 33 shows the nucleotide and amino acid sequence of the part of the plasmid pMycHis6 differing from vector pCOCK (SEQ.ID.Nos. 97 and 98). Vector pMycHis6 was constructed by cleaving vector pCOCK (Engelhardt et al., 1994, *Biotechniques*, 17: 44–46) with NotI and EcoRI and insertion of the oligonucleotides: mychis6-co: 5'ggcgcga-gaacaanaactcatctcagaagaggatct gaatggggcggcaccatcac-cacatcataataag 3' (SEQ ID.No. 79) and mychis-ic: 5' aattct-tattagtgtgggtgtaggtgatgtgcccgcattcagatcctctctt gagatgagttttgtctgc (SEQ.ID.No. 80).

FIG. 34 shows the nucleotide and amino acid sequence of 198AB2 scFv (linked to the c-myc-tag and the His6tag): ORF of the expression vector pMycHis6-198AB2#102. Vector pMycHis6 was constructed by cleaving vector pCOCK (Engelhardt O. et al, *BioTechniques* 17, 44–46, 1994) NotI-EcoRI and inserting the following annealed oligonucleotides: (5'-GGCCGCAGAACAAAACTCATCTCAGAA GAGGATCTGAATGGGGCGGCACATCA CCATCACCATCACTAATAAG-3' (SEQ.ID.No. 103) and 5'-TTATTAGTGATGGTGATGGT GATGTGCC GCCCATTCAGATCCTCTTCTGAGATGAGTTTTTG TTCTGC-3'(SEQ.ID.NO. 104)). The resultant vector, named pMycHis6, was cleaved SfiI-NotI and the gene of scFv 198AB2 was swapped into this vector from vector pDAP2-198AB2#100.

FIG. 35 shows the nucleotide and amino acid sequence of the mAB #8860 scFv linked to the c-myc-tag and the His6-tag (vector p8860-M/H#4c, SEQ.ID.NOs. 101 and 102). Plasmid pMycHis6 was cleaved with SfiI and NotI and the DNA sequence coding for the scFv 8860#11 protein was inserted from pDAP2-8860scFv#11 (see FIG. 29) yielding plasmid p8860-M/H#4c.

FIG. 36 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) scFv fragment (MycHis-198AB2#102) in the presence of 2.3 nM human FIXa. As a positive control 4.8 pM FVIII was used whereas a unrelated scFv (8860-M/H#4c) and plain reaction buffer (IZ) served as negative controls.

Antibodies and Antibody Derivatives

The present invention also comprises the nucleic acids encoding the inventive antibodies and antibody derivatives, expression vectors, hybridoma cell lines, and methods for producing the same.

Antibodies are immunoglobulin molecules having a specific amino acid sequence which only bind to antigens that induce their synthesis (or its immunogen, respectively) or to antigens (or immunogens) which are very similar to the former. Each immunoglobulin molecule consists of two types of polypeptide chains. Each molecule consists of large, identical heavy chains (H chains) and two light, also identical chains (L chains). The polypeptides are connected by disulfide bridges and non-covalent bonds. In vivo, the heavy and light chains are formed on different ribosomes, assembled in the cell, and secreted as intact immunoglobulins (Roitt I. et al., in: *Immunology*, second ed., 1989).

6

The inventive antibodies and antibody derivatives and organic compounds derived there from comprise human and animal monoclonal antibodies or fragments thereof, single chain antibodies and fragments thereof and miniantibodies, bispecific antibodies, diabodies, triabodies, or di-, oligo- or multimers thereof. Also included are peptidomimetics or peptides derived from the antibodies according to the invention, e.g. they comprise one or several CDR regions, preferably the CDR3 region.

Further included are human monoclonal antibodies and peptide sequences which, based on a structure activity connection, are produced through an artificial modeling process (Greer J. et al., *J. Med. Chem.*, 1994, Vol. 37, pp. 1035–1054).

The term factor IX/IXa activating antibodies and antibody derivatives may also include proteins produced by expression of an altered, immunoglobulin-encoding region in a host cell, e.g. “technically modified antibodies” such as synthetic antibodies, chimeric or humanized antibodies, or mixtures thereof, or antibody fragments which partially or completely lack the constant region, e.g. Fv, Fab, Fab' or F(ab)₂ etc. In these technically modified antibodies, e.g., a part or parts of the light and/or heavy chain may be substituted. Such molecules may, e.g., comprise antibodies consisting of a humanized heavy chain and an unmodified light chain (or chimeric light chain), or vice versa. The terms Fv, Fc, Fd, Fab, Fab' or F(ab)₂ are used as described in the prior art (Harlow E. and Lane D., in “Antibodies, A Laboratory Manual”, Cold Spring Harbor Laboratory, 1988).

The present invention also comprises the use of Fab fragments or F(ab)₂ fragments which are derived from monoclonal antibodies (mAb), which are directed against factor IX/factor IXa and cause an increase of the procoagulant activity of factor IXa.

Preferably, the heterologous framework regions and constant regions are selected from the human immunoglobulin classes and isotypes, such as IgG (subtypes 1 to 4), IgM, IgA and IgE. In the course of the immune response, a class switch of the immuno-globulins may occur, e.g. a switch from IgM to IgG; therein, the constant regions are exchanged, e.g. from p to y. A class switch may also be caused in a directed manner by means of genetic engineering methods (“directed class switch recombination”), as is known from the prior art (Esser C. and Radbruch A., *Annu. Rev. Immunol.*, 1990, Vol. 8, pp. 717–735). However, the antibodies and antibody derivatives according to the present invention need not comprise exclusively human sequences of the immunoglobulin proteins.

In one particular embodiment, a humanized antibody comprises complement determining regions (CDRs) from murine monoclonal antibodies which are inserted in the framework regions of selected human antibody sequences. However, human CDR regions can also be used. Preferably, the variable regions in the human light and heavy chains are technically altered by one or more CDR exchanges. It is also possible to use all six CDRs or varying combinations of less than six CDRs.

The humanized antibody according to the present invention preferably has the structure of a human antibody or of a fragment thereof and comprises the combination of characteristics necessary for a therapeutic application, e.g., the treatment of coagulation disorders in patients, preferably factor VIII inhibitor patients.

A chimeric antibody differs from a humanized antibody in that it comprises the entire variable regions including the framework regions of the heavy and light chains of non-human origin in combination with the constant regions of

both chains from human immuno-globulin. A chimeric antibody consisting of murine and human sequences may, for example, be produced. According to the present invention, the antibodies and antibody derivatives may also be single chain antibodies or miniantibodies (scFv fragments, which, e.g., are linked to proline-rich sequences and oligomerisation domains, e.g. Pluckthun A. and Pack P., *Immunotechnology*, 1997, Vol. 3, pp. 83–105) or single chain Fv (sFv) which incorporate the entire antibody binding region in one single polypeptide chain. For instance, single chain antibodies may be formed by linking the V-genes to an oligonucleotide which has been constructed as a linker sequence and connects the C terminus of the first V region with the N terminus of the second V region, e.g. in the arrangement VH-Linker-VL or VL-Linker-V_H; both, V_H and V_L thus may represent the N-terminal domain (Huston JS et al., *Int. Rev. Immunol.*, 1993, Vol. 10, pp. 195–217; Raag R. and Whitlow M., *FASEB J.*, 1995, Vol. 9, pp. 73–80). The protein which can be used as linker sequence may, e.g., have a length of up to 150 Å, preferably up to 80 Å, and more preferably up to 40 Å. Linker sequences containing glycine and serine are particularly preferred for their flexibility, or glutamine and lysine, respectively, for their solubility. The choice of the amino acid is effected according to the criteria of immunogenicity and stability, also depending on whether or not these single chain antibodies are to be suitable for physiological or industrial applications (e.g. immunoaffinity chromatography). The single chain antibodies may also be present as aggregates, e.g. as trimers, oligomers or multimers. The linker sequence may, however, also be missing, and the connection of the V_H and V_L chains may occur directly.

Bispecific antibodies are macromolecular, heterobifunctional cross-linkers having two different binding specificities within one single molecule. In this group belong, e.g., bispecific (bs) IgGs, bs IgM-IgAs, bs IgA-dimers, bs (Fab')₂, bs(scFv)₂, diabodies, and bs bis Fab Fc (Cao Y. and Suresh M. R., *Bioconjugate Chem.*, 1998, Vol. 9, pp. 635–644).

By peptidomimetics, protein components of low molecular weight are understood which imitate the structure of a natural peptide component, or of templates which induce a specific structure formation in an adjacent peptide sequence (Kemp DS, *Trends Biotechnol.*, 1990, pp. 249–255). The peptidomimetics may, e.g., be derived from the CDR3 domains. Methodical mutational analysis of a given peptide sequence, i.e. by alanine or glutamic acid scanning mutational analysis, allows for the identification of peptide residues critical for procoagulant activity. Another possibility to improve the activity of a certain peptide sequence is the use of peptide libraries combined with high throughput screening.

The term antibodies and antibody derivatives may also comprise agents which have been obtained by analysis of data relating to structure-activity relationships. These compounds may also be used as peptidomimetics (Grassy G. et al., *Nature Biotechnol.*, 1998, Vol. 16, pp. 748–752; Greer J. et al., *J. Med. Chem.*, 1994, Vol. 37, pp. 1035–1054).

Examples of hybridoma cells expressing the antibodies or antibody derivatives according to the invention were deposited on 9 Sep. 1999 under the numbers 99090924 (#198/A1), 99090925 (#198/B1) and 99090926 (#198/BB1) and on Dec. 16, 1999 under the numbers 99121614 (#193/A0), 99121615 (#196/c4), 99121616 (#198/D1), 99121617 (198/T2), 99121618 (#198/G2), 99121619 (#198/AC1) and 99121620 (#198/U2) according to the Budapest Treaty.

Methods of Production:

The antibodies of the present invention can be prepared by methods known from the prior art, e.g. by conventional

hybridoma techniques, or by means of phage display gene libraries, immunoglobulin chain shuffling or humanizing techniques (Harlow E. and Lane D., in: *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988).

The production of the inventive antibodies and antibody derivatives may, for instance, be made by conventional hybridoma techniques (*Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, Eds. Harlow and Lane, pp. 148–242). According to the present invention, human and also non-human species may be employed therefor, such as cattle, pigs, monkeys, chickens and rodents (mice, rats). Normal, immunocompetent Balb/c mice or FIX-deficient mice may, e.g., be used (factor IX-deficient mice may be obtained from Dr. Darrel Stafford from the University of North Carolina, Chapel Hill). Immunization may, e.g., be effected with factor IX, factor IXα or completely activated factor IXαβ, or with fragments thereof.

The hybridomas are selected with a view to the fact that the antibodies and antibody derivatives in the supernatants of the hybridoma cells bind to factor IX/factor IXα and cause an increase of the procoagulant activity of factor IXα. The increase in the procoagulant activity may, e.g., be proven by assaying methods as known from the prior art for the measurement of factor VIII-like activity, e.g. chromogenic assays.

Alternatively, the antibodies and antibody derivatives of the invention may also be produced by recombinant production methods. In doing so, the DNA sequence of the antibodies according to the invention can be determined by known techniques, and the entire antibody DNA or parts thereof can be expressed in suitable systems. Recombinant production methods can be used, such as those involving phage display, synthetic and natural libraries, expression of the antibody proteins in known expression systems, or expression in transgenic animals (Jones et al., *Nature*, 19B6, Vol. 321, pp. 522–525; *Phage Display of Peptides and Proteins, A Laboratory Manual*, 1996, Eds. Kay et al., pp. 127–139; U.S. Pat. No. 4,873,316; Vaughan T. J. et al., *Nature Biotechnology*, 1998, pp. 535–539; Persic L. et al., *Gene*, 1997, pp. 9–18; Ames R. S. et al., *J.Immunol.Methods*, 1995, pp. 177–186).

The expression of recombinantly produced antibodies may be effected by means of conventional expression vectors, such as bacterial vectors, such as pBr322 and its derivatives, pSKF or eukaryotic vectors, such as pMSG and SV40 vectors. Those sequences which encode the antibody may be provided with regulatory sequences which regulate the replication, expression and secretion from the host cell. These regulatory sequences comprise promoters, e.g. CMV or SV40, and signal sequences.

The expression vectors may also comprise selection and amplification markers, such as the dihydrofolate reductase gene (DHFR), hygromycin-B phosphotransferase, thymidine-kinase etc.

The components of the vectors used, such as selection markers, replicons, enhancers etc., may either be commercially obtained or prepared by means of conventional methods. The vectors may be constructed for the expression in various cell cultures, e.g. for mammalian cells such as CHO, COS, fibroblasts, insect cells, yeast or bacteria, such as *E. coli*. Preferably, those cells are used which allow for an optimal glycosylation of the expressed protein. Particularly preferred is the vector pBax (cf. FIG. 17) which is expressed in CHO cells or in SK-Hep.

The production of Fab fragments or F(ab)₂ fragments may be effected according to methods known from the prior art, e.g. by cleaving a mAb with proteolytic enzymes, such as

papain and/or pepsin, or by recombinant methods. These Fab and F(ab)₂ fragments may also be prepared by means of a phage display gene library (Winter et al., 1994, *Ann. Rev. Immunol.*, 12: 433–455).

The antibody derivatives may also be prepared by means of methods known from the prior art, e.g. by molecular modeling, e.g. from Grassy G. et al., *Nature Biotechnol.*, 1998, Vol. 16, pp. 748–752, or Greer J. et al., *J. Med. Chem.*, Vol. 37, pp. 1035–1054, or Rees A. et al., in: “Protein Structure Prediction: A practical approach”, ed. Sternberg M. J. E., IRL press, 1996, chapt. 7–10, pp. 141–261.

The purification of the inventive antibodies and antibody derivatives may also be carried out by methods described in the prior art, e.g., by ammonium sulfate precipitation, affinity purification (protein G-Sepharose), ion exchange chromatography, or gel chromatography. The following methods may be used as the test methods to show that the antibodies and antibody derivatives of the present invention bind to factor IX/factor IXa, increase the procoagulant activity of factor IXa or have factor VIII-like activity: the one step coagulation test (Mikaelsson and Oswaldson, *Scand. J. Haematol., Suppl.*, 33, pp. 79–86, 1984) or the chromogenic tests, such as COATEST VIII:C® (Chromogenix) or Immunochrom (IMMUNO). In principle, all the methods used for determining factor VIII activity may be used. As the control blank value for the measurements, e.g., unspecific mouse-IgG antibody may be used.

The present antibodies and antibody derivatives are suitable for therapeutic use in the treatment of coagulation disorders, e.g. in the case of hemophilia A, for factor VIII inhibitor patients etc. Administration may be effected by any method suitable to effectively administer the therapeutic agent to the patient, e.g. by oral, subcutaneous, intramuscular, intravenous or intranasal administration.

Therapeutic agents according to the invention may be produced as preparations which comprise a sufficient amount of antibodies or of antibody derivatives as the active agent in a pharmaceutically acceptable carrier substance. These agents may be present either in liquid or in powdered form. Moreover, the preparations according to the invention may also comprise mixtures of different antibodies, the derivatives thereof and/or organic compounds derived therefrom, as well as mixtures consisting of antibodies and factor Ix and/or factor IXa. Factor IXa may be present as factor IXa α and/or factor IXa β . An example of an aqueous carrier substance is, e.g., saline. The solutions are sterile, sterilisation being effected by conventional methods.

The antibodies or antibody derivatives according to the invention may be present in lyophilized form for storage and be suspended in a suitable solvent before administration. This method has proven generally advantageous for conventional immunoglobulins, and known lyophilisation and reconstitution methods may be applied in this case.

Moreover, the antibodies and antibody derivatives according to the invention may also be used for industrial applications, e.g. for the purification of factor IX/factor IXa by means of affinity chromatography, or as a component of detection methods (e.g. ELISA assays), or as an agent for identification of and interaction with functional domains of a target protein.

The present invention will be described in more detail by way of the following examples and drawing figures, to which, however, it shall not be restricted.

EXAMPLES

Example 1

Immunization of Immunocompetent Mice and Generation of Anti-FIX/IXa Antibody Secreting Hybridoma Cells

Groups of 1–3 normal immunocompetent 5–8 week old Balb/c mice were immunized with 100 μ g antigen (100 μ l

doses) via the intraperitoneal (i.p.) route. In a typical experiment, mice were inoculated with either recombinant human coagulation factor (F) IX (Benefix™), human activated FIXa α (Enzyme Research Laboratories, Lot: FIXa α 1190L) or human FIXa β (Enzyme Research Laboratories, Lot: HFIXAa β 1332 AL,) adjuvanted with Al(OH)₃ or KFA.

Individual mice were boosted at various times with 100 μ g antigen (10011 doses, i.p) and sacrificed two days later. Spleen cells were removed and fused to P3 \times 63-Ag8 6.5.3 myeloma cells essentially as described by Lane et al., 1985 (*J. Immunol. Methods*, Vol. 81, pp. 223–228). Each fusion experiment was individually numbered, i.e. #193, 195, 196 or 198.

Hybridoma cells were grown in 96 well plates on a macrophage feeder layer (app. 10⁵ cells/ml) and selected in HAT-medium (RPMI-1640 medium supplemented with antibiotics, 10% FCS, Na-pyruvate, L-glutamine, 2-mercaptoethanol and HAT (HAT 100x: 1.0 \times 10⁻²M hypoxanthine in H₂O (136.1 mg/100 ml H₂O), 4.0 \times 10⁻⁵M aminopterin in H₂O (1.76 mg/100 ml H₂O) and 1.6 \times 10⁻³M thymidine in H₂O (38.7 mg/100 ml H₂O). Medium was first changed after 6 days and thereafter twice a week. After 2–3 weeks HAT-medium was changed to HT-medium (RPMI-1640 supplemented with antibiotics, 10% FCS, Na-pyruvate, L-glutamine, 2-mercaptoethanol and HT) and later on (after additional 1–2 weeks) to normal growth medium (RPMI-1640 medium supplemented with 10% FCS, Na-pyruvate, L-glutamine and 2-mercaptoethanol) (see: HYBRIDOMA TECHNIQUES, EMBO, SKMB Course 1980, Base1).

In another set of experiments FIX deficient C57B16 mice (Lin et al., 1997, *Blood*, 90: 3962) were used for immunization and subsequent hybridoma production. Since FIX knockout (k.o.) mice do not express endogenous FIX, the anti (a)-FIX antibody spectrum achievable is supposed to be different compared to normal Balb/c mice (due to lack of tolerance).

Example 2

Assaying for FVIII-like Activity in Supernatants of Anti-Fix/FIXa Antibody Secreting Hybridoma Cells

In order to assay the FVIII-like activity of anti-FIXa antibodies secreted by hybridoma cells, the commercially available test-kit COATEST VIII:C/4® (Chromogenix) was employed. The assay was done essentially as described by the manufacturer with the following modifications:

To allow high throughput screening, the assay was down-scaled to microtiter plate format. Briefly, 25 μ l aliquots of hybridoma supernatants were transferred to microtiter plate (Costar, #3598) wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (1–2581), factor (F) IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Per reaction, 50 μ l of the phospholipid/FIXa/FX solution were combined with 25 μ l CaCl₂ (25 mM) and 50 μ l of the substrate/inhibitor cocktail. To start the reaction, 125 μ l of the premix were added to the hybridoma supernatant in the microtiter plates and incubated at 37° C. Absorbency at 405 nm and 490 nm of the samples was read at various times (30 min to 12 h) against a reagent blank (MLW, cell culture medium instead of hybridoma supernatant) in a Labsystems iEMS Reader MF™ microtiter plate reader. FVIII-like activity of the samples was calculated by comparing the absorbency of the samples against the absorbency of a diluted FVIII reference standard (IMMUNO AG # 5T4AR00) using GENESIS™ software.

The results of a screening for FVIII-like activity in hybridoma cell culture supernatants are shown in FIG. 1. Pre-selected clones derived from fusion experiments #193, #195 and #196 (see above) were examined in a chromogenic FVIII assay as described. Clones 193/M1, 193/N1 and 193/P1 are subclones derived from the master clone 193/C0 (see below). Master clone 195/10 was derived from fusion experiment #195 and clones 196/A0, 196/B0 and 196/C0 were derived from fusion experiment #196. In a typical screening experiment, approximately 1000 clones (in 96 wells) from a single fusion experiment were pre-screened for FVIII-like activity. Subsequently, selected clones were grown on a larger scale (3–5 ml supernatant) and re-analyzed in a chromogenic assay. As a negative control cell culture medium was assayed on each plate (MLW).

Wells either exhibiting high FVIII-like activity or substantial FVIII-like activity were subjected to subcloning procedures. The selection and subcloning process is exemplified for the screening and subcloning of an IgG producing cell line (i.e. 193/C0) but has been done exactly the same way for an IgM (i.e. 196/C0, see below, FIG. 5) producing clone.

The selection process was done by initially plating all hybridoma cell clones derived from a single fusion experiment on ten 96 well plates thereby creating the so called "master plates". Singular positions (wells) on a master plate usually contained more than one hybridoma cell clone (usually 3 to 15 different clones). Subsequently, the antibody secreted by only several thousand cells was tested. These cells grew under conditions suboptimal for antibody production, which is known to be best in dying cells. So the expected specific anti-FIX antibody concentration in the supernatant may be in the range of 10–12 to 10–14 M. This explains why incubation periods had to be extended compared to standard FVIII assays.

Results of a screening for an IgG mediated FVIII-like activity in hybridoma cell culture supernatants of a master plate are shown in FIG. 2. Supernatants were examined in a chromogenic FVIII assay. Shown are the results derived from the fifth master plate of fusion experiment number #193 (Balb/c mice immunized with FIX α). Absorbance was read after 4 hours of incubation at 37° C. Position ES was identified as exhibiting FVIII like activity significantly higher than the blank (MLW). This cell pool was designated 193/C0 and was further subcloned (FIG. 3). As each well of the master plate contains more than one hybridoma cell clone, cells of a single positive well were expanded and plated at a calculated cell density of 2–0.2 cells/well on a 96 well plate. Again, the supernatants were tested for FVIII-like activity and positive positions were subjected to another round of subcloning. Typically three to four rounds of subcloning were performed with each clone displaying FVIII-like activity to obtain homogenous cell populations. Here the results of the chromogenic assay of the 193/C0 subclones are shown. Absorbance was read after a 4 hour incubation period at 37° C. Positions A6 and D5 exhibited substantial FVIII-like activity and were named 193/M1 and 193/P1, respectively. These two clones were subjected to another round of subcloning. As a negative control plain cell culture medium was assayed on each plate (MLW(H1)).

A comparison of chromogenic FVIII-like activity and FIX-ELISA reactivity of small scale (3 ml) hybridoma cultures is shown in FIG. 4. Before a decision was made whether a master clone (or subclone) was to be further subcloned, clones were grown at a 3–5 ml scale and the supernatants were checked again. This graph shows the FIX specific ELISA results and the FVIII-like chromogenic

activity of the master clone 193/C0 and all its subclones which were identified as positives and re-checked. Blanks (absorbency of the chromogenic reagent itself) were subtracted in the case of the ELISA as well as the chromogenic assay readings depicted here. Clone 193/M1 was subcloned and yielded clones 193/V2, 193/M2 and 193/U2. The other clones of the 2nd round came from 193/P1, 193/AB2 and 193/P2 were subcloned. 193/AF3, 193/AB3 and 193/AE3 are subclones of 193/AB2. The other clones of the 3rd round came from 193/P2. Finally 193/AF3 (\rightarrow 193/AF4), AE3 (\rightarrow 193/AE4, 193/AL4, 193/AN4 and 193/AO4) and 193/AD3 (\rightarrow 193/AG4, 193/AH4, 193/AD4, 193/AI4, 193/AK4) were subcloned.

From each fusion experiment, several (5–15) master clones (selected from the master plate) were identified and subjected to subcloning. After 3 rounds of sub-cloning, most of the cell lines were homogenous as demonstrated by ELISA and chromogenic activity analysis (see FIG. 4) as well as by cDNA sequence analysis. A specific master clone and all its subclones produce the same FIX/FIXa binding antibody. However, there are huge differences in the antibody protein sequences of clones derived from different master clones (see Example 11). Most hybridoma cell lines express antibodies from the IgG subclass (i.e. clones #193, #198, like 198/A1, 198/B1, 198/BB1). However, we were also able to select some clones expressing IgM antibodies.

The chromogenic activity of hybridoma supernatant of some important master clones and subclones was determined. Absorbance was measured after a 1 h 30 min and 3 h 30 min incubation period at 37° C. (FIG. 5). In contrast to all the clones from the 193rd fusion, clone 196/C0 and its subclone 196/AP2 produced a FIX/FIXa-specific IgM antibody that gave a strong chromogenic activity even after a short period of incubation.

The following cell lines have been deposited with the European Collection of Cell Cultures (ECACC) in accordance with the Budapest Treaty: 198/B1 (ECACC No. 99090925, deposited Sep. 9, 1999); 198/A1 (ECACC No. 99090924, deposited Sep. 9, 1999); 198/BB1 (ECACC No. 99090926, deposited Dec. 16, 1999); 193/AO (ECACC No. 99121614, deposited Dec. 16, 1999); 196/C4 (ECACC No. 99121615, deposited Dec. 16, 1999); 198/DI (ECACC No. 99121616, deposited Dec. 16, 1999); 198/T2 (ECACC No. 99121617, deposited Dec. 16, 1999); 198/G2 (ECACC No. 99121618, deposited Dec. 16, 1999); 198/AC1 (ECACC No. 99121619, deposited Dec. 16, 1999); and 198/U2 (ECACC No. 99121620, deposited Dec. 16, 1999). The address of the ECACC is Salisbury, Wiltshire SP4 0JG, UK.

To do a more in depth analysis of the biochemical properties of certain antibodies, homogenous hybridoma cell lines expressing different antibodies with FVIII-like activity were expanded and used to express the antibody in question on a larger scale (100–1000 ml). These antibodies were affinity purified (see Example 3) prior to being used in further experiments.

Example 3

Factor IX/FIX $_{(\alpha,\beta)}$ Binding Properties of Antibodies Exhibiting FIX/FIXa Activating Activity

Factor IX and the two activated forms of FIX, FIX α and FIX β (FIX/FIX $_{(\alpha,\beta)}$) were diluted in TBS (25 mM Tris HCl, 150 mM NaCl, pH 7.5) to a final concentration of 2 μ g/ml. Nunc Maxisorp ELISA plates were coated with 100 μ l FIX/FIX $_{(\alpha,\beta)}$ solution according to standard procedures (4° C., overnight) and washed several times with TBST

13

(TBS, 0.1% (v/v) Tween 20). 50 μ l hybridoma supernatant was diluted 1:1 with 50 μ l TBST/2% BSA and added to the coated ELISA plate. After an incubation period of 2 h at room temperature (RT), plates were washed 4 times with TBST and incubated (2 h, RT) with 100 μ l/well of a 1:25000 dilution (in TBST/1% BSA) of an anti-mouse IgG (Fc-specific) peroxidase conjugated antibody (Sigma, #A-0168). Wells were washed 5 times with TBST and finally stained with 100 μ l freshly prepared staining solution (10 ml 50M sodium citrate, pH 5 supplemented with 100 μ l OPD (60 mg OPD/ml) and 10 μ l 30% H₂O₂). The reaction was stopped by the addition of 50 ml H₂SO₄ and the optical density recorded at 492 nm and 620 nm in a Labsystems iEMS Reader MF™ microtiter plate reader employing GENESIS™ software.

In certain cases, instead of an anti-mouse IgG ELISA, an anti-mouse IgM ELISA was carried out.

Purification of Mouse-IgG from Hybridoma Cell Culture Supernatants

Hybridoma supernatant (100–500 ml) was supplemented with 200 mM Tris/HCl buffer (pH 7.0) and solid NaCl to give final concentrations of 20 mM Tris and 3M NaCl, respectively. The supernatant was then clarified by centrifugation at 5500 \times g for 10 minutes. A 1 ml protein G affinity chromatography column (Protein G Sepharose Fast Flow, Amersham-Pharmacia) was washed with 15 ml 20 mM Tris/Cl pH 7.0 and afterwards equilibrated with 10 ml of 20 mM Tris/Cl buffer pH 7.0 containing 3M NaCl. The hybridoma supernatant containing 3M NaCl was then loaded onto the column by gravity. The column was washed with 15 ml of 20 mM Tris/Cl buffer, pH 7.0, containing 3M NaCl. Bound IgG was further eluted with 12 ml glycine/HCl buffer pH 2.8 and 1 ml fractions were collected. 100 μ l of 1M Tris pH 9.0 were added to each fraction for neutralization. Fractions containing the IgG were identified by mixing 50 \times 1 with 150 μ l of a staining solution (BioRad concentrate, 1:5 diluted with water) in wells of a microplate. Positive fractions were pooled, concentrated to 1 ml in an ultrafiltration concentrator device (Centricon Plus 20, Amicon) according to the manufacturer. The concentrate was diluted with 19 ml TBS (20 mM Tris/Cl buffer pH 7.0 containing 150 mM NaCl) and again concentrated to 1 ml. The diluting-concentrating step was repeated for two more times in order to bring IgG into TBS.

Purification of Mouse-IgM from Hybridoma Cell Supernatants

100–500 ml of hybridoma cell culture supernatant were concentrated to 5–10 ml either with an ultra-filtration concentrator device (Centricon Plus 20, Amicon) according to the manufacturer or by ammonium sulfate precipitation (40% saturation, 0° C.) and redissolving the precipitate with 5–10 ml of TBS. In either case the concentrate was dialyzed against 20 mM Tris Cl buffer pH 7.4 containing 1.25M NaCl and further concentrated to 1 ml in a Centricon Plus 20, (Amicon) ultrafiltration device. IgM was purified from this concentrate with the Immunopure IgM Purification Kit (Pierce) according to the manufacturer. Fractions collected during elution from the maltose binding protein-column were tested for IgM, pooled, concentrated and brought into TBS as described for IgG.

Determination of IgG Concentrations in Purified Preparations

Total IgG content 280 nm–extinction of appropriate dilutions were measured. E280=1.4 corresponds to 1 mg/ml protein.

Factor IXa Specific IgG (Quantitative ELISA)

Wells of a microplate (Nunc Maxisorp) were incubated with 2 μ g/ml factor IXa diluted in TBS (25 mM Tris/HCl pH

14

7.5 containing 150 mM NaCl) overnight at 4° C. Wells were washed four times with TBST (25 mM Tris/HCl pH 7.5 containing 150 mM NaCl and 0.1% (v/v) Tween 20). As a standard monoclonal AB the HIX1 anti-FIX (accurate) was used. Standard and samples were diluted in TBST containing 2%(w/v) BSA. The standard dilution series and appropriate dilutions of the samples were incubated on the ELISA-plate for 2 hours at room temperature. Plates were washed 4 times with TBST and incubated (2 h, RT) with 100 μ l/well of a 1:25000 dilution (in TBST/1% BSA) of an anti-mouse IgG (Fc-specific) peroxidase conjugated antibody (Sigma, #A-0168) FIXa. Wells were washed 5 times with TBST and finally stained with 100 μ l freshly prepared staining solution (10 ml 50 mM sodium citrate, pH 5 supplemented with 100 μ l OPD (60 mg OPD/ml) and 10 μ l 30% H₂O₂). The reaction was stopped by the addition of 50 ml H₂SO₄ and after 30 minutes the optical density was recorded at 492 nm and 620 nm in a Labsystems iEMS Reader MF™ microtiter plate reader employing GENESIS™ software.

Example 4

Anti-FIX/FIXa Antibodies Exhibiting FVIII-like Activity in a Chromogenic FVIII Assay

Several anti-FIX/FIXa antibody producing hybridoma clones were subcloned up to four times and the resulting monoclonal hybridoma cell line used to produce monoclonal antibody containing supernatant. IgG isotype antibodies derived from these supernatants were purified over affinity columns and dialyzed against TBS (see above). IgM antibodies were used as unpurified supernatant fractions. The following experiments were done with two sets of representative antibodies: 193/AD3 and 198/AC1/1 (IgG isotype, the antibody 198/AC1/1 is a preparation from the parent 198/AC1 hybridoma clone, i.e. that a (frozen) vial containing 198/AC1 cells is cultivated and antibodies are produced. The supernatant is then used for these experiments.) and 196/AF2 and 196/AF1 (IgM isotype) (FIG. 6A and FIG. 6B). Briefly, 25 μ l aliquots of monoclonal antibody containing sample (unpurified hybridoma supernatant or, where indicated, a certain amount of FIX specific antibody) were transferred to microtiter plate wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor (F) IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Per reaction, 50 μ l of the phospholipid/FIXa/FX solution were combined with 25 μ l CaCl₂ (25 mM) and 50 μ l of the substrate/inhibitor cocktail. To start the reaction, 125 μ l of the premix were added to the monoclonal antibody solution in the microtiter plates and incubated at 37° C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 6 h) against a reagent blank (cell culture medium instead of hybridoma supernatant) in a Labsystems iEMS Reader MF™ microtiter plate reader using GENESIS™ software.

The time course of FVIII-like activity exhibited by monoclonal antibodies 193/AD3 (IgG isotype) and 196/AF2 (IgM isotype) compared to human FVIII (12 and 16 mU/ml), TBS and to cell culture medium is shown in FIG. 6A. After a lag phase, both antibodies give rise to chromogenic substrate cleavage, as judged by the increasing optical density measurable at 405 nm wavelength.

The time course of FVIII-like activity exhibited by monoclonal antibodies 198/AC1/1 (IgG isotype, 10 μ g/ml) and 196/AF1 (IgM isotype, unpurified supernatant) compared to human FVIII (16 mU/ml) and 10 μ g/ml of mouse IgG is

shown in FIG. 6B. After a lag phase, both antibodies give rise to chromogenic substrate cleavage, as judged by the increasing optical density measurable at 405 nm wavelength.

Example 5

FVIII-like Activity Exhibited by Anti-FIX/FIXa-antibodies Generates Factor Xa and is Phospholipid, FIXa/FX and Ca²⁺ Dependent

Factor VIII activity is usually determined with a chromogenic assay and/or an APTT-based clotting assay. Both types of assays rely on FVIIIa/FIXa-mediated factor Xa generation. In the case of a chromogenic FVIII assay, the factor Xa produced will subsequently react with a chromogenic substrate, which can be monitored spectroscopically, e.g., in an ELISA reader. In an APTT based clotting assay free factor Xa will assemble with FVa on a phospholipid surface in the so-called prothrombinase complex and activate prothrombin to thrombin. Thrombin in turn gives rise to fibrin generation and finally to clot formation. Central to the two assay systems is generation of factor Xa by the FVIIIa/FIXa complex.

To demonstrate that the FVIII-like activity exhibited by anti-FIX/FIXa-antibodies indeed generates factor Xa, the following experiment was carried out. Several 25 μ l aliquots of unpurified hybridoma supernatant 196/AF2 (IgM isotype) were transferred to microtiter plate wells and warmed to 37° C. As a positive control, 16mU of Recombinate™ were diluted into hybridoma medium (196 HM 007/99) and treated exactly the same way as the hybridoma supernatant. As a negative control, plain hybridoma medium was used. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor IXa and FX were reconstituted in sterile water and FIXa/FX was mixed with phospholipids according to the supplier's protocol. Pefabloc Xa®, a factor Xa specific proteinase inhibitor (Pentapharm, LTD), was reconstituted with water to a final concentration of 1 mM/l. Per reaction, 5011 of the phospholipid/FIXa/FX solution were combined with 25 μ l CaCl₂ (25 mM) and 50 μ l of the substrate/thrombin-inhibitor cocktail. To start the reaction, 125 μ l of the premix were added to the samples in the microtiter plates and incubated at 37° C. Where indicated, 35 μ M Pefabloc Xa® were added. Absorbance at 405 nm and 490 nm was read at various times (every 5 minutes to 6 h) against a reagent blank (cell culture medium) in a Lab-systems iEMS Reader MF™ microtiter plate reader employing the GENESIS™ software.

The results of the factor IXa stimulation by the FVIII-like activity exhibited by the IgM anti FIX/FIXa-antibody 196/AF2 in generating factor Xa as judged by the readily measurable cleavage of the chromogenic substrate S-2222 (compare "16 mU FVIII" and "196/AF2") is shown in FIG. 7A. Factor Xa activity is effectively blocked by the FXa specific inhibitor "Pefabloc Xa®" (compare "196/AF2" versus "196/AF2 351M Pefabloc Xa®") indicating that indeed FXa was generated.

The same experiment was performed using purified IgG preparations of clone 198/AM1 (FIG. 7B). Purified IgG was diluted in TBS to a final concentration of 0,4 mg/ml and 25 μ l (i.e. a total of 10 μ g), transferred to microtiter plate wells and warmed to 37° C. As a positive control, 6 mU plasma derived FVIII was used. 10 μ g unspecific mouse IgG (Sigma, I-5381) served as a negative control. The assay was performed as described above.

Further experiments show the factor IXa stimulation by the FVIII-like activity exhibited by the IgG anti-FIX/FIXa-

antibody 198/AM1 generates factor Xa as judged by the readily measurable cleavage of the chromogenic substrate S-2222 (FIG. 7B). Again factor VIII and antibody 198/AM1 generate FXa which is effectively blocked by the FXa specific inhibitor "Pefabloc Xa®". As a negative control, unspecific mouse IgG (Sigma, 15381) was assayed.

In another set of experiments, the dependence of the FVIII-like activity of either purified anti-FIX/FIXa-antibodies (IgM, FIG. 8A) or of unpurified antibodies derived from cell culture supernatants (IgG, FIG. 8B) on the presence of phospholipids (PL), FIXa/FX and Ca²⁺ was demonstrated. Mouse IgG was used as a control (FIG. 8C). Factor VIII-like activity was assayed essentially as described above. When indicated, either the FIXa/FX mixture, the PL or Ca²⁺ was omitted from the reaction. Absorbency at 405 nm and 490 nm of the samples was read at various times against a reagent blank (buffer instead of purified antibody) in a Labsystems iEMS Reader MF™ microtiter plate reader. The results are shown in FIG. 8A, FIG. 8B and FIG. 8C.

The dependence of the FVIII-like activity of purified anti-FIXa-antibody 198/AC1/1 (IgG isotype, concentration used throughout the assay was 10 μ g/ml) on the presence of phospholipids (PL), FIXa/FX and Ca²⁺ is further shown in FIG. 8A. As is easily recognizable, only the complete assay, including antibody, PL, Ca²⁺, and FIXa/FX gives rise to a reasonable FXa generation. The dependence of the FVIII-like activity of cell culture supernatant containing unpurified IgM isotype anti-FIX/FIXa-antibody (196/AF1) on the presence of phospholipids, FIXa/FX and Ca²⁺ is shown in FIG. 8B.

Again, as already shown for the purified IgG preparation (FIG. 8A), antibody 198/AC1/1, only the complete assay, including PL, Ca²⁺, FIXa/FX, will give a reasonable amount of FXa generation. To demonstrate the specificity of the reaction, total IgG prepared from normal mouse plasma was assayed under the same conditions as above. The results are shown in FIG. 8C. No FVIII-like activity could be detected. There is, as expected, no activity detectable in the absence of phospholipids, FIXa/FX and Ca²⁺. All experiments were done in a microtiter plate and the OD405 was scanned every 5 minutes for 6 h.

Example 6

Certain anti-FIX/FIXa-antibodies are procoagulant in the presence of FIXa

During normal hemostasis, FIX becomes initially activated either by the tissue factor (TF)/factor VIIa pathway or later on by activated factor XI (FXIa). Subsequent to its activation, FIXa associates on the platelet surface in a membrane bound complex with activated FVIII. Factor IXa by itself has little or no enzymatic activity towards FX, but becomes highly active in the presence of FVIIIa. To demonstrate that certain anti-FIX/FIXa antibodies have FVIII-like activity and hence are procoagulant in a FVIII deficient human plasma, the following experiment was carried out. Different amounts of antibody 193/AD3 or mouse IgG (as a control) were used in a standard aPTT based one stage clotting assay. Briefly, 100 μ l of antibody-containing samples were incubated with 100 μ l of FVIII deficient plasma (DP) and with 100 μ l of DAPTTIN (PTT Reagent for determining activated Thromboplastin Time; IMMUNO AG) reagent, in a KC10A clotting analyzer. Where indicated, a total amount of 50 ng activated FIX was included in the reaction mixture. After a 4 minute

17

incubation, the reaction was started by the addition of 100 μ l CaCl_2 (25 mM). The results are shown in Table 1 and FIG. 9.

μ g AB	clotting time (sec)	
	193/AD3 50 ng FIXa	mouse IgG 50 ngFIXa
9	101.6	102.5
4.5	95.6	103.2
2.25	93.1	103.2
1.8	93.7	101.9
1.35	91.4	103.4
0.9	94.4	102.2
0.45	98.1	101.9
0.34	97.1	103.9
0.23	99.3	103.7

Table 1: Clotting times of FVIII deficient plasma in an APTT based clotting assay employing various amounts of procoagulant (193/AD3) and control antibody (mouse IgG) in the presence of 50 ng activated FIX (0.01UFIX). The molar ratio of antibody in the reaction and activated FIX is 10:1. The molar ratio between antibody and total FIX (FIX and FIXa, assuming that human FVIII deficient plasma contains 1 U (5% g) FIX) varies between 6:1 (9% g antibody in reaction) and 1:6 (0.23% g antibody in reaction). At the optimal shortening of the clotting time, the molar ratio between antibody and total FIX is 1:1. The clotting time without the addition of FIXa is in the range of 120 seconds.

FIG. 9 is a graphical representation of the clotting times of FVIII deficient plasma in an aPTT based clotting assay employing various amounts of procoagulant (193/AD3) and control (mouse IgG) antibody in the presence of 50 ng activated FIX. There is a clear dose-dependent reduction of the clotting time in samples supplemented with antibody 193/AD3. These results imply that antibody 193/AD3 is procoagulant in the presence of FIXa.

Example 7

Anti-FIX/FIXa-antibodies are Procoagulant in the Presence of FVIII Inhibitors and FIXa

A severe complication of the standard FVIII substitution therapy is the development of alloantibodies directed against FVIII, leading to FVIII neutralization and a condition where the patient's blood will not clot.

To demonstrate that certain anti-FIXa-antibodies have FVIII-like activity even in the presence of FVIII inhibitors, the following experiment was carried out. Different amounts of antibody 193/AD3 or, as a control, mouse IgG were used in a standard APTT based one-stage clotting assay. Briefly, 100 μ l antibody samples were incubated with either 100 μ l of FVIII deficient plasma (FIG. 10A) or FVIII inhibitor plasma (inhibitor potency 400 BU/ml), FIG. 10B) as well as with 100 μ l of DAPTTIN reagent, in a KC10A clotting analyzer. In addition, a total amount of 50 ng activated FIXa was included in the reaction mixture. After a 4 minute incubation, the reaction was started by the addition of 100 μ l CaCl_2 (25 mM). To ensure equal conditions, the experiments employing FVIII deficient plasma and FVIII inhibitor plasma were done side by side. The results are shown in FIGS. 10A and 10B. As already shown in Example 6, there is a clear dose-dependent reduction of the clotting time in samples supplemented with antibody 193/AD3 in the presence of FVIII inhibitors.

18

Example 8

Anti-FIX/FIXa-antibodies are Procoagulant in the Presence of Defective FVIII and FIXa

To demonstrate that certain anti-FIXa-antibodies have FVIII-like activity in the presence of defective FVIII, the following experiment may be carried out. Increasing amounts of antibody 193/AD3 or, as a control, mouse IgG are used in a standard aPTT-based one stage clotting assay. In this clotting assay, a hemophilia A patient's plasma having very low clotting activity due to the presence of defective FVIII (DF8) is used. Briefly, 100 μ l antibody samples are incubated with either 100 μ l of DF8 plasma or FVIII deficient plasma as well as with 100 μ l of DAPTTIN reagent, in a KC10A clotting analyzer. In addition, a total amount of 50 ng activated FIXa is included in the reaction mixture. After a short incubation, the reaction will be started by the addition of 100 μ l CaCl_2 (25 mM). To ensure equal conditions, the experiment employing FVIII deficient plasma and DF8 plasma is done side by side.

Example 9

Anti-FIX/FIXa-antibodies with Procoagulant Activity in the Presence of FIXa Distinguish Between Human and Bovine FIXa

FIX/FIXa specific monoclonal antibodies selected from the 198th fusion experiment were purified from the respective hybridoma supernatant and quantified as described in Example 3. These antibodies were analyzed in a modified one-stage clotting assay (as described in Example 6) and some showed procoagulant activity.

The chromogenic activity of these antibody preparations was measured in the following FXa generation kinetic assay: 10 μ g of monoclonal antibody (in 25 μ l) were transferred to microtiter plate wells and warmed to 37° C. Chromogenic substrate (S-2222), synthetic thrombin inhibitor (I-2581), factor IXa and FX were reconstituted in sterile water and FIXa/FX (both bovine) were mixed with phospholipids according to the supplier's protocol. Per reaction, 50 μ l of the phospholipid/FIXa/FX solution were combined with 25 μ l CaCl_2 (25 mM) and 50 μ l of the substrate/inhibitor cocktail. To start the reaction, 125 μ l of the premix were added to the monoclonal antibody solution in the microtiter plates and incubated at 37° C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 2 h) against a reagent blank (25 ml TBS instead of monoclonal antibodies) in a Labsystems iEMS Reader MFTTM microtiter plate reader using GENESISTM software. In parallel, the same reactions were performed except that 50 ng human FIXa were added per reaction. Those antibodies that showed procoagulant activity had no chromogenic activity in the case of bovine FIX, but displayed high activity when human FIXa was present.

FIG. 11 shows the time course of the FVIII-like activity exhibited by the monoclonal antibodies 198/A1, 198/B1 and 198/AP1 with (+) and without (-) addition of 50 ng human FIXa β . Non-specific polyclonal mouse IgG was used as a control. 198/A1 and 198/B1 show procoagulant activity (similar as 193/AD3 in example 6) whereas 198/AP1 does not. Antibody 198/BB1 had the same activity pattern (data not shown).

Further monoclonal antibodies selected from the 198th fusion experiment include 198/D1 (ECACC NO. 99121616), 198/T2 (ECACC No. 99121617), 198/G2 (ECACC No.99121118), 198/U2 (ECACC No. 99121620).

Example 10

Structure and Procoagulant Activity of Antibody
Derivatives Derived from Anti-FIX/FIXa-
antibodies; Subcloning Antibody Variable Domains
from Hybridoma Cell Lines 193/AD3, 193/K2,
198/A1 and 198/B1 (Clone AB2)

Cloning procedure: Messenger RNA was prepared from 1×10^6 hybridoma cells of the respective cell line (either 193/AD3, 193/K2, 198/A1 or 198/B1 (clone AB2)) employing the "QuickPrep® Micro mRNA Purification Kit" (Pharmacia) according to the manufacturer's instructions. The corresponding cDNA was produced by retro transcription of mRNA using the "Ready-To-Go-You-Prime-First-Strand Beads kit" (Pharmacia) according to the manufacturer's instructions. Heavy and light chain encoding sequences were converted to the corresponding cDNA employing a set of primers. To reverse transcribe heavy chain-specific mRNA (VH), an equimolar mixture of the oligonucleotides MOCG1-2FOR (5' CTC AAT TTT CTT GTC CAC CTT GGT GC 3') (SEQ.ID.NO. 1), MOCG3FOR (5'CTC GAT TCT CTT GAT CAA CTC AGT CT 3') (SEQ.ID.NO. 2) and MOCMFOR (5' TGG AAT GGG CAC ATG CAG ATC TCT 3') (SEQ.ID.NO. 3) was used (RTmix1). In the same reaction tube, light chain-specific cDNA (VL) was synthesized using primer MOCKFOR- (5'CTC ATT CCT GTT GAA GCT CTT GAC 3') (SEQ.ID.NO. 4).

The coding sequences for VH were amplified by PCR using the primer-sets depicted in FIG. 12 and the specific cDNA, derived from the reverse transcription mixture (RTmix1) described above, as the template. VK-chain genes were amplified using the primer sets depicted in FIG. 13 and also employing Rtmix1 as a template. The VF-PCR product was cleaved SfiI-AscI and inserted into SfiI-AscI digested vector pDAP2 (GeneBank accession no.: U35316). The pDAP2-VH constructs obtained thereby were named pDAP2-193AD3/VH, pDAP2-198A1/VH, pDAP2-198AB2/VH (derived from antibody 198/B1) and pDAP2-193/K2/VH, respectively. The plasmids were subsequently cleaved with AscI-NotI and the corresponding AscI-NotI digested VK-gene PCR product was inserted. The resultant vectors were designated pDAP2-193/AD3scFv, pDAP2-198/A1scFv, pDAP2-198/AB2scFv (derived from antibody 198/B1) and pDAP2-193/K2scFv and code for the VH-gene and the VL-gene of the monoclonal antibodies 193/AD3, 198/A1, 198/AB2 (derived from antibody 198/B1) and 193/K2. Heavy and light chains are linked by the coding sequence for an artificial, flexible linker (G_4 SGGRASG $_4$ S (SEQ ID NO:111); Engelhardt et al., 1994) and enables expression of the scFv variant of the respective antibody.

In FIG. 14, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 193/AD3 are depicted. Nucleotides 1 to 357 code for the heavy chain variable domain, nucleotides 358 to 402 code for the artificial flexible linker and nucleotides 403 to 726 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence YGNSP-KGFAY (SEQ ID NO:5) and is given in bold letters. The artificial linker sequence (G_4 SGGRASG $_4$ S; SEQ ID NO:111) is shown.

In FIG. 15, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 193/K2 is shown. Nucleotides 1 to 363 code for the heavy chain variable domain, nucleotides 364 to 408 code for the artificial flexible linker, and nucleotides 409 to 747 code for the

light chain variable region. The protein sequence of the CDR3 of the heavy chain has the sequence DGGHGYGSS-FDY (SEQ ID NO:6), and is given in bold letters. The artificial linker sequence (G_4 SGGRASG $_4$ S; SEQ ID NO:111) is shown.

In FIG. 16, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 198/AB2 (derived from antibody 198/B1) are depicted. Nucleotides 1 to 366 code for the heavy chain variable domain, nucleotides 367 to 411 code for the artificial flexible linker, and nucleotides 412-747 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence EGGGFTVNWYFDV (SEQ ID NO:7) and is given in bold letters. The artificial linker sequence (G_4 SGGRASG $_4$ S; SEQ ID NO:111) is also shown.

In FIG. 17, the DNA and the deduced protein sequence of the scFv derived from the hybridoma cell line 198/A1 are depicted. Nucleotides 1 to 366 code for the heavy chain variable domain, nucleotides 367 to 411 code for an artificial flexible linker, and nucleotides 412-747 code for the light chain variable region. The protein sequence of the CDR3 region of the heavy chain has the sequence EGGGYVNWYFDV (SEQ ID NO:8) and is given in bold letters. The artificial linker sequence (G_4 SGGRASG $_4$ S; SEQ ID NO:111) is also shown.

Example 11

Procoagulant Activity of Peptides Derived from
CDR3 Regions of Anti-FIX/FIXa-Antibodies

In principle, the antibody molecule can be envisioned as a biological device for the presentation of a combinatorial array of peptide elements in three dimensional space (see Gao et al., 1999, PNAS, 96:6025). Therefore, an antibody (or an antibody derivative, e.g. scFv, Fab, etc.) can be used either as a tool for the detection of functionally important domains of a specific target protein, or on the other hand, for the delineation of amino acid sequences specifically mediating certain interactions, i.e. activating or enhancing the activity of FIXa towards the physiological substrate FX. The latter process has led to the evaluation of a number of heavy chain CDR3 region (CDR3H) derived peptide sequences as FIXa enhancing agents.

Enhancing the procoagulant activity of peptides which exhibit such activity may be accomplished through sequence variation within the peptide regions critical for mediating the FIXa activity enhancement. As a possible step towards peptide sequences with enhanced procoagulant activity, the binding site of an antibody, i.e. 198/A1 or 198/B1, on the FIXa molecule is mapped by employing sequence comparison analyses, competitive binding assays, Western blot analyses and competitive ELISA analyses. Since the crystal structure of FIX is known, molecular modeling is subsequently used to improve the fitting of i.e. 198/B1 derived peptides in the 198/B1 binding site on human FIXa.

On the other hand, methodical mutational analysis of a given peptide sequence such as 198/A1 or 198/B1 CDR3H derived peptide sequences by, e.g., "alanine scanning mutational analysis" allows for the identification of peptide residues critical for procoagulant activity. Another way to improve the activity of a certain peptide sequence is the use of peptide libraries combined with high throughput screening.

The antigen binding site of an antibody is derived from the juxtaposition of the six "complement determining regions (CDR's)" at the N-terminal end of the VL-HL dimer

(or Fv region). The contribution of a single CDR to the antibody specificity for a given antigen may vary considerably, but in general it is thought that the CDR3 region of the heavy chain (CDR3_H) is of special influence, i.e. the particular protein sequence of CDR3_H region may be highly important for antigen recognition. The length of CDR3_H regions has been reported to vary considerably and is in the range of 4–25 amino acids (Borrebaeck, p. 16).

An example of a methodical mutational analysis of peptide sequences is given below. To improve the solubility/procoagulant efficacy of peptides derived from the CD3-region of anti FIX/FIXa antibodies, the N-terminal as well as the C-terminal amino acid sequences were changed. In addition, a series of mutated peptides was constructed and analyzed.

The principle of such a study is exemplified by a series of peptides derived from CDR3_H region of antibodies 198/A1 and 198/B1. The original peptide A1 (see table 2) is derived from the CDR3_H region of antibody 198/A1 and peptide B1 is derived from the CDR3_H region of antibody 198/B1, respectively (see example 10, FIGS. 16 and 17). The term “scrambled version” means that a peptide has the same amino acids but in random order.

FVIII assay was developed (see examples 2 and 4). The basic principle is, that without a cofactor, FIXa will have very limited activity towards its natural substrate FX. Only in the presence of a substance having FIXa activation properties, i.e. FVIII or a substance exhibiting FVIII-like activity, a substantial amount of FXa is produced by cleavage of FX through the FIXa/activator complex. The amount of FXa generated is monitored by cleavage of a chromogenic substrate. The principle of the revised chromogenic assay is described for two representative peptides: A1/3 and A1/5 (Table 2). Briefly, 25 µl aliquots of peptide stock solution (in imidazole buffer (IZ) 50 mM imidazole, 100 mM NaCl, pH7.2) were transferred to microtiter plate wells and warmed to 37° C. Chromogenic FXa substrate (S-2222), synthetic thrombin inhibitor (I-2581), bovine FIXa and bovine FX were reconstituted in sterile water and FIXa/FX mixed with phospholipids according to the supplier's protocol. Since the peptides do not react with bovine FIXa, (which comes as a mixture with bovine FX in the Test Kit) 2,9 nM (in most cases 2.3 nM) human FIXa (ERL) were added (see Example 11, FIG. 19). Per reaction, 50 µl of the phospholipid/FIXa/FX solution were combined with 251 CaCl₂ (25 mM) and 50 µl of the substrate/inhibitor cocktail. To start the reaction, 125 µl of the premix were added to the

Peptide	Sequence	Amino-acids	MW (D)	pI	Remark
A1	EGGGYYVNWYFDV (SEQ ID NO:8)	(13aa)	1569	7.2	Decreased solubility
A1/1	VYGFVGWGYEVNDY (SEQ ID NO:10)	(13aa)	1569	7.1	Scrambled version of A1,
A1/2	EEEEGGGGYYVNWYFDEEE (SEQ ID NO:11)	(18aa)	2244	5.8	Acidic pI, soluble,
A1/3	RRREGGGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble,
A1/4	EYGEYGEVNEYDEFWE (SEQ ID NO:13)	(18aa)	2244	5.8	Scrambled version of A1/2
A1/5	VRYRNRWRWGYRGRFGDE (SEQ ID NO:14)	(18aa)	2407	9.9	Scrambled version of A1/3
A1/3-scr3	RRRGEYGVYWNGDFYRRR (SEQ ID NO:15)	(18aa)	2407	9.9	Scrambled version of A1/3
A1/3-Rd	RdRdRdEGGGYYVNWYFDRdRdRd	(18aa)	2407	9.9	Peptide A1/3 but substitute D-Arg for L-Arg
A1/3-Rd-srmb	RdRdRdGEYGVYWNGDFYRdRdRd	(18aa)	2407	9.9	Scrambled version of A1/3-Rd

Table 2

List of a series of antibody 198/A1 derived peptides. Listed are the length of the peptide (aa, amino acids #), the calculated molecular weight (MW, in Dalton (D)) and the statistical isoelectric point (pI). D-Arg is abbreviated as Rd.

In a first series of experiments we improved the solubility of the original CDR3_H peptide sequence (A1; EGGGGYYVNWYFDV; SEQ ID NO:8) by removing the C-terminal Val residue and adding several charged residues at the N— as well as the C-terminal end of the peptide. The resulting peptides, A1/2 (acidic pI), A1/3 (basic pI) and their respective scrambled versions A1/4, A1/5 and A1/3scr3 were readily soluble in a variety of buffer systems at physiological pH.

To analyze the FVIII-like (FIXa activating) activity of the peptides, an assay system based on a commercial available

peptide solution in the microtiter plate and incubated at 37° C. Absorbance at 405 nm and 490 nm of the samples was read at various times (5 min to 2 h) against a reagent blank in a Labsystems iEMS Reader MF™ microtiter plate reader using GENESIS™ software.

The result of this experiment are shown in Example 11, FIG. 18. Peptide A1/3 induced a readily measurable FXa generation in the presence of 2.9 nM human FIXa, whereas the scrambled version A1/5 was inactive. In addition, the acidic peptide A1/2 as well as the scrambled versions A1/4 and A1/3-scr3 did not give any significant chromogenic activity when tested under comparable conditions (data not shown). To prove that the peptide A1/3 like the parental antibody 198/A1 does not react with bovine FIXa and FX the experiment shown in FIG. 19 was done. The peptide

23

A1/3 was incubated as described above with (A1/3 (24 μ M), +hFIXa) and without (A1/3 (24 μ M), w/o hFIXa) 2.3 nM human FIXa (hFIXa). In a control experiment we added plain dilution buffer (IZ) supplemented with 2.3 nM hFIXa to the reaction mixture. As shown in FIG. 19, the reaction takes place only in the presence of human FIXa.

FIG. 18 demonstrates the chromogenic FVIII-like activity of peptide A1/3 in the presence of 2.9 nM human FIXa (hFIXa). The scrambled version of peptide A1/3, peptide A1/5 does not give rise to any FXa generation. FIG. 19 demonstrates the dependence of the chromogenic FVIII-like activity of peptide A1/3 on the presence of human FIXa (hFIXa). In the absence of human FIXa, peptide A1/3 does not give rise to any FXa generation. The buffer control, plain imidazole buffer is designated IZ.

The peptides were also analyzed for their potential to reduce the clotting time in a FVIII deficient plasma. The aPTT based one stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation were compared either against FVIII, a buffer control (IZ) or a control peptide (scrambled version). The results of two typical clotting experiments done with two different aPTT reagents (DAPTTIN and Pathromtin SL) are shown in table 3A and table 3B.

	peptide conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
Exp. 1							
IZ	0	107.7	106.8	107	93.1	94.5	94
A1/3	15 μ M	78.2	77.1	78	59.3	59.9	60
	12.5 μ M	80.2	80.6	80	60.2	58.9	60
	7.5 μ M	97.8	97.9	98	73.1	72.7	73
	2.5 μ M	105.2	104.8	105	91.1	91	91
A1/3-scr3	15 μ M	122.5	122	122	106.1	105.5	106
	12.5 μ M	116	117.6	117	103.1	104.5	104
	7.5 μ M	114.2	113.9	114	100.8	100.6	101
	2.5 μ M	107.8	107.4	108	96.3	95.2	96
Exp. 2							
IZ	0	111	109.7	110	94.7	95.5	95
A1/3	12.5 μ M	83.6	85.5	85	56.7	56.7	57
	10 μ M	79.1	78.5	79	63.1	62.5	63
	7.5 μ M	100.1	100.5	100	71.6	73.9	73
	5 μ M	103.4	104.8	104	77	76	77
	2.5 μ M	110.1	108.9	110	88	88.8	88
	1.25 μ M	108.7	109.3	109	90.7	90.8	91

Table 3A. Clotting activity of peptides A1/3 and A1/3-scr (scrambled version of A1/3) in FVIII deficient plasma either in the presence or in the absence (w/o) of 2.2 nM human FIXa. Shown are two independent representative experiments (Exp. 1 and Exp. 2). All clotting experiments have been done in duplicate. Given are the clotting times for the individual experiments and the average clotting time in seconds (sec). Experiments shown in table 3A have been done employing the aPTT reagent DAPTTIN (Baxter Hyland Immuno). Compared to the buffer control (IZ, imidazole buffer) the peptide A1/3 gave rise to a dose dependent reduction in the clotting time. The reduction in the clotting time became much more pronounced by the addition of 2.2 nM activated human FIX to the reaction mix. The scrambled version of peptide A1/3, A1/3-scr3 did not show any reduction of the clotting time. In fact, at concentrations above 2.5 μ M, the scrambled peptide became inhibitory and therefore prolonged the clotting time. Peptides A1/1, A1/2, A1/4 and A1/5 did not give any reduction in the

24

clotting time indicating that they lack procoagulant activity (data not shown).

	Final conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
IZ	0	131.8	132.1	132	107.9	108.7	108
FVIII	12.5 mU/ml	68.9	69	69	52.9	53.6	53
	6.25 mU/ml	77.8	77.9	78	58.6	58.9	59
A1/3	15 μ M	152.8	149.3	151	75.4	75.2	75
	10 μ M	135.7	134.6	135	76.2	79.8	78
	5 μ M	152.6	155.6	154	86.6	90.2	88
	1 μ M	138.3	138.8	139	103.7	105.9	105

Table 3B. Clotting activity of peptide A1/3 in FVIII deficient plasma when Pathromtin SL (DADE Behring) is used as an aPTT reagent. The experiments were done in duplicate, either in the presence or in the absence (w/o) of 2.2 nM human FIXa. Given are the clotting times for the individual experiments and the average clotting time in seconds (sec). Factor VIII and imidazole buffer (IZ) were included as positive and negative control respectively.

In contrast to the experiments shown in table 3A the experiments shown in table 3B have been done employing the aPTT reagent Pathromtin SL. In the presence of FIXa, the peptide A1/3 gave rise to a dose dependent reduction in the clotting time whereas in the absence of FIXa no reduction of the clotting time was detectable.

In another series of experiments we set out to improve the plasma stability (protection from, e.g., proteolytic degradation) of peptide A1/3. One approach was to substitute the N- and C-terminal L-Arg residues with D-Arg residues (exemplified by peptides A1/3-rd and A1/3-Rd-srmb). Peptides A1/3-rd and A1/3-Rd-srmb (scrambled version of the peptide) were then analyzed in a chromogenic as well as in the aPTT based clotting assay. These experiments revealed that exchanging the terminal L-Arg residues for D-Arg residues did not change the FVIII-like activity as measured in the chromogenic assay, indicating that chirality of the Arg-residues does not play a major role in chromogenic activity (FIG. 20). In addition, the aPTT based one-stage clotting activity, although somewhat reduced, was still easily detectable (Table 4).

	Peptide conc.	w/o FIXa sec	w/o FIXa sec	average sec	2.2 nM FIXa sec	2.2 nM FIXa sec	average sec
IZ	0	110	109.1	110	96	96	96
A1/3	15 μ M	77.8	78	78	56.1	55.5	56
	12.5 μ M	99.4	100.5	100	65	68	67
	10 μ M	104.4	104.5	104	72	73.2	73
	7.5 μ M	105.2	105.2	105	80.7	80.5	81
	5 μ M	108.4	107.7	108	89.7	88.3	89
	2.5 μ M	107.9	107.6	108	93.6	93.3	93
A1/3-Rd	1.25 μ M	106.7	107	107	94.4	95	95
	15 μ M	96.4	95.4	96	76.1	74.4	75
	12.5 μ M	98	98.6	98	72.3	73.7	73
	10 μ M	93.5	95.8	95	74.2	77.2	76
	7.5 μ M	97.6	98.1	98	80.9	82.2	82
	5 μ M	99.2	99.1	99	86	85.1	86
	2.5 μ M	102.7	103.4	103	94.4	94.7	95
	1.25 μ M	107.5	107.7	108	96.6	96	96
A1/3-Rd-srmb	15 μ M	121.9	121.3	122	112.7	112.4	113
	12.5 μ M	117.2	118	118	108.1	107.8	108
	10 μ M	115.8	115.3	116	107.2	107.8	108
	7.5 μ M	114.6	113.6	114	107.6	106.6	107
	5 μ M	113.1	112.4	113	108.5	108.2	108

-continued

Peptide conc.	w/o		average sec	2.2 nM		average sec
	FIXa sec	FIXa, sec		FIXa sec	FIXa sec	
2.5 μ M	111.9	111.9	112	105	104.2	105
1.25 μ M	107.2	107.1	107	101.1	105.3	103

Table 4. One stage clotting activity of peptides A1/3, A1/3-Rd and A1/3-Rd-srmb (sequences see table 2). IZ, buffer control.

FIG. 20 demonstrates the unchanged chromogenic activity of peptide A1/3-Rd. Peptides at a final concentration of 12 μ M or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa (+). The chromogenic activity of peptide A1/3 and A1/3-Rd was found to be virtually unchanged and gave almost identical results in the chromogenic assay. The scrambled version of peptide A1/3, A1/5 as well as the buffer gave no significant FXa generation.

In the next series of experiments we set out to determine the individual role of any amino acid of the peptide core sequence by substituting each residue for the amino acid Alanine (Table 5).

100 mM NaCl, 1% human albumin, pH7.4) to the desired final concentration. The peptides were analyzed for their chromogenic activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma. The one-stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation) were compared either against a buffer control or a control peptide (scrambled version).

Some of the results of the "Alanine scan" are given for the peptides A1/3-2 and A1/3-3. The change of G₃-A₃ as exemplified in the peptide A1/3-2 yields high chromogenic activity and a strong reduction of the one-stage clotting time (34 seconds at a concentration of 12.5 μ M) in the presence of 2.2 nM human FIXa. Peptide A1/3-3 (G₄-A₄) exhibits an optimum of chromogenic activity around a final concentration of 12 μ M with decreased activity at either higher or lower concentrations. The peptide is somewhat inhibitory in a one-stage clotting assay at higher concentrations (12.5 μ M) in the absence of FIXa but becomes strongly active in the presence of 2.2 nM FIXa (31 seconds, 12.5 μ M).

In the next series of experiments we set out to determine the individual role of any amino acid of the peptide core sequence by substituting each core residue for the amino acid glutamic acid (E) (see Table 6).

Peptide	Sequence	Amino acid #	MW (D)	pI	Remark
A1/3	RRREGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble.
A1/3-13	RRRAGGGYYVNWYFDRRR (SEQ ID NO:19)	(18aa)	2349	10.4	E ₁ -A ₁
A1/3-1	RRREAGGYVNWYFDRRR (SEQ ID NO:20)	(18aa)	2421	9.9	G ₂ -A ₂
A1/3-2	RRREGAGYYVNWYFDRRR (SEQ ID NO:21)	(18aa)	2421	9.9	G ₃ -A ₃
A1/3-3	RRREGGAYVNWYFDRRR (SEQ ID NO:22)	(18aa)	2421	9.9	G ₄ -A ₄
A1/3-4	RRREGGGAYVNWYFDRRR (SEQ ID NO:23)	(18aa)	2315	9.9	Y ₅ -A ₅
A1/3-5	RRREGGGYAVNWYFDRRR (SEQ ID NO:24)	(18aa)	2315	9.9	Y ₆ -A ₆
A1/3-6	RRREGGGYYANWYFDRRR (SEQ ID NO:25)	(18aa)	2379	9.9	V ₇ -A ₇
A1/3-7	RRREGGGYYVAWYFDRRR (SEQ ID NO:26)	(18aa)	2364	9.9	N ₈ -A ₈
A1/3-8	RRREGGGYYVNAYFDRRR (SEQ ID NO:27)	(18aa)	2292	9.9	W ₈ -A ₉
A1/3-9	RRREGGGYYVNWAFDRRR (SEQ ID NO:28)	(18aa)	2315	9.9	Y ₁₀ -A ₁₀
A1/3-10	RRREGGGYYVNWYADRRR (SEQ ID NO:29)	(18aa)	2331	9.9	F ₁₁ -A ₁₁
A1/3-11	RRREGGGYYVNWYFARRR (SEQ ID NO:30)	(18aa)	2363	10.5	D ₁₂ -A ₁₂
A1/3-12smb	RRRYVYNGWGYFEGARRR (SEQ ID NO:31)	(18aa)	2363	10.4	Scrambled version

55

Table 5. Listed are the peptides designed to elucidate the role of any single amino acid within the peptide core sequence (E₁G₂G₃G₄Y₅Y₆V₇N₈W₉Y₁₀F₁₁D₁₂; SEQ ID NO:112). The subscripted numbers describe the position of the amino acid within the peptide. Alanine, an uncharged small amino acid, was substituted for each amino acid ("Alanine scan"). Also listed are the lengths of the peptides (amino acids #), the calculated molecular weights (MW, in Dalton (D)) and the statistical isoelectric points (pI).

Each of the peptides was dissolved individually in imidazole buffer (50 mM imidazole, 100 mM NaCl, pH7.2) and subsequently diluted in clotting buffer (50 mM imidazole,

Peptide	Sequence	Amino-Acids	MW (D)	pI	Remark
A1/3	RRREGGGYYVNWYFDRRR (SEQ ID NO:12)	(18aa)	2407	9.9	Basic pI, soluble,
A1/3-22	RRREGGGYYVNWYFDRRR (SEQ ID NO:32)	(18aa)	2479	9.5	G ₂ -E ₂
A1/3-23	RRREGGGYYVNWYFDRRR	(18aa)	2479	9.5	G ₃ -E ₃

60

65

-continued

Peptide	Sequence	Amino-Acids	MW (D)	pI	Remark
	(SEQ ID NO:33)				
A1/3-24	RRREGGEYVNWYFDRRR	(18aa)	2479	9.5	G ₄ -E ₄
A1/3-26	RRREGGGEYVNWYFDRRR	(18aa)	2373	9.4	Y ₅ -E ₅
A1/3-27	RRREGGGYEVNWYFDRRR	(18aa)	2373	9.4	Y ₆ -E ₆
A1/3-28	RRREGGGYVNWYFDRRR	(18aa)	2437	9.5	V ₇ -E ₇
A1/3-29	RRREGGGYVVEWYFDRRR	(18aa)	2422	9.5	N ₈ -E ₈
A1/3-30	RRREGGGYVNEVFDRRR	(18aa)	2350	9.5	W ₉ -E ₉
A1/3-31	RRREGGGYVNWVEFDRRR	(18aa)	2373	9.4	Y ₁₀ -E ₁₀
A1/3-32	RRREGGGYVNWYEDRRR	(18aa)	2389	9.5	F ₁₁ -E ₁₁
A1/3-33	RRREGGGYVNWYFERRR	(18aa)	2421	9.9	D ₁₂ -E ₁₂
A1/3-34smb	RRRGEYGEYWNWDFYRRR	(18aa)	2437	9.5	Scrambled version

Table 6. Listed are the peptides designed to elucidate the role of any single amino acid within the peptide core sequence (E₁G₂G₃G₄Y₅Y₆V₇N₈W₉Y₁₀F₁₁D₁₂; SEQ ID NO:112). The subscripted numbers describe the position of the amino acid within the peptide. Glutamic acid, a negatively charged large amino acid, was substituted for each amino acid of the core sequence ("Glutamic acid scan"). Also listed are the lengths of the peptide (amino acids #), the calculated molecular weights (MW, in Dalton) and the statistical isoelectric points (pI).

Each of the peptides was solved individually in imidazole buffer (50 mM imidazole, 100 mM NaCl, pH7.2) and subsequently diluted in clotting buffer (50 mM imidazole, 100 mM NaCl, 1% human albumin, pH7.4) to the desired final concentration. The peptides derived from the "Glutamic acid scan" series were analyzed for their chromogenic FVIII-like activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma. The one-stage clotting assay was essentially done as described (see example 6).

The peptide A1/3-24 showed some interesting properties. The molecule exhibited high chromogenic FVIII-like activity at concentrations between 6.5 μM-12 μM but lost activity at higher concentrations (up to 24 μM). The peptide had no procoagulant activity in the absence of human FIXa but was strongly active in the presence of 2.2 nM hFIXa.

In a second series of experiments we set out to improve the procoagulant activity of the antibody-198/B1 CDR3H derived peptide sequence B1. In a first step we improved the solubility of the original peptide sequence (B1; EGGGFTVNWYFDV; SEQ ID NO:7) by removing the C-terminal Val residue and adding several charged residues at the N- as well as the —C-terminal end of the peptide. The resulting peptides B1/4, B1/6 (acidic pI), B1/7 (basic pI) and their scrambled versions B1/5, B1/7scr3 are readily soluble in a variety of buffer systems at physiological pH.

Peptide	Sequence	Amino-acids	MW (D)	pI	Remark
B1	EGGGFTVNWYFDV	(13aa)	1491	6.0	Decreased solubility
B1/4	REGGGFTVNWYFDR	(14aa)	1704	7.9	Soluble,
B1/5	FGVGYRGETRNFWD	(14aa)	1704	8.0	Scrambled version, soluble
B1/6	EEEEGGGFTVNWYFDEEE	(18aa)	2166	5.0	Acidic pI soluble
B1/7	RRREGGGFTVNWYFDRRR	(18aa)	2329	9.9	Basic pI soluble
B1/7scr3	RRRFVGVYGETNFDRRR	(18aa)	2329	9.9	Basic pI, soluble, scrambled version

Table 7 is a list of a series of antibody 198/B1 derived peptides. Listed are the length of the peptide (aa, amino acids #), the calculated molecular weight (MW, in Dalton (D)) and the statistical isoelectric point (pI).

Peptides B1/4 and B1/5 were soluble in 50 mM Tris, 100 mM NaCl, pH=6.5. Both peptides were analyzed in a chromogenic FVIII assay. Peptide B1/4 but not the scrambled version B1/5 was found to have some chromogenic activity (data not shown).

Subsequently peptides B1/6, B1/7 and B1/7scr3 were analyzed. Each of the peptides was solved individually in 50 mM imidazole, 100 mM NaCl, pH7.2 and subsequently diluted either in clotting buffer (50 mM imidazole, 100 mM NaCl, 1% human albumin, pH7.4) or in imidazole buffer to the desired final concentration. The peptides were analyzed for their chromogenic activity as well as for their potential to reduce the clotting time in a FVIII deficient plasma (table 8 & 9). The one stage clotting assay was essentially done as described (see example 6). Clotting times (time from starting the reaction to the "clot"-formation) were compared either against a buffer control or a control peptide (scrambled version).

The FIXa activating activity (FVIII cofactor-like activity) from peptide B1/7 was first measured in the chromogenic assay described above.

As shown in FIG. 21, the addition of 2.4 μM peptide B1/7 to the reaction mixture led to a well measurable generation of FXa. In contrast, the addition of 35 μM Pefabloc Xa, a specific inhibitor of FXa protease activity, resulted in a significant reduction of the chromogenic substrate cleavage reaction (FIG. 22) thereby proving that there was indeed a peptide-FIXa mediated FXa generation. If there was no addition of FIXa and FX to the reaction mixture, no FXa was synthesized (FIG. 22). Peptide B1/6 and the control peptides B1/5 and B1/7scr3 exhibited no activity (data not shown).

FIG. 21 demonstrates the chromogenic activity of peptide B1/7. The peptide at a final concentration of 2.4 μM or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa.

In FIG. 22 peptide B1/7 at a final concentration of 2.4 μM or the buffer control (IZ) were incubated in the presence of 2.3 nM human FIXa (as indicated either as "+2.3 nM hFIXa" or "+") The chromogenic activity of peptide B1/7 was found to be dependent on the presence of FIXa and FX since no reaction is detectable when FIXa and FX are left out of the reaction (w/o FIXa/FX). To prove that the peptide B1/7 mediates indeed FXa generation, the FXa specific protease inhibitor Pefabloc Xa was added to the reaction mix (35 μM Pefabloc Xa). In a second set of experiments, the procoagu-

lant effect of peptides B1/6, B1/7 and B1/7scr3 were tested in a aPTT based one-step coagulation assay. The experiments were done essentially as described in Example 6. The results are shown in tables 8 and 9.

Pep- tide	12.5 μ M (-)	1.25 μ M (-)	0.125 μ M (-)	12.5 nM (-)	Buffer (-)	remarks
B1/6	115	110	111	111	110	
B1/7	157	112	109	110	110	
B1/7 scr3	115	105	106	105	107	

Table 8: FVIII deficient plasma was incubated either with peptides B1/6, B1/7scr3 or B1/7 in the absence of activated human FIX. As a negative control, plain buffer was added to the deficient plasma. The clotting times for the various combinations are given. Under these conditions, peptide B1/7 at its highest concentration (12.5 μ M) becomes inhibitory to the coagulation process as indicated by the extended clotting time of 157 seconds.

Pep- tide	12.5 μ M (+)	1.25 μ M (+)	0.125 μ M (+)	12.5 nM (+)	Buffer (+)	remarks
B1/6	103	100	101	100	100	
B1/7	83	92	99	99	100	
B1/7 scr3	102	94	94	94	94	

Table 9: FVIII deficient plasma was incubated either with peptides B1/6, B1/7scr3 or B1/7 in the presence of activated human FIX. As a negative control, plain buffer was added to the deficient plasma. The clotting times for the various combinations are given. In the presence of FIXa, peptide B1/7 becomes procoagulant as indicated by the reduced clotting time (83 seconds compared to 102 seconds for the scrambled peptide and 100 seconds for the buffer control).

Example 12

Procoagulant Activity of Peptide Derivatives Obtained from CDR3 Regions of Anti-FIX/FIXa- Antibodies in FVIII Inhibitor Plasma

To assay for the procoagulant activity of peptide A1/3 in FVIII inhibitor plasma the following experiment was carried out. We performed a standard aPTT based one stage clotting assay, but instead of FVIII deficient plasma we employed FVIII inhibitor plasma. The inhibitory potency of the plasma was 8.1 Bethesda Units per ml.

TABLE 10

	Peptide conc.	w/o FIXa sec	w/o FIXa sec	Average sec	FIXa sec	FIXa sec	average sec
IZ	0	104.9	103.6	104	94.2	94.1	94
A1/3	12.5 μ M	85.8	85.3	86	61	60.2	61
	10 μ M	88.4	87.9	88	61.3	61.8	62
	7.5 μ M	93.7	92.7	93	68.8	70.9	70
	5 μ M	101.5	101.1	101	81	82	82
	2.5 μ M	106.1	105.3	106	90.2	90.5	90
	1.25 μ M	104.5	104.3	104	91.3	91.4	91

Table 10: Various amounts of peptide A1/3 (12.5 μ M-1.25 μ M) were added to FVIII inhibitor plasma (either in the

presence (FIXa) of 2.2 nM FIXa or in the absence (w/o FIXa). As a negative control, plain buffer was added to the plasma (IZ). Experiments were done in duplicate and the average (aver.) was calculated. The clotting times (in seconds) for the various combinations are given. It is easily appreciable that the peptide A1/3 reduces (in a dose dependent manner) the clotting time of FVIII inhibitor plasma in the presence of FIXa but, although albeit to a much lesser extent, also in the absence of FIXa.

Example 13

Conversion of the 196/C4 IgM into IgG1

Since some IgM antibodies demonstrate high FVIII-like activity in chromogenic assays, attempts were made to convert such IgM antibodies into IgG antibodies (though antibody derivatives such as Fab, F(ab)₂, scFv, etc. could also be produced). Described in detail below is the rescue of the IgM variable region genes. Expression vector pBax-IgG1 (FIG. 23) was first constructed from vectors pSI (Promega) and pEF/Bsd (Invitrogen) through multiple cloning steps. B-lymphocytes of a donor are purified from blood and mature mRNA purified from these cells using the "micro-mRNA purification-kit" (Pharmacia). The cDNA of a human kappa chain and a human gamma 1 chain are prepared employing the "you-primefirst-strand-cDNA-"kit" (Pharmacia) using specific primers.

The coding sequence of a human kappa light chain constant domain is amplified from the cDNA by PCR using specific primers.

The gene of a human gamma 1 chain constant region (CH1-hinge-CH2—CH3) is amplified from the cDNA by PCR using specific primers.

The PCR product of the light chain constant domain is digested with XbaI and NheI and inserted into digested pSI. The resultant vector is cleaved with EcoRI and XbaI and annealed oligonucleotides are inserted, resulting in vector pSI-Ckappa. The annealed oligonucleotides provide for the leader and the SacI-XbaI sites for insertion of the kappa chain variable region. The PCR product of the human gamma 1 chain constant region is digested with SpeI and BamHI and inserted into digested pSI. The resultant vector is cleaved with SpeI and NotI and annealed oligonucleotides are inserted resulting in vector pSI-Cgamma. The annealed oligonucleotides provide for the leader and the XhoI-BstEI sites for insertion of the heavy chain variable region. Vector pEF/Bsd is digested NheI and SfiI, blunt ended by Klenow treatment and the whole expression cassette of pSI-Ckappa, excised with BglII and BamHI, is inserted (after Klenow treatment). The resultant vector is digested with EcoRI and HindIII and treated with Klenow. The whole expression cassette of pSI-Cgamma is excised with BglII and BamHI and is inserted (after Klenow treatment). The resultant vector is named pBax-IgG1.

The light chain variable region can be inserted in between the SacI-XbaI sites, yielding the complete coding-sequence of a kappa light chain. The heavy chain variable region can be cloned in between the XhoI-BstEI sites, resulting in a complete IgG1 heavy chain gene. Both open reading frames are expressed under the control of the SV40-promoter and harbour the coding sequence of a signal peptide at the 5' end of the genes for secretion of the heavy and light chains into the endoplasmic reticulum. Transfection into COS cells allows the expression of an IgG1 with the same binding properties as the parental IgM.

Construction of the plasmid pBax-196/C4 is further accomplished by amplifying the VH of the 196/C4 scFv

(subcloned as described in Experiment 10) by PCR using specific primers. The PCR product is digested with XhoI and BstEII and inserted into XhoI and BstEII digested pBax IgG1. The VL of the 196/C4 scFv is amplified by PCR using specific primers. The PCR product is digested with SacI and XbaI and inserted into SacI and XbaI-digested pBax IgG1-VH. The resultant vector (pBax-196/C4) is transfected into COS cells by electroporation, and hybrid IgG1 molecules (murine variable region and human constant region) with the same specificity as the parental IgM is expressed.

Example 14

Activation of FIXa Amydolytic Activity by Anti-FIXa Antibodies

Briefly, 20±1 factor IXa (containing 20 mU FIXa (Stago)) were incubated at 37° C., with 200 µl of reaction buffer (50 mM Tris HCl pH7.4, 100 mM NaCl, 5 mM CaCl₂ and 40% Ethyleneglycol), 25 µl of FIXa substrate (CH₃SO₂-D-CHG-Gly-Arg-pNA, AcOH, 10M/ml, Pentapharm LTD) in the absence or presence of various amounts of anti-FIX antibodies 198/B1 (IgG isotype) or 196/AF1 (IgM isotype). Specific cleavage of FIXa substrate was monitored at 405 nm in an ELISA reader.

The presence of the anti-FIX antibodies enhanced the amydolytic activity of FIXa at least 2 fold. FIG. 24 shows the increase of the amidolytic activity of FIXa in the presence of antibody 198/B1 (FIG. 24A) and antibody 198/AF1 (FIG. 24B).

Example 15

FVIII-like Activity Exhibited by Fab Fragments Derived from Anti FIX/FIXa-antibodies

Fab fragments of anti-FIX/FIXa antibodies were prepared and purified according to standard protocols. Briefly, 1 ml antibody 198/A1(4 mg/ml in 50 mM imidazole, 100 mM NaCl, pH7.4) was incubated overnight with 87 µl fragmentation buffer (1M Na Acetate, 10 mM EDTA 67.5 mg/ml L-cysteine) and 0.25 mg papain (immobilized on agarose beads), at 37° C. The preparation was filtered to remove the papain. L-histidine was added (final concentration 50 mM) and afterwards the pH was adjusted to 7.0. Finally, solid NaCl is added to give a final concentration of 1M.

Subsequently, the 198/A1 Fab fragment was purified by binding to protein L: we used ImmunoPure Immobilized PROTEIN L Plus (Pierce) in a PHARMACIA XK 16/20 Column (gel-volume: 2 ml) Buffers for chromatography were: 1) equilibration-buffer: 50 mM L-histidine pH 7.0; 1M NaCl; 0.1% (w/v) NaN₃; 2) wash-buffer: 50 mM L-Histidine pH 7.0; 0.1 (w/v) NaN₃; 3) elution-buffer: 100 mM glycine pH 2.5; 0.1% (w/v) NaN₃; and 4) neutralization buffer: 2M Tris/Cl pH 8,0;

Chromatography was essentially done by following steps 1 to 7 described in table 11. In order to neutralize the low pH of the elution buffer "Fraction-tubes" were pre-loaded with 0.2 ml 2M Tris pH 8.0.

TABLE 11

STEP	BUFFER	Flow rate	Vol.	CV	Fractions
1.	column-wash	2.0 ml/min	10 ml	5	waste
2.	equilibration	2.0 ml/min	10 ml	5	waste

TABLE 11-continued

STEP	BUFFER	Flow rate	Vol.	CV	Fractions	
3.	sample-load	1.0 ml/min	x ml	x	flow-through	
4.	wash 1	equi-buffer	1.0 ml/min	20 ml	10	flow-through
5.	wash 2	wash-buffer	1.0 ml/min	10 ml	5	flow-through
6.	elution	elution-buffer	1.0 ml/min	15 ml	7.5	1,0 ml fractions-
7.	neutralization	wash-buffer	2.0 ml/min	10 ml	5	waste

Table 11

The final 198/A1 Fab preparation was dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 25). Compared to an intact antibody, the 198/A1 Fab fragment has somewhat less activity; however, the Fab fragment still gives rise to FIX dependent FXa generation.

FIG. 25 demonstrates the chromogenic FVIII-like activity of the antibody 198/A1 Fab fragment in the presence of 2.3 nM human FIXa. As a positive control we used the intact antibody 198/A1 as well as 7.5 pM FVIII. Buffer control (IZ) instead of 198/A1 Fab fragment or FVIII was used as a negative control.

Example 16

FVIII-like Activity Exhibited by Fusion Proteins Between scFv Fragments of Anti-FIX/FIXa Antibodies and *E. coli* Alkaline Phosphatase

The single chain Fv fragment (see example 10) of antibody 198/B1 (subclone AB2) was fused to the N-terminus of *E. coli* alkaline phosphatase employing the pDAP2 vector system (Kerschbaumer et al., 1996). Two identical clones were isolated and designated pDAP2-198AB2#1 and pDAP2-198AB2#100 (FIG. 26). The resulting fusion proteins were expressed in *E. coli*, purified by metal affinity chromatography (Kerschbaumer et al., 1997) and analysed in a standard chromogenic assay (FIG. 27).

FIG. 27 demonstrates the chromogenic FVIII-like activity of two antibody 198/B1 (subclone AB2) scFv fragment-alkaline phosphatase fusion proteins (198AB2#1 and 198AB2#100) in the presence of 2.3 nM human FIXa. As a positive control we used 7.5 pM FVIII.

Example 17

FVIII-like Activity Exhibited by a Bivalent Miniantibody

In order to obtain a bivalent miniantibody, the scFv fragment of antibody 198/B1 (subclone AB2) was fused to a amphipatic helical structure employing the pZip1 vector system (Kerschbaumer et al. (Analytical Biochemistry 249, 219-227, 1997). Briefly, the gene of the 198/B1 scFv fragment was isolated from the plasmid pDAP-198AB2#100 (example 16) by digestion with SfiI and NotI. The DNA fragment was gel purified and inserted in the SfiI/NotI digested vector pZip1. The resulting plasmid was sequenced and designated pZip-198AB2#102 (FIG. 28). In parallel, we constructed a miniantibody version from an irrelevant monoclonal antibody termed #8860. In a first step, the single chain Fv fragment of antibody #8860 was assembled in the vector pDAP2. The cloning was done essentially as described in example 10. The construct was

named pDAP2-8860scFv#11 (FIG. 29). Subcloning of the scFv fragment contained within pDAP2-8860scFv#11 into plasmid pZip1 (see above) yielded the miniantibody construct p8860-Zip#1.2 (FIG. 30). Since antibody #8860 does not react with FIX/FIXa (as judged by Western Blot and ELISA analysis) it represents an appropriate negative control. Subsequently, the miniantibody proteins were expressed in *E. coli* and purified from bacterial supernatants by binding to Protein L according to the following protocol: For affinity chromatography we used ImmunoPure Immobilized PROTEIN L Plus (Pierce) in a PHARMACIA XK 16/20 Columns having a gel-volume of 4 ml Buffers employed were: 1) equilibration-buffer: 5 mM L-Histidine pH 7.0, 1M NaCl, 0.1% (w/v) NaN₃, wash-buffer: 50 mM L-histidine pH 7.0, 0.1% (w/v) NaN₃; elution-buffer: 100 mM glycine pH 2.5, 0.1% (w/v) NaN₃; and neutralization buffer: 2M Tris/Cl pH 8.0.

Samples were prepared as follows: The bacterial culture supernatant was obtained by centrifugation of the bacterial expression culture (11,000×g, 4° C., 10 minutes). 470 g of ammonium-sulphate was added to 1 liter of supernatant and the solution stirred on ice for 1 hour to precipitate the protein. The precipitate was pelleted at 14,000×g for 35 minutes at 2° C. and re-dissolved in 100 ml 20 mM Tris pH 7.0. Subsequently the concentrate was dialyzed against 20 mM Tris pH 7.0, L-histidine was added to a final concentration of 50 mM and the pH was adjusted to 7.0. Finally, solid NaCl was added to give a final concentrations of 1M. Before loading on the column, a sample was first centrifuged at 16,000×g for 15 min at room temperature and then filtered through a 0.45 µm sterile filter.

Chromatography was essentially done by following steps 1 to 7 described in table 12. In order to neutralize the low pH of the elution buffer "Fraction-tubes" were pre-loaded with 0.2 ml 2M Tris pH 8.0.

STEP	BUFFER	Flow rate	Vol.	CV	Fractions	
1.	column-elution-buffer	2.0 ml/min	20 ml	5	waste	
2.	wash equilibration	equi-buffer	2.0 ml/min	20 ml	5	waste
3.	sample-load	sample	1.0 ml/min	x ml	x	flow-through
4.	wash 1	equi-buffer	1.0 ml/min	40 ml	10	flow-through
5.	wash 2	wash-buffer	1.0 ml/min	20 ml	5	flow-through
6.	elution	elution-buffer	1.0 ml/min	30 ml	7.5	1.0 ml fractions-
7.	neutralization	wash-buffer	2.0 ml/min	20 ml	5	waste

Table 12. The final 198/B1 (subclone AB2) miniantibody preparation (designated 198AB-Zip#102) and the negative control 8860-Zip#1.2 were dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 31).

As can be seen in FIG. 31, the miniantibody construct 198AB-Zip#102 gives rise to substantial FXa generation (compare to FVIII) whereas the negative control miniantibody 8860-Zip#1.2 does not.

FIG. 31 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) miniantibody 198AB-Zip#102 in the presence of 2.3 nM human FIXa. As a positive control we used 4.8 pM FVIII whereas an unrelated miniantibody (8860-Zip#1.2) and plain reaction buffer (IZ) served as negative controls.

Example 18

FVIII-like Activity Exhibited by Anti-FIXa/FIX Antibody scFv Fragments

The single chain Fv fragment of antibody 198/B1 (subclone AB2) as well as the scfv fragment of antibody

#8860 were expressed employing the pMycHis6 vector system. Vector pMycHis6 (FIGS. 32 & 33) was constructed by cleaving vector pCOCK (Engelhardt et al., 1994, Biotechniques, 17: 44-46) with NotI and EcoRI and insertion of the following oligonucleotides: mychis6-co: 5' ggc-cgcagaacaaaactcatctcagaagaggatct gaatggggcggcacatcacatcaccatcactaataag 3' (SEQ. ID.NO.

79) and mycchis-ic: 5'aattcttattagtgatggtgatggtgat-gtgcgcgccattcagatcctct tctgagatgagttttgttctgc 3' (SEQ.ID.NO. 80) FIG. 32 shows a schematic representation of the plasmid pMycHis6. The c-myc-tag sequence is used to detect the scFv fragment in an ELISA or a Western Blot analysis (Evan et al., Mol.Cell.Biol., 1985, 5(12), pp. 3610-6). The His6-tag sequence was included to facilitate the purification of scFv fragments by metal ion chromatography (Hochuli et al., 1988. Biotechnology, 6: 1321-1325). The plasmid contains the lacZ gene promoter (PlacZ) the PelB-leader sequence (see legend FIG. 26) an *E. coli* origin of replication (colE1ori) and a M13 phage origin of replication (M13ori). To allow for specific selection, the plasmid also carries the gene for the enzyme β-lactamase (AmpR) mediating resistance against the antibiotic ampicillin.

The gene of the 198/B1 (clone AB2)-scFv was rescued from plasmid pDAP2-198AB2#100 (example 16) by digestion with SfiI and NotI and inserted into SfiI/NotI cleaved pMycHis6. The resultant plasmid was designated pMycHis-198AB2#102. FIG. 34 shows the nucleotide and amino acid sequence of 198AB2 scFv (linked to the c-myc-tag and the His6tag):the resulting ORF of the expression vector is named pMycHisG-198AB2#102. Vector pMycHis6 was constructed by cleaving vector pCOCK (Engelhardt O. et al, BioTechniques 17, 44-46, 1994) NotI-EcoRI and inserting the following annealed oligonucleotides: (5'-GGCCGCAGAACAAAACACTCATCTCAGAA-GAGGATCTGAATGGG GCGGCACATCACCATCACCATCACTAATAAG-3' (SEQ.ID.No. 103) and 5'-TTATTAGTGATGGTGATGGT GATGTGCCGCCCATTCAGATCCTCTTCTGAGATGA GTTTTTGTCTGC-3'(SEQ.ID.NO. 104)). The resultant vector, named pMycHis6, was cleaved SfiI-NotI and the gene of scFv 198AB2 was swapped into this vector from vector pDAP2-198AB2#100.

In analogy to the 198AB2 construct, the #8860 scFv fragment was cloned from a plasmid designated pDAP2-8860scFv clone 11. The pure scFv protein of #8860 was designated 8860-M/H#4c (plasmid p8860-M/H#4c, FIG. 35). The scFv proteins were expressed in *E. coli* and affinity purified from bacterial supernatants on Protein L columns (see example 17). The final MycHis-198AB2#102 and 8860-M/H#4c preparations were dialyzed against 50 mM imidazole, 100 mM NaCl, pH7.4 and analyzed in a chromogenic FVIII assay as described above (FIG. 36).

As can be seen in FIG. 36, the scfv construct MycHis-198AB2#102 gave rise to a substantial FXa generation whereas the negative controls 8860-M/H#4c and plain reaction buffer (IZ) did not.

FIG. 36 demonstrates the chromogenic FVIII-like activity of the 198/B1 (subclone AB2) scFv fragment (MycHis-198AB2#102) in the presence of 2.3 nM human FIXa. As a positive control we used 4.8 pM FVIII whereas an unrelated scfv (8860-M/H#4c) and plain reaction buffer (IZ) served as negative controls.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 112

<210> SEQ ID NO 1
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
 oligonucleotide MOCG1-2FOR

<400> SEQUENCE: 1

ctcaattttc ttgtccacct tgggtgc 26

<210> SEQ ID NO 2
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
 oligonucleotide MOCG3FOR

<400> SEQUENCE: 2

ctcgattctc ttgatcaact cagtct 26

<210> SEQ ID NO 3
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
 oligonucleotide MOCMPOR

<400> SEQUENCE: 3

tggaatgggc acatgcagat ctct 24

<210> SEQ ID NO 4
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:primer
 MOCKFOR

<400> SEQUENCE: 4

ctcattcctg ttgaagctct tgac 24

<210> SEQ ID NO 5
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma
 cell line 193/AD3 heavy chain CDR3 region

<400> SEQUENCE: 5

Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr
 1 5 10

<210> SEQ ID NO 6
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma
 cell line 193/K2 heavy chain CDR3 region

-continued

<400> SEQUENCE: 6

Asp Gly Gly His Gly Tyr Gly Ser Ser Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 7

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell line 193/AB2 (derived from antibody 198/B1) heavy chain CDR3 region, peptide B1

<400> SEQUENCE: 7

Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Val
 1 5 10

<210> SEQ ID NO 8

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:hybridoma cell line 198/A1 heavy chain CDR3 region, peptide A1

<400> SEQUENCE: 8

Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Val
 1 5 10

<210> SEQ ID NO 9

<400> SEQUENCE: 9

000

<210> SEQ ID NO 10

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1 derived mutated peptide A1/1 scrambled version of A1

<400> SEQUENCE: 10

Val Tyr Gly Phe Gly Trp Gly Tyr Glu Val Asn Asp Tyr
 1 5 10

<210> SEQ ID NO 11

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1 derived mutated peptide A1/2

<400> SEQUENCE: 11

Glu Glu Glu Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Glu
 1 5 10 15

Glu Glu

<210> SEQ ID NO 12

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody 198/A1 derived mutated peptide A1/3

-continued

<400> SEQUENCE: 12

Arg Arg Arg Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 13

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutated peptide A1/4 scrambled version of A1/2

<400> SEQUENCE: 13

Glu Tyr Gly Glu Gly Tyr Gly Glu Val Asn Glu Tyr Asp Glu Phe Glu
 1 5 10 15

Trp Glu

<210> SEQ ID NO 14

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutated peptide A1/5 scrambled version of A1/3

<400> SEQUENCE: 14

Val Arg Tyr Arg Asn Arg Tyr Arg Trp Gly Tyr Arg Gly Arg Phe Gly
 1 5 10 15

Asp Glu

<210> SEQ ID NO 15

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutated peptide A1/3-scr3 scrambled version of A1/3

<400> SEQUENCE: 15

Arg Arg Arg Gly Glu Tyr Gly Val Tyr Trp Asn Gly Asp Phe Tyr Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 16

<400> SEQUENCE: 16

000

<210> SEQ ID NO 17

<400> SEQUENCE: 17

000

<210> SEQ ID NO 18

<400> SEQUENCE: 18

000

<210> SEQ ID NO 19

-continued

```

<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-13 Alanine scan E-1-A-1

<400> SEQUENCE: 19

```

```

Arg Arg Arg Ala Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
  1             5             10             15

```

Arg Arg

```

<210> SEQ ID NO 20
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-1 Alanine scan G-2-A-2

<400> SEQUENCE: 20

```

```

Arg Arg Arg Glu Ala Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
  1             5             10             15

```

Arg Arg

```

<210> SEQ ID NO 21
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-2 Alanine scan G-3-A-3

<400> SEQUENCE: 21

```

```

Arg Arg Arg Glu Gly Ala Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
  1             5             10             15

```

Arg Arg

```

<210> SEQ ID NO 22
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-3 Alanine scan G-4-A-4

<400> SEQUENCE: 22

```

```

Arg Arg Arg Glu Gly Gly Ala Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
  1             5             10             15

```

Arg Arg

```

<210> SEQ ID NO 23
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
    198/A1 derived mutant peptide A1/3-4 Alanine scan Y-5-A-5

<400> SEQUENCE: 23

```

```

Arg Arg Arg Glu Gly Gly Gly Ala Tyr Val Asn Trp Tyr Phe Asp Arg
  1             5             10             15

```

Arg Arg

-continued

<210> SEQ ID NO 24
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-5 Alanine scan Y-6-A-6

<400> SEQUENCE: 24

Arg Arg Arg Glu Gly Gly Tyr Ala Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 25
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-6 Alanine scan V-7-A-7

<400> SEQUENCE: 25

Arg Arg Arg Glu Gly Gly Tyr Tyr Ala Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 26
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-7 Alanine scan N-8-A-8

<400> SEQUENCE: 26

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Ala Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 27
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-8 Alanine scan W-9-A-9

<400> SEQUENCE: 27

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Ala Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 28
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-9 Alanine scan Y-10-A-10

<400> SEQUENCE: 28

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Ala Phe Asp Arg
 1 5 10 15

Arg Arg

-continued

<210> SEQ ID NO 29
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-10 Alanine scan F-11-A-11

<400> SEQUENCE: 29

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Ala Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 30
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-11 Alanine scan D-12-A-12

<400> SEQUENCE: 30

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Ala Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 31
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-12srmb scrambled version

<400> SEQUENCE: 31

Arg Arg Arg Tyr Val Tyr Asn Gly Trp Gly Tyr Phe Glu Gly Ala Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 32
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-22 Glutamic acid scan G-2-E-2

<400> SEQUENCE: 32

Arg Arg Arg Glu Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 33
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-23 Glutamic acid scan G-3-E-3

<400> SEQUENCE: 33

Arg Arg Arg Glu Gly Glu Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

-continued

<210> SEQ ID NO 34
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-24 Glutamic acid scan G-4-E-4

<400> SEQUENCE: 34

Arg Arg Arg Glu Gly Gly Glu Tyr Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 35
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-26 Glutamic acid scan Y-5-E-5

<400> SEQUENCE: 35

Arg Arg Arg Glu Gly Gly Gly Glu Tyr Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 36
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-27 Glutamic acid scan Y-6-E-6

<400> SEQUENCE: 36

Arg Arg Arg Glu Gly Gly Gly Tyr Glu Val Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 37
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-28 Glutamic acid scan V-7-E-7

<400> SEQUENCE: 37

Arg Arg Arg Glu Gly Gly Gly Tyr Tyr Glu Asn Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 38
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-29 Glutamic acid scan N-8-E-8

<400> SEQUENCE: 38

Arg Arg Arg Glu Gly Gly Gly Tyr Tyr Val Glu Trp Tyr Phe Asp Arg
 1 5 10 15

-continued

Arg Arg

<210> SEQ ID NO 39
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-30 Glutamic acid scan W-9-E-9

<400> SEQUENCE: 39

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Glu Trp Tyr Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 40
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-31 Glutamic acid scan Y-10-E-10

<400> SEQUENCE: 40

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Glu Phe Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 41
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-32 Glutamic acid scan F-11-E-11

<400> SEQUENCE: 41

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Glu Asp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 42
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-33 Glutamic acid scan D12-E-12

<400> SEQUENCE: 42

Arg Arg Arg Glu Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Glu Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 43
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:antibody
 198/A1 derived mutant peptide A1/3-34srmb scrambled version

<400> SEQUENCE: 43

Arg Arg Arg Gly Glu Tyr Gly Glu Tyr Trp Asn Gly Asp Phe Tyr Arg
 1 5 10 15

-continued

Arg Arg

<210> SEQ ID NO 44

<400> SEQUENCE: 44

000

<210> SEQ ID NO 45

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/4

<400> SEQUENCE: 45

Arg Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Arg
1 5 10

<210> SEQ ID NO 46

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/5 scrambled version

<400> SEQUENCE: 46

Phe Gly Val Gly Tyr Arg Gly Glu Thr Arg Asn Phe Asp Trp
1 5 10

<210> SEQ ID NO 47

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/6

<400> SEQUENCE: 47

Glu Glu Glu Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Glu
1 5 10 15

Glu Glu

<210> SEQ ID NO 48

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/7

<400> SEQUENCE: 48

Arg Arg Arg Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Arg
1 5 10 15

Arg Arg

<210> SEQ ID NO 49

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:antibody
198/B1 derived mutated peptide B1/7scr3 scrambled version

-continued

<400> SEQUENCE: 49

Arg Arg Arg Phe Gly Val Gly Tyr Gly Glu Thr Asn Phe Asp Trp Arg
 1 5 10 15

Arg Arg

<210> SEQ ID NO 50

<211> LENGTH: 57

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
back primer VH1BACK-Sfi

<400> SEQUENCE: 50

catgccatga ctgcgggcc agccggccat ggccsaggtg marctgcags agtcwgg 57

<210> SEQ ID NO 51

<211> LENGTH: 56

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
back primer VH1BACKSfi

<400> SEQUENCE: 51

gtcctcgcaa ctgcggccca gccggccatg gccgaggtgc agcttcagga gtcagg 56

<210> SEQ ID NO 52

<211> LENGTH: 56

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
back primer VH2BACKSfi

<400> SEQUENCE: 52

gtcctcgcaa ctgcggccca gccggccatg gccgatgtgc agcttcagga gtcrgg 56

<210> SEQ ID NO 53

<211> LENGTH: 56

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
back primer VH3BACKSfi

<400> SEQUENCE: 53

gtcctcgcaa ctgcggccca gccggccatg gccaggtgc agctgaagsa gtcagg 56

<210> SEQ ID NO 54

<211> LENGTH: 56

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
back primer VH4/6BACKSfi

<400> SEQUENCE: 54

gtcctcgcaa ctgcggccca gccggccatg gccgaggtgc agctgcarca rtctgg 56

<210> SEQ ID NO 55

<211> LENGTH: 56

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H

-continued

back primer VH5/9BACKSfi

<400> SEQUENCE: 55

gtcctcgcaa ctgcggccca gccggccatg gccaggtgc arctgcagca gytg 56

<210> SEQ ID NO 56
 <211> LENGTH: 56
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
 back primer VH7BACKSfi

<400> SEQUENCE: 56

gtcctcgcaa ctgcggccca gccggccatg gccgargtga agctggtgga rtctg 56

<210> SEQ ID NO 57
 <211> LENGTH: 56
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
 back primer VH8BACKSfi

<400> SEQUENCE: 57

gtcctcgcaa ctgcggccca gccggccatg gccgaggttc agcttcagca gtctg 56

<210> SEQ ID NO 58
 <211> LENGTH: 56
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
 back primer VH10BACKSfi

<400> SEQUENCE: 58

gtcctcgcaa ctgcggccca gccggccatg gccgaagtgc agctgktgga gwtg 56

<210> SEQ ID NO 59
 <211> LENGTH: 56
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse V-H
 back primer VH11BACKSfi

<400> SEQUENCE: 59

gtcctcgcaa ctgcggccca gccggccatg gccagatcc agttgctgca gtctg 56

<210> SEQ ID NO 60
 <211> LENGTH: 68
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
 forward primer VH1FOR2LiAsc

<400> SEQUENCE: 60

accgccagag gcgccccac ctgaaccgcc tccacctgag gagacgtgga ccgtggtccc 60

ttggcccc 68

<210> SEQ ID NO 61
 <211> LENGTH: 60
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

```

<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH1FORLiAsc

<400> SEQUENCE: 61

accgccagag gcgcgccac ctgaaccgcc tccacctgag gagacggtga cctggtccc 60

<210> SEQ ID NO 62
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH2FORLiAsc

<400> SEQUENCE: 62

accgccagag gcgcgccac ctgaaccgcc tccacctgag gagactgtga gactggtgcc 60

<210> SEQ ID NO 63
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH3FORLiAsc

<400> SEQUENCE: 63

accgccagag gcgcgccac ctgaaccgcc tccacctgca gagacagtga ccagagtccc 60

<210> SEQ ID NO 64
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse J-H
forward primer JH4FORLiAsc

<400> SEQUENCE: 64

accgccagag gcgcgccac ctgaaccgcc tccacctgag gagacggtga ctgaggtccc 60

<210> SEQ ID NO 65
<211> LENGTH: 60
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK2BACK-LiAscI

<400> SEQUENCE: 65

ggttcagatg ggcgcgctc tggcggtggc ggatcggaca ttgagctcac ccagtctcca 60

<210> SEQ ID NO 66
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
V-kappa back primer VK1BACKLi Asc

<400> SEQUENCE: 66

ggttcagatg ggcgcgctc tggcggtggc ggatcggaca ttgtgatgwc acagtctcc 59

<210> SEQ ID NO 67
<211> LENGTH: 59
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse

```

-continued

V-kappa back primer VK2BACKLi Asc

<400> SEQUENCE: 67

ggttcagatg ggcgcgcctc tggcgggtggc ggatcggatg tktgatgac ccaaactcc 59

<210> SEQ ID NO 68
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK3BACKLi Asc

<400> SEQUENCE: 68

ggttcagatg ggcgcgcctc tggcgggtggc ggatcggata ttgtgatrac bcaggcwgcc 59

<210> SEQ ID NO 69
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK4BACKLi Asc

<400> SEQUENCE: 69

ggttcagatg ggcgcgcctc tggcgggtggc ggatcggaca ttgtgctgac mcartctcc 59

<210> SEQ ID NO 70
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK5BACKLi Asc

<400> SEQUENCE: 70

ggttcagatg ggcgcgcctc tggcgggtggc ggatcgsaaa wtgkctcac ccagtctcc 59

<210> SEQ ID NO 71
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK6BACKLi Asc

<400> SEQUENCE: 71

ggttcagatg ggcgcgcctc tggcgggtggc ggatcggaya tyvwgatgac mcagwctcc 59

<210> SEQ ID NO 72
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK7BACKLi Asc

<400> SEQUENCE: 72

ggttcagatg ggcgcgcctc tggcgggtggc ggatcgcaaa ttgttctcac ccagtctcc 59

<210> SEQ ID NO 73
 <211> LENGTH: 59
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mouse
 V-kappa back primer VK8BACKLi Asc

-continued

<400> SEQUENCE: 73
ggttcagatg ggcgcgcctc tggcgggtggc ggatcgtcat tattgcaggt gcttggtggg 59

<210> SEQ ID NO 74
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK1NOT10

<400> SEQUENCE: 74
gagtcattct gcggccgccc gtttgatttc cagcttggtg cc 42

<210> SEQ ID NO 75
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK2NOT10

<400> SEQUENCE: 75
gagtcattct gcggccgccc gttttatttc cagcttggtc cc 42

<210> SEQ ID NO 76
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK3NOT10

<400> SEQUENCE: 76
gagtcattct gcggccgccc gttttatttc cagcttggtc cc 42

<210> SEQ ID NO 77
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK4NOT10

<400> SEQUENCE: 77
gagtcattct gcggccgccc gttttatttc caactttgtc cc 42

<210> SEQ ID NO 78
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mouse
J-kappa forward primer JK5NOT10

<400> SEQUENCE: 78
gagtcattct gcggccgccc gtttcagctc cagcttggtc cc 42

<210> SEQ ID NO 79
<211> LENGTH: 74
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:
oligonucleotide mychis6-co

-continued

<400> SEQUENCE: 79

ggccgcagaa caaaaactca tctcagaaga ggatctgaat ggggcggcac atcaccaatca 60
 ccatcactaa taag 74

<210> SEQ ID NO 80

<211> LENGTH: 74

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:
 oligonucleotide mycchis-ic

<400> SEQUENCE: 80

aattcttatt agtgatgggt atggtgatgt gccgccccat tcagatcctc ttctgagatg 60
 agtttttggt ctgc 74

<210> SEQ ID NO 81

<211> LENGTH: 726

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 193/AD3

<400> SEQUENCE: 81

gaggtgaagc tgggtggatc tggacctgag ctgaagaagc ctggagagac agtcaagatc 60
 tcctgcaagg cttctgggta tatcttcaca aactatggaa tgaactgggt gaagcaggct 120
 ccaggaaggg gtttaaagtg gatgggctgg ataacacct aactgggaga gccaacatat 180
 gctgatgact tcaagggacg gtttgcttc tctttgaaa cctctgccag cactgcctat 240
 ttgcagatca acaacctcaa aatgaggac acggctacat atttctgtgc attatatggt 300
 aactccccta aggggtttgc ttactggggc caagggactc tggctactgt ctctgcagg 360
 ggaggcgggt caggtggggc cgcctctggc ggtggcggat cggatatcca gatgacacag 420
 tctcccaaat tctgtctgt atcagcagga gacagggtta ccataacctg caaggccagt 480
 cagagtgtga gtaatgatgt agcttggtac caacagaagc cggggcagtc tcctaaacta 540
 ctgatgtact atgcaccaa tcgctacact ggagtccctg atcgcttcac tggcagtgga 600
 tatgggacgg atttcacttt caccatcagc actgtgcagg ctgaagacct ggcagtttat 660
 ttctgtcagc aggattatgg ctctcctccc acgttcggag ggggcaccaa gctggaatt 720
 aaacgg 726

<210> SEQ ID NO 82

<211> LENGTH: 242

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 193/AD3

<400> SEQUENCE: 82

Glu Val Lys Leu Val Glu Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
 1 5 10 15
 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Asn Tyr
 20 25 30
 Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
 35 40 45
 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe

-continued

50	55	60
Lys Gly Arg Phe Ala Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80		
Leu Gln Ile Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys 85 90 95		
Ala Leu Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr Trp Gly Gln Gly 100 105 110		
Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly Arg Ala 115 120 125		
Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Lys Phe 130 135 140		
Leu Leu Val Ser Ala Gly Asp Arg Val Thr Ile Thr Cys Lys Ala Ser 145 150 155 160		
Gln Ser Val Ser Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln 165 170 175		
Ser Pro Lys Leu Leu Met Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val 180 185 190		
Pro Asp Arg Phe Thr Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr 195 200 205		
Ile Ser Thr Val Gln Ala Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln 210 215 220		
Asp Tyr Gly Ser Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 225 230 235 240		
Lys Arg		

<210> SEQ ID NO 83
 <211> LENGTH: 747
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 193/K2

<400> SEQUENCE: 83
 gaagtcagc tggaggagtc tgggggagcc ctagtgaagc ctggagggtc cctgaaactc 60
 tcctgtgcag cctctggatt cactttcagt acctatacca tgtcttgggt tcgccagact 120
 ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtgtagtta cacctactat 180
 ccagacagtg tgaggggccc attcaccatc tccagagaca atgccaagaa cacctgtac 240
 ctgcaaatga gcagtctgaa gtctgaggac acagccatgt attactgtac aagagatggg 300
 ggacacgggt acggtagtag ctttgactac tggggccaag gcaccactct cacagtctcc 360
 tcaggtggag gcggttcagg tgggcgccc tctggcgtg gcgatcgca aattgtgctc 420
 acccagtctc cactctccct gcctgtcagt cttggagatc aagcctccat ctcttgacga 480
 tctagtcaga gcattgtaca tagtaatgga aacacctatt tagaatgga cctgcagaaa 540
 ccaggccagt ctccaaagct cctgatctac aaagtttcca accgattttc tggggctcca 600
 gacaaattca gtggcagtg atcagggaca gatttcacac tcaagatcag cagagtggag 660
 gctgaggatc tgggagtta ttactgcttt caaggttcac atgttccgtg gacgttcggt 720
 ggaggcacca agctggaaat caaacgg 747

<210> SEQ ID NO 84
 <211> LENGTH: 249
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 193/K2

<400> SEQUENCE: 84

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr
 20 25 30
 Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35 40 45
 Ala Thr Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
 50 55 60
 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Thr Arg Asp Gly Gly His Gly Tyr Gly Ser Ser Phe Asp Tyr Trp Gly
 100 105 110
 Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
 115 120 125
 Arg Ala Ser Gly Gly Gly Gly Ser Gln Ile Val Leu Thr Gln Ser Pro
 130 135 140
 Leu Ser Leu Pro Val Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg
 145 150 155 160
 Ser Ser Gln Ser Ile Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp
 165 170 175
 Tyr Leu Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val
 180 185 190
 Ser Asn Arg Phe Ser Gly Val Pro Asp Lys Phe Ser Gly Ser Gly Ser
 195 200 205
 Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu
 210 215 220
 Gly Val Tyr Tyr Cys Phe Gln Gly Ser His Val Pro Trp Thr Phe Gly
 225 230 235 240
 Gly Gly Thr Lys Leu Glu Ile Lys Arg
 245

<210> SEQ ID NO 85
 <211> LENGTH: 747
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
 hybridoma cell line 198/AB2 (subclone of 198/B1)

<400> SEQUENCE: 85

gaggtgcagc ttcaggagtc agggggaggc ttagtgaagc ctggagggtc cctgaaactc 60
 tcctgtgcag cctctggatt cactttcagt agctatacca tgtcttgggt tcgccagact 120
 ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtggtagttc cacctactat 180
 ccagacagtg tgaagggccg attcaccatc tccagagaca atgccaagaa caccctgtac 240
 ctgcaaatga gcagtctgag gtctgaggac acagccatgt attactgtac aagagagggg 300
 ggtggtttca ccgtcaactg gtacttcgat gtctggggcg cagggactct ggtcactgtc 360
 tctgcaggty gaggcggttc aggtggggcg gcctctggcg gtggcggatc ggaaaatgtg 420

-continued

```

ctcaccagct ctccagcttc ttggctgtg tctctagggc agagggccac catatcctgc 480
agagccagtg aaagtgtga tagttatggc tataatttta tgcactggta tcagcagata 540
ccaggacagc caccCAAact cctcatctat cgtgcatcca acctagagtc tgggatccct 600
gccaggttca gtggcagtggt gtctaggaca gacttcaccc tcaccattaa tctgtggag 660
gctgatgatg ttgcaaccta ttactgtcag caaagtaatg aggatccgct cacgttcggt 720
actgggacca gactggaaat aaaacgg 747
    
```

```

<210> SEQ ID NO 86
<211> LENGTH: 249
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv from
hybridoma cell line 198/AB2 (subclone of 198/B1)
    
```

<400> SEQUENCE: 86

```

Glu Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
 1           5           10           15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20           25           30
Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
 35           40           45
Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr Tyr Tyr Pro Asp Ser Val
 50           55           60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65           70           75
Leu Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys
 85           90           95
Thr Arg Glu Gly Gly Gly Phe Thr Val Asn Trp Tyr Phe Asp Val Trp
100           105           110
Gly Ala Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly
115           120           125
Gly Arg Ala Ser Gly Gly Gly Gly Ser Glu Asn Val Leu Thr Gln Ser
130           135           140
Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
145           150           155
Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Tyr Asn Phe Met His Trp
165           170           175
Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala
180           185           190
Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
195           200           205
Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val
210           215           220
Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly
225           230           235           240
Thr Gly Thr Arg Leu Glu Ile Lys Arg
245
    
```

```

<210> SEQ ID NO 87
<211> LENGTH: 747
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv derived
from hybridima cell line 198/A1
    
```

-continued

```

<220> FEATURE:
<221> NAME/KEY: modified_base
<222> LOCATION: (1)..(747)
<223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 87

gagggtcagc ttcaggagtc agggggaggc ttagtgaagc ctggagggtc cctgaaactc      60
tcctgtgcag cctctggatt catttttagt agttatacca tgtcttgggt tcgccagact      120
ccggagaaga ggctggagtg ggtcgcaacc attagtagtg gtggtagttc cacctactat      180
ccagacagtg tgaagggccg attcaccatc tccagagaca atgccaagaa caccctgtac      240
ctgcaaatga gcagtctgaa gtctgaggac acagccatgt atcactgtac aagagagggg      300
ggtggttatt acgtcaactg gtacttcgat gtctggggcg caggcaccac tctcacagtc      360
tcctcaggtg gaggcgggtc aggtggggcg gcctctggcg gtggcggatc ggacattgag      420
ctcacncagt ctccagcttc ttggctgtg tctctagggc agagggccac catatcctgc      480
agagccagtg aaagtgtga tagttatggc aagagtttta tgcactggta ccagcagaaa      540
ccagggcagc caccxaaact cctcatctat cgtgcatcca acctagaatc tgggatccct      600
gccaggttca gtggcagtg gtctaggaca gacttcaccc tcaccattaa tcctgtggag      660
gctgatgatg ttgcnaccta ttactgtcag caaagtaatg aggatcccct cacgttcggt      720
gctgggacca gactggaaat aaaacgg                                         747

```

```

<210> SEQ ID NO 88
<211> LENGTH: 249
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:scFv derived
from hybridima cell line 198/A1

```

```

<400> SEQUENCE: 88

Glu Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
  1                    5              10              15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ile Phe Ser Ser Tyr
  20              25              30

Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val
  35              40              45

Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr Tyr Tyr Pro Asp Ser Val
  50              55              60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
  65              70              75              80

Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr His Cys
  85              90              95

Thr Arg Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp Val Trp
  100             105             110

Gly Ala Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
  115             120             125

Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp Ile Glu Leu Thr Gln Ser
  130             135             140

Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys
  145             150             155             160

Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly Lys Ser Phe Met His Trp
  165             170             175

Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala
  180             185             190

```

-continued

Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
 195 200 205
 Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val
 210 215 220
 Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Leu Thr Phe Gly
 225 230 235 240
 Ala Gly Thr Arg Leu Glu Ile Lys Arg
 245

<210> SEQ ID NO 89
 <211> LENGTH: 2199
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:198A2
 scFv-alkaline phosphatase fusion protein (ORF of expression
 vector pDAP2-198AB2#100)
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (228)
 <223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 89

atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
 atggcgagg tgaagctggt ggagctctgg ggaggcttag tgaagcctgg agggtcctctg 120
 aaactctcct gtgcagcctc tggattcact ttcagtagct ataccatgtc ttgggttcgc 180
 cagactccgg agaagaggct ggagtgggtc gcaaccatta gtagtgngg tagttccacc 240
 tactatccag acagtgtgaa gggccgattc accatctcca gagacaatgc caagaacacc 300
 ctgtacctgc aaatgagcag tctgaggctt gaggacacag ccatgtatta ctgtacaaga 360
 gaggggggtg gtttcaccgt caactggtac ttcgatgtct gggcgccagg aacctcagtc 420
 accgtctcct caggtggagg cggttcaggt gggcgccgct ctggcggtgg cggatcggac 480
 attgtgctga cacagctctc agcttctttg gctgtgtctc tagggcagag gggccaccata 540
 tcctgcagag ccagtgaaag tgttgatagt tatggctata attttatgca ctggtatcag 600
 cagataccag gacagccacc caaactcctc atctatcgtg catccaacct agagtctggg 660
 atccttgcca ggttcagtgg cagtggttct aggacagact tcaccctcac cattaatcct 720
 gtggaggctg atgatgttgc aacctattac tgtcagcaa gtaatgagga tccgctcacc 780
 ttcggtactg ggaccagact ggaaataaaa cgggcggccg cagcccgggc accagaaatg 840
 cctgttcttg aaaaccgggc tgctcagggc gatattactg caccgggggg tgctcggcgt 900
 ttaacgggtg atcagactgc cgctctgcgt gattctctta gcgataaacc tgcaaaaaat 960
 attattttgc tgattggcga tgggatgggg gactcggaaa ttactgcgcg acgtaattat 1020
 gccgaagggt cggcgcgctt ttttaaaggt atagatgcct taccgcttac cgggcaatac 1080
 actcactatg cgctgaataa aaaaaccggc aaaccggact acgtcaccga ctcggtgca 1140
 tcagcaaccg cctggtcaac cgggtgcaaa acctataacg gcgcgctggg cgtcgatatt 1200
 cacgaaaaag atcacccaac gattctggaa atggcaaaag ccgcaggtct ggcgaccggt 1260
 aacgtttcta ccgcagagtt gcaggatgcc acgcccgctg cgctggtggc acatgtgacc 1320
 tcgcgcaaat gctacggtcc gagcgcgacc agtgaaaaat gtcggggtaa cgctctggaa 1380
 aaaggcggaa aaggatcgat taccgaacag ctgcttaacg ctcgtgccga cgttacgctt 1440
 ggcggcggcg caaaaacctt tgctgaaacg gcaaccgctg gtgaatggca gggaaaaacg 1500

-continued

```

ctgctggaac aggcacagcg gcgtggttat cagttggtga gcgatgctgc ctcaactgaat 1560
tcggtgacgg aagcgaatca gcaaaaaccc ctgcttgccc tgtttgctga cggcaatatg 1620
ccagtgcgct ggctaggacc gaaagcaacg taccatggca atatcgataa gcccgagtc 1680
acctgtacgc caaatccgca acgtaatgac agtgtaccaa ccctggcgca gatgaccgac 1740
aaagccattg aattgttgag taaaaatgag aaaggctttt tcctgcaagt tgaaggtgag 1800
tcaatcgata aacaggatca tgctgcgaat ccttgtgggc aaattggcga gacggtcgat 1860
ctcgtatgaag ccgtacaacg ggcgctggaa ttcgctaaaa aggagggtaa cacgctggtc 1920
atagtcaccg ctgatcacgc ccacgccagc cagattgttg cgccggatac caaagctccg 1980
ggcctcaccg aggcgctaaa taccaaagat ggcgcagtga tggatgatgag ttacgggaac 2040
tccgaagagg attcacaaga acataccggc agtcagttgc gtattgcggc gtatggcccg 2100
catgccgcca atgttgttgg actgaccgac cagaccgatc tcttctacac catgaaagcc 2160
gctctggggg atatcgaca ccatcacat caccattaa 2199
    
```

```

<210> SEQ ID NO 90
<211> LENGTH: 732
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:198A2
        scFv-alkaline phosphatase fusion protein (ORF of expression
        vector pDAP2-198AB2#100)
    
```

```

<400> SEQUENCE: 90
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1             5             10             15
Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu Ser Gly Gly Gly
 20             25             30
Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
 35             40             45
Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu
 50             55             60
Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr
 65             70             75             80
Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 85             90             95
Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
 100            105            110
Thr Ala Met Tyr Tyr Cys Thr Arg Glu Gly Gly Gly Phe Thr Val Asn
 115            120            125
Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
 130            135            140
Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp
 145            150            155            160
Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln
 165            170            175
Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly
 180            185            190
Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys
 195            200            205
Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg
 210            215            220
Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro
    
```

-continued

225				230						235				240	
Val	Glu	Ala	Asp	Asp	Val	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Ser	Asn	Glu
				245						250				255	
Asp	Pro	Leu	Thr	Phe	Gly	Thr	Gly	Thr	Arg	Leu	Glu	Ile	Lys	Arg	Ala
			260						265					270	
Ala	Ala	Ala	Arg	Ala	Pro	Glu	Met	Pro	Val	Leu	Glu	Asn	Arg	Ala	Ala
			275						280					285	
Gln	Gly	Asp	Ile	Thr	Ala	Pro	Gly	Gly	Ala	Arg	Arg	Leu	Thr	Gly	Asp
		290					295					300			
Gln	Thr	Ala	Ala	Leu	Arg	Asp	Ser	Leu	Ser	Asp	Lys	Pro	Ala	Lys	Asn
	305					310					315				320
Ile	Ile	Leu	Leu	Ile	Gly	Asp	Gly	Met	Gly	Asp	Ser	Glu	Ile	Thr	Ala
				325						330					335
Ala	Arg	Asn	Tyr	Ala	Glu	Gly	Ala	Gly	Gly	Phe	Phe	Lys	Gly	Ile	Asp
			340						345					350	
Ala	Leu	Pro	Leu	Thr	Gly	Gln	Tyr	Thr	His	Tyr	Ala	Leu	Asn	Lys	Lys
			355					360						365	
Thr	Gly	Lys	Pro	Asp	Tyr	Val	Thr	Asp	Ser	Ala	Ala	Ser	Ala	Thr	Ala
		370					375						380		
Trp	Ser	Thr	Gly	Val	Lys	Thr	Tyr	Asn	Gly	Ala	Leu	Gly	Val	Asp	Ile
					390						395				400
His	Glu	Lys	Asp	His	Pro	Thr	Ile	Leu	Glu	Met	Ala	Lys	Ala	Ala	Gly
				405						410					415
Leu	Ala	Thr	Gly	Asn	Val	Ser	Thr	Ala	Glu	Leu	Gln	Asp	Ala	Thr	Pro
			420						425					430	
Ala	Ala	Leu	Val	Ala	His	Val	Thr	Ser	Arg	Lys	Cys	Tyr	Gly	Pro	Ser
			435					440						445	
Ala	Thr	Ser	Glu	Lys	Cys	Pro	Gly	Asn	Ala	Leu	Glu	Lys	Gly	Gly	Lys
			450					455					460		
Gly	Ser	Ile	Thr	Glu	Gln	Leu	Leu	Asn	Ala	Arg	Ala	Asp	Val	Thr	Leu
					470						475				480
Gly	Gly	Gly	Ala	Lys	Thr	Phe	Ala	Glu	Thr	Ala	Thr	Ala	Gly	Glu	Trp
					485						490				495
Gln	Gly	Lys	Thr	Leu	Arg	Glu	Gln	Ala	Gln	Ala	Arg	Gly	Tyr	Gln	Leu
			500						505					510	
Val	Ser	Asp	Ala	Ala	Ser	Leu	Asn	Ser	Val	Thr	Glu	Ala	Asn	Gln	Gln
			515					520					525		
Lys	Pro	Leu	Leu	Gly	Leu	Phe	Ala	Asp	Gly	Asn	Met	Pro	Val	Arg	Trp
			530				535						540		
Leu	Gly	Pro	Lys	Ala	Thr	Tyr	His	Gly	Asn	Ile	Asp	Lys	Pro	Ala	Val
			545				550				555				560
Thr	Cys	Thr	Pro	Asn	Pro	Gln	Arg	Asn	Asp	Ser	Val	Pro	Thr	Leu	Ala
				565						570					575
Gln	Met	Thr	Asp	Lys	Ala	Ile	Glu	Leu	Leu	Ser	Lys	Asn	Glu	Lys	Gly
			580						585					590	
Phe	Phe	Leu	Gln	Val	Glu	Gly	Ala	Ser	Ile	Asp	Lys	Gln	Asp	His	Ala
			595					600					605		
Ala	Asn	Pro	Cys	Gly	Gln	Ile	Gly	Glu	Thr	Val	Asp	Leu	Asp	Glu	Ala
			610					615					620		
Val	Gln	Arg	Ala	Leu	Glu	Phe	Ala	Lys	Lys	Glu	Gly	Asn	Thr	Leu	Val
			625				630					635			640
Ile	Val	Thr	Ala	Asp	His	Ala	His	Ala	Ser	Gln	Ile	Val	Ala	Pro	Asp
				645						650					655

-continued

Thr Lys Ala Pro Gly Leu Thr Gln Ala Leu Asn Thr Lys Asp Gly Ala
 660 665 670
 Val Met Val Met Ser Tyr Gly Asn Ser Glu Glu Asp Ser Gln Glu His
 675 680 685
 Thr Gly Ser Gln Leu Arg Ile Ala Ala Tyr Gly Pro His Ala Ala Asn
 690 695 700
 Val Val Gly Leu Thr Asp Gln Thr Asp Leu Phe Tyr Thr Met Lys Ala
 705 710 715 720
 Ala Leu Gly Asp Ile Ala His His His His His His
 725 730

<210> SEQ ID NO 91
 <211> LENGTH: 978
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:plasmid
 pZip-198AB2#102
 <220> FEATURE:
 <221> NAME/KEY: modified_base
 <222> LOCATION: (1)..(978)
 <223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 91

atgaaatacc tattgctac gccagccgct ggattgttat tactcgcggc ccagccggcc 60
 atggcggagg tgaagctggt ggagctctgg ggaggcttag tgaagcctgg agggctccctg 120
 aaactctcct gtgcagcctc tggattcact ttcagtagct ataccatgtc ttgggttcgc 180
 cagactccgg agaagaggct ggagtggttc gcaaccatta gtagtggngg tagttccacc 240
 tactatccag acagtgtgaa gggccgattc accatctcca gagacaatgc caagaacacc 300
 ctgtacctgc aaatgagcag tctgaggtct gaggacacag ccatgtatta ctgtacaaga 360
 gaggggggtg gtttcaccgt caactggtac ttcgatgtct ggggcgcagg aacctcagtc 420
 accgtctcct caggtggagg cggttcaggt gggcgcgcct ctggcgggtg cggatcggac 480
 attgtgctga cacagntcc agcttctttg gctgtgtctc tagggcagag ggccaccata 540
 tcntgcagag ccagtgaaag tgttgatagt tatggctata attttatgca ctggtatcag 600
 cagataccag gacagccacc caaactcctc atctatcgtg catccaacct agagtctggg 660
 atccctgcca ggttcagtgg cagtggttct aggacagact tcaccctcac cattaatcct 720
 gtggaggctg atgatgttc aacctattac tgtcagcaa gtaatgagga tccgctcagc 780
 ttcggtactg ggaccagact gaaataaaa cgggcggccg caccgaagcc ttccactccg 840
 cccgggtcct cccgtatgaa acagctgtaa gacaaagtag aggagctcct tagcaagaac 900
 taccatctag aaaacagggt agctcgtctg aaaaagcttg ttggtgaacg tgggtgtcac 960
 catcaccatc accattaa 978

<210> SEQ ID NO 92
 <211> LENGTH: 325
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:plasmid
 pZip-198AB2#102
 <220> FEATURE:
 <221> NAME/KEY: MOD_RES
 <222> LOCATION: (166)
 <223> OTHER INFORMATION: Xaa = Cys, Tyr, Ser or Phe

<400> SEQUENCE: 92

-continued

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu Ser Gly Gly Gly
 20 25 30
 Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
 35 40 45
 Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu
 50 55 60
 Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr
 65 70 75 80
 Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 85 90 95
 Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
 100 105 110
 Thr Ala Met Tyr Tyr Cys Thr Arg Glu Gly Gly Gly Phe Thr Val Asn
 115 120 125
 Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
 130 135 140
 Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Ser Asp
 145 150 155 160
 Ile Val Leu Thr Gln Xaa Pro Ala Ser Leu Ala Val Ser Leu Gly Gln
 165 170 175
 Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly
 180 185 190
 Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys
 195 200 205
 Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg
 210 215 220
 Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro
 225 230 235 240
 Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu
 245 250 255
 Asp Pro Leu Thr Phe Gly Thr Gly Thr Arg Leu Glu Ile Lys Arg Ala
 260 265 270
 Ala Ala Pro Lys Pro Ser Thr Pro Pro Gly Ser Ser Arg Met Lys Gln
 275 280 285
 Leu Glu Asp Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu
 290 295 300
 Asn Glu Val Ala Arg Leu Lys Lys Leu Val Gly Glu Arg Gly Gly His
 305 310 315 320
 His His His His His
 325

<210> SEQ ID NO 93
 <211> LENGTH: 2190
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB#8860
 scFv-alkaline phosphatase fusion protein (vector construct
 pDAP2-8860scFv#11)
 <400> SEQUENCE: 93

atgaaatacc tattgacctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
 atggccgagg ttcagcttca gcagctctgga cctgagctgg tgaagcccg ggcctcagt 120

-continued

```

aagatttcct gcaaagcttc tggctacgca ttcagtagct cttggatgaa ctgggtgaag 180
cagaggcctg gacagggctc tgagtggatt ggacggattt atcctggaaa tggagatact 240
aactacaatg ggaagttcaa gggcaaggcc aactgactg cagacaaatc ctccagcaca 300
gcctacatgc agctcagcag cctgacctct gtggactctg cgtctatatt ctgtgcagat 360
ggtaacgcat attactatgc tatggactac tggggtaag gaacctcagt caccgtctcc 420
tcaggtggag gcggttcagg tgggcgcgcc tctggcggtg gcggatcgca aattgttctc 480
accagctctc ctgcttcctt agctgtatct ctggggcaga gggccaccat ctcatgcagg 540
gccagcaaaa gtgtcagtac atctggctat agttatatgc actggtacca acagaaacca 600
ggacagccac ccaaactcct catctatctt gcacccaacc tagaatctgg ggtccctgcc 660
aggttcagtg gcagtggttc tgggacagac ttcaccctca acatccatcc tgtggaggag 720
gaggatgctg caacctatta ctgtcagcac agtagggagc ttcctcggac gttcggtgga 780
ggcaccaagc tggaaatcaa acgggcggcc gcagcccggg caccagaaat gcctgttctg 840
gaaaaccggg ctgctcaggg cgatattact gcacccggcg gtgctcggcg tttaacgggt 900
gatcagactg ccgctctcgc tgattctctt agcgataaac ctgcaaaaaa tattatattg 960
ctgattggcg atgggatggg ggactcggaa attactgccg cacgtaatta tgccgaaggt 1020
gcgggcggct tttttaaagg tatagatgcc ttaccgctta ccgggcaata cactcactat 1080
gcgctgaata aaaaaaccg caaaccggac tacgtaccg actcggctgc atcagcaacc 1140
gcctgtgcaa ccggtgtcaa aacctataac ggcgcgctgg gcctcgatat tcacgaaaaa 1200
gatcacccaa cgattctgga aatggcaaaa gccgcagtc tggcgaccgg taacgtttct 1260
accgcagagt tgcaggatgc cacgcccgtc gcgctggtg cacatgtgac ctgcgcgcaa 1320
tgctacggtc cgagcgcgac cagtgaaaaa tgtccgggta acgctctgga aaaaggcggg 1380
aaaggatcga ttaccgaaca gctgcttaac gctcgtgccg acgttacgct tggcggcggc 1440
gcaaaaaact ttgctgaaac ggcaaccgct ggtgaatggc agggaaaaac gctgcgtgaa 1500
caggcacagg cgcgtggtta tcagttggtg agcgatgctg cctcactgaa ttcggtgacg 1560
gaagcgaatc agcaaaaacc cctgcttggc ctgtttctg acggcaatat gccagtgcgc 1620
tggctaggac cgaaagcaac gtaccatggc aatatcgata agcccgcagt cacctgtacg 1680
ccaaatccgc aacgtaatga cagtgtacca accctggcgc agatgaccga caaagccatt 1740
gaattgttga gtaaaaaatga gaaaggcttt ttcctgcaag ttgaagggtc gtcaatcgat 1800
aaacaggatc atgctcggaa tccttgtggg caaattggcg agacggtoga tctogatgaa 1860
gccgtacaac gggcgtgga attcgctaaa aaggagggta acacgctggt catagtcacc 1920
gctgatcagc cccacgccag ccagattgtt gcgccggata ccaaagctcc gggcctcacc 1980
caggcgctaa ataccaaaga tggcgcagtg atggtgatga gttacgggaa ctccgaagag 2040
gattcacaag aacataaccg cagtcagttg cgtattgcgg cgtatggccc gcatgccgcc 2100
aatgttggtg gactgaccga ccagaccgat ctcttctaca ccatgaaagc cgctctgggg 2160
gatatcgcac accatcacca tcaccattaa 2190

```

<210> SEQ ID NO 94

<211> LENGTH: 729

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:mAB#8860
scFv-alkaline phosphatase fusion protein (vector construct

-continued

pDAP2-8860scFv#11)

<400> SEQUENCE: 94

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Gln Ser Gly Pro Glu
 20 25 30
 Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
 35 40 45
 Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
 50 55 60
 Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
 65 70 75 80
 Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
 85 90 95
 Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
 100 105 110
 Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Tyr Ala Met
 115 120 125
 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
 130 135 140
 Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Gln Ile Val Leu
 145 150 155 160
 Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
 165 170 175
 Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
 180 185 190
 Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 195 200 205
 Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly
 210 215 220
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu
 225 230 235 240
 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg
 245 250 255
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Ala
 260 265 270
 Arg Ala Pro Glu Met Pro Val Leu Glu Asn Arg Ala Ala Gln Gly Asp
 275 280 285
 Ile Thr Ala Pro Gly Gly Ala Arg Arg Leu Thr Gly Asp Gln Thr Ala
 290 295 300
 Ala Leu Arg Asp Ser Leu Ser Asp Lys Pro Ala Lys Asn Ile Ile Leu
 305 310 315 320
 Leu Ile Gly Asp Gly Met Gly Asp Ser Glu Ile Thr Ala Ala Arg Asn
 325 330 335
 Tyr Ala Glu Gly Ala Gly Gly Phe Phe Lys Gly Ile Asp Ala Leu Pro
 340 345 350
 Leu Thr Gly Gln Tyr Thr His Tyr Ala Leu Asn Lys Lys Thr Gly Lys
 355 360 365
 Pro Asp Tyr Val Thr Asp Ser Ala Ala Ser Ala Thr Ala Trp Ser Thr
 370 375 380
 Gly Val Lys Thr Tyr Asn Gly Ala Leu Gly Val Asp Ile His Glu Lys
 385 390 395 400

-continued

Asp His Pro Thr Ile Leu Glu Met Ala Lys Ala Ala Gly Leu Ala Thr
 405 410 415

Gly Asn Val Ser Thr Ala Glu Leu Gln Asp Ala Thr Pro Ala Ala Leu
 420 425 430

Val Ala His Val Thr Ser Arg Lys Cys Tyr Gly Pro Ser Ala Thr Ser
 435 440 445

Glu Lys Cys Pro Gly Asn Ala Leu Glu Lys Gly Gly Lys Gly Ser Ile
 450 455 460

Thr Glu Gln Leu Leu Asn Ala Arg Ala Asp Val Thr Leu Gly Gly Gly
 465 470 475 480

Ala Lys Thr Phe Ala Glu Thr Ala Thr Ala Gly Glu Trp Gln Gly Lys
 485 490 495

Thr Leu Arg Glu Gln Ala Gln Ala Arg Gly Tyr Gln Leu Val Ser Asp
 500 505 510

Ala Ala Ser Leu Asn Ser Val Thr Glu Ala Asn Gln Gln Lys Pro Leu
 515 520 525

Leu Gly Leu Phe Ala Asp Gly Asn Met Pro Val Arg Trp Leu Gly Pro
 530 535 540

Lys Ala Thr Tyr His Gly Asn Ile Asp Lys Pro Ala Val Thr Cys Thr
 545 550 555 560

Pro Asn Pro Gln Arg Asn Asp Ser Val Pro Thr Leu Ala Gln Met Thr
 565 570 575

Asp Lys Ala Ile Glu Leu Leu Ser Lys Asn Glu Lys Gly Phe Phe Leu
 580 585 590

Gln Val Glu Gly Ala Ser Ile Asp Lys Gln Asp His Ala Ala Asn Pro
 595 600 605

Cys Gly Gln Ile Gly Glu Thr Val Asp Leu Asp Glu Ala Val Gln Arg
 610 615 620

Ala Leu Glu Phe Ala Lys Lys Glu Gly Asn Thr Leu Val Ile Val Thr
 625 630 635 640

Ala Asp His Ala His Ala Ser Gln Ile Val Ala Pro Asp Thr Lys Ala
 645 650 655

Pro Gly Leu Thr Gln Ala Leu Asn Thr Lys Asp Gly Ala Val Met Val
 660 665 670

Met Ser Tyr Gly Asn Ser Glu Glu Asp Ser Gln Glu His Thr Gly Ser
 675 680 685

Gln Leu Arg Ile Ala Ala Tyr Gly Pro His Ala Ala Asn Val Val Gly
 690 695 700

Leu Thr Asp Gln Thr Asp Leu Phe Tyr Thr Met Lys Ala Ala Leu Gly
 705 710 715 720

Asp Ile Ala His His His His His His
 725

<210> SEQ ID NO 95
 <211> LENGTH: 969
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
 scFv-leucine zipper fusion protein (miniantibody vector construct
 p8860-Zip#1.2)

<400> SEQUENCE: 95
 atgaaatacc tattgacctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
 atggcggagg ttcagcttca gcagctctgga cctgagctgg tgaagcccgg ggcctcagtg 120

-continued

```

aagatttcct gcaaagcttc tggctacgca ttcagtagct cttggatgaa ctgggtgaag 180
cagaggcctg gacagggctt tgagtggatt ggacggattt atcctggaaa tggagatact 240
aactacaatg ggaagttcaa gggcaaggcc aactgactg cagacaaatc ctccagcaca 300
gcctacatgc agctcagcag cctgacctct gtggactctg cggctatatt ctgtgcagat 360
ggtaacgtat attactatgc tatggactac tggggtaag gaacctcagt caccgtctcc 420
tcaggtggag gcggttcagg tgggcgcgcc tctggcggtg gcggatcgca aattgttctc 480
accagctctc ctgcttcctt agctgtatct ctggggcaga gggccaccat ctcatgcagg 540
gccagcaaaa gtgtcagtac atctggctat agttatatgc actggtacca acagaaacca 600
ggacagccac ccaaactcct catctatctt gcacccaacc tagaatctgg ggtccctgcc 660
aggttcagtg gcagtgggtc tgggacagac ttcaccctca acatccatcc tgtggaggag 720
gaggatgctg caacctatta ctgtcagcac agtagggagc ttcctcggac gttcgggtga 780
ggaccaaacg tggaaatcaa acgggcggcc gcaccgaagc cttccactcc gcccggtct 840
tcccgatga aacagctgga agacaaagta gaggagctcc ttagcaagaa ctaccatcta 900
gaaaacgagg tagctcgtct gaaaagctt gttggtgaac gtggtggtca ccatcaccat 960
caccattaa 969
    
```

```

<210> SEQ ID NO 96
<211> LENGTH: 322
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
        scFv-leucine zipper fusion protein (miniantibody vector construct
        p8860-Zip#1.2)
    
```

<400> SEQUENCE: 96

```

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1           5           10          15
Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Gln Ser Gly Pro Glu
 20          25          30
Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
 35          40          45
Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
 50          55          60
Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
 65          70          75          80
Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
 85          90          95
Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
100         105         110
Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Tyr Ala Met
115         120         125
Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
130         135         140
Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Gln Ile Val Leu
145         150         155         160
Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
165         170         175
Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
180         185         190
Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
    
```

-continued

195	200	205
Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly 210 215 220		
Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu 225 230 235 240		
Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg 245 250 255		
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Pro 260 265 270		
Lys Pro Ser Thr Pro Pro Gly Ser Ser Arg Met Lys Gln Leu Glu Asp 275 280 285		
Lys Val Glu Glu Leu Leu Ser Lys Asn Tyr His Leu Glu Asn Glu Val 290 295 300		
Ala Arg Leu Lys Lys Leu Val Gly Glu Arg Gly Gly His His His His 305 310 315 320		
His His		

<210> SEQ ID NO 97
 <211> LENGTH: 270
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:part of plasmid pMycHis6 differing from vector pCOCK

<400> SEQUENCE: 97
 caggaaacag ctatgacat gattacgcc agcttccatg aaaattctat ttcaaggaga 60
 cagtcataat gaaataccta ttgcctacgg cagccgctgg attgttatta ctgcggccc 120
 agccggccat ggcccagggt cagctgcagg cgcgcctgca ggtcgacctc gagatcaaac 180
 gggcggccgc agaacaaaaa ctcctctcag aagaggatct gaatggggcg gcacatcacc 240
 atcaccatca ctaataagaa ttcaactggcc 270

<210> SEQ ID NO 98
 <211> LENGTH: 61
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:part of plasmid pMycHis6 differing from vector pCOCK

<400> SEQUENCE: 98
 Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Ala Arg Leu Gln Val
 20 25 30
 Asp Leu Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys Leu Ile Ser Glu
 35 40 45
 Glu Asp Leu Asn Gly Ala Ala His His His His His His
 50 55 60

<210> SEQ ID NO 99
 <211> LENGTH: 888
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:198AB2 scFv linked to c-myc-tag and His6 tag (ORF of expression vector pMycHis6-198AB2#102)
 <220> FEATURE:

-continued

```

<221> NAME/KEY: modified_base
<222> LOCATION: (228)
<223> OTHER INFORMATION: n = g, a, c or t

<400> SEQUENCE: 99
atgaaatacc tattgcctac ggcagccgct ggattgttat tactcgcggc ccagccggcc 60
atggccgagg tgaagctggt ggagtctggg ggaggcttag tgaagcctgg agggtcctctg 120
aaactctcct gtgcagcctc tggattcact ttcagtagct ataccatgtc ttgggttcgc 180
cagactccgg agaagaggct ggagtgggtc gcaaccatta gtagtgngg tagttccacc 240
tactatccag acagtgtgaa gggccgattc accatctcca gagacaatgc caagaacacc 300
ctgtacctgc aaatgagcag tctgaggctt gaggacacag ccatgtatta ctgtacaaga 360
gagggggggtg gtttcaccgt caactggtac ttcgatgtct ggggcgcagg aacctcagtc 420
accgtctcct caggtggagg cggttcaggt gggcgcgcct ctggcgggtg cggatcggac 480
attgtgctga cacagtctcc agcttctttg gctgtgtctc tagggcagag ggccaccata 540
tcctgcagag ccagtgaaa tgttgatagt tatggctata atttatgca ctggtatcag 600
cagataccag gacagccacc caaactcctc atctatcgtg catccaacct agagtctggg 660
atccctgccca ggttcagtgg cagtgggtct aggacagact tcaccctcac cattaatcct 720
gtggaggctg atgatgttc aacctattac tgtcagcaaa gtaatgagga tccgctcagc 780
ttcggtagctg ggaccagact ggaaataaaa cgggcggccg cagaacaaaa actcatctca 840
gaagaggatc tgaatggggc ggcacatcac catcaccatc actaataa 888

```

```

<210> SEQ ID NO 100
<211> LENGTH: 294
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence:198AB2 scFv
linked to c-myc-tag and His6 tag (ORF of expression vector
pMycHis6-198AB2#102)

```

```

<400> SEQUENCE: 100
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
 1             5             10             15
Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu Ser Gly Gly Gly
 20             25             30
Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly
 35             40             45
Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu
 50             55             60
Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly Gly Ser Ser Thr
 65             70             75             80
Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
 85             90             95
Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
 100            105            110
Thr Ala Met Tyr Tyr Cys Thr Arg Glu Gly Gly Gly Phe Thr Val Asn
 115            120            125
Trp Tyr Phe Asp Val Trp Gly Ala Gly Thr Ser Val Thr Val Ser Ser
 130            135            140
Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Asp
 145            150            155            160
Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln

```

-continued

165	170	175
Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly 180 185 190		
Tyr Asn Phe Met His Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro Lys 195 200 205		
Leu Leu Ile Tyr Arg Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala Arg 210 215 220		
Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr Leu Thr Ile Asn Pro 225 230 235 240		
Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu 245 250 255		
Asp Pro Leu Thr Phe Gly Thr Gly Thr Arg Leu Glu Ile Lys Arg Ala 260 265 270		
Ala Ala Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala 275 280 285		
His His His His His His 290		

<210> SEQ ID NO 101
 <211> LENGTH: 876
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
 scFv linked to c-myc-tag and His6-tag designated 8860-M/H#4c
 (plasmid vector p8860-M/H#4c)

<400> SEQUENCE: 101

```

atgaaatacc tattgcttac ggcagccgct ggattgttat tactcgcggc ccagccggcc    60
atggccgagg ttcagcttca gcagctctga cctgagctgg tgaagcccgg ggccctcagt   120
aagatttctt gcaaagcttc tggtacgca ttcagtagct cttggatgaa ctgggtgaag   180
cagaggcctg gacaggttct tgagtggatt ggacggattt atcctggaaa tggagatact   240
aactacaatg ggaagttcaa gggcaaggcc aactgactg cagacaaatc ctccagcaca   300
gcctacatgc agctcagcag cctgaactct gtggactctg cggtctatct ctgtgcagat   360
ggtaacgtat attactatgc tatggactac tggggtaag gaacctcagt caccgtctcc   420
tcaggtggag gcggttcagg tgggcgcgcc tctggcggtg gcggatcgca aattgttctc   480
accagtctc ctgcttcctt agctgtatct ctggggcaga gggccaccat ctcatgcagg   540
gccagcaaaa gtgtcagtac atctggctat agttatatgc actggtacca acagaacca   600
ggacagccac ccaaactcct catctatctt gcattccaacc tagaatctgg ggtccctgcc   660
aggttcagtg gcagtgggtc tgggacagac ttcacctca acatccatcc tgtggaggag   720
gaggatgctg caacctatta ctgtcagcac agtagggagc ttcctcggac gttcggtgga   780
ggcaccaagc tggaaatcaa acgggcggcc gcagaacaaa aactcatctc agaagaggat   840
ctgaatgggg cggcacatca ccatcaccat cactaa                               876

```

<210> SEQ ID NO 102
 <211> LENGTH: 291
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:mAB #8860
 scFv linked to c-myc-tag and His6-tag designated 8860-M/H#4c
 (plasmid vector p8860-M/H#4c)

<400> SEQUENCE: 102

-continued

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Ala
 1 5 10 15
 Ala Gln Pro Ala Met Ala Glu Val Gln Leu Gln Ser Gly Pro Glu
 20 25 30
 Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
 35 40 45
 Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly
 50 55 60
 Gln Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asn Gly Asp Thr
 65 70 75 80
 Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys
 85 90 95
 Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Val Asp
 100 105 110
 Ser Ala Val Tyr Phe Cys Ala Asp Gly Asn Val Tyr Tyr Tyr Ala Met
 115 120 125
 Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser Gly Gly Gly
 130 135 140
 Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser Gln Ile Val Leu
 145 150 155 160
 Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala Thr
 165 170 175
 Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
 180 185 190
 Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 195 200 205
 Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly
 210 215 220
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu
 225 230 235 240
 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg Glu Leu Pro Arg
 245 250 255
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Ala Ala Glu
 260 265 270
 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala His His His
 275 280 285
 His His His
 290

<210> SEQ ID NO 103
 <211> LENGTH: 74
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of Artificial Sequence:annealed
 oligonucleotide

<400> SEQUENCE: 103

ggcgcgagaa caaaaactca tctcagaaga ggatctgaat gggcgggcac atcaccatca 60
 ccatcactaa taag 74

<210> SEQ ID NO 104
 <211> LENGTH: 69
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:

-continued

<223> OTHER INFORMATION: Description of Artificial Sequence:annealed oligonucleotide

<400> SEQUENCE: 104

ttattagtga tggatgatgt gatgtgccgc cccattcaga tcctcttctg agatgagttt 60

ttgttctgc 69

<210> SEQ ID NO 105

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:CDR3 peptide

<220> FEATURE:

<221> NAME/KEY: MOD_RES

<222> LOCATION: (1)..(16)

<223> OTHER INFORMATION: Xaa = any amino acid

<400> SEQUENCE: 105

Cys Xaa Xaa Tyr Gly Asn Ser Pro Lys Gly Phe Ala Tyr Xaa Xaa Cys

1 5 10 15

<210> SEQ ID NO 106

<211> LENGTH: 16

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:CDR3 peptide

<400> SEQUENCE: 106

Phe Arg Asn Arg Gly Met Thr Ala Leu Leu Lys Val Ser Ser Cys Asp

1 5 10 15

<210> SEQ ID NO 107

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:portion of plasmid pMycHis6 with pelB-leader, polylinker and c-myc tag

<400> SEQUENCE: 107

Leu Ala Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Ala Arg Leu

1 5 10 15

Gln Val Asp Leu Glu Ile Lys Arg Ala Ala Ala Glu Gln Lys

20 25 30

<210> SEQ ID NO 108

<211> LENGTH: 90

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:portion of plasmid pMycHis6 with pelB-leader, polylinker and c-myc tag

<400> SEQUENCE: 108

ctcgcggccc agccggccat ggcccagggtg cagctgcagg cgcgcctgca ggtcgacctc 60

gagatcaaac gggcggccgc agacaacaaa 90

<210> SEQ ID NO 109

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:c-myc-tag

-continued

<400> SEQUENCE: 109

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly
 1 5 10

<210> SEQ ID NO 110

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:His6-tag

<400> SEQUENCE: 110

His His His His His His
 1 5

<210> SEQ ID NO 111

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:flexible linker

<400> SEQUENCE: 111

Gly Gly Gly Gly Ser Gly Gly Arg Ala Ser Gly Gly Gly Gly Ser
 1 5 10 15

<210> SEQ ID NO 112

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence:Al peptide core sequence

<400> SEQUENCE: 112

Glu Gly Gly Gly Tyr Tyr Val Asn Trp Tyr Phe Asp
 1 5 10

What is claimed is:

1. An isolated antibody or antibody fragment thereof that binds Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa.

2. The antibody or antibody fragment according to claim 1 that increases the procoagulant activity of Factor IXa in the presence of Factor VIII inhibitors.

3. The antibody or antibody fragment according to claim 1 wherein the antibody is an IgG, IgM, IgA or IgE antibody.

4. The antibody or antibody fragment according to claim 1, wherein said antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a bispecific antibody, a diabody, and di-, oligo- or multimers thereof.

5. A CDR3 peptide of the antibody or antibody fragment according to claim 1 consisting of an amino acid sequence selected from the group consisting of:

Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr (SEQ ID NO:5); and

Asp-Gly-Gly-His-Gly-Tyr-Gly-Ser-Ser-Phe-Asp-Tyr (SEQ ID NO:6).

6. The antibody or antibody fragment according to claim 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-119 and amino acids 135-242 as listed in SEQ ID NO:82.

7. The antibody or antibody fragment according to claim 6 that additionally comprises an artificial linker sequence.

8. The antibody or antibody fragment according to claim 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-121 and amino acids 137-249 as listed in SEQ ID NO:84.

9. The antibody or antibody fragment according to claim 8 that additionally comprises an artificial linker sequence.

10. The antibody or antibody fragment according to claim 1, wherein the variable region of said antibody or antibody fragment comprises amino acids 1-122 and amino acids 138-249 as listed in SEQ ID NO:86.

11. The antibody or antibody fragment according to claim 10 that additionally comprises an artificial linker sequence.

12. A hybridoma cell line secreting an antibody that binds Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa.

13. The hybridoma cell line according to claim 12 that is selected from the group consisting of cell lines having ECACC deposit numbers 99090924, 99090925, 99090926, 99121614, 99121615, 99121616, 99121617, 99121618, 99121619 and 99121620.

14. An antibody that is secreted by a hybridoma cell line according to claim 12.

15. A preparation comprising an antibody or antibody fragment according to claim 1 and a pharmaceutically acceptable carrier.

103

16. The preparation according to claim **15**, additionally comprising Factor IX α and/or Factor IX β .

17. A method of obtaining an antibody that interacts with Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa, comprising the steps of:

immunizing an immunocompetent mouse with an antigen selected from the group consisting of FIX, FIX α , FIX β or fragments thereof,

isolating spleen cells of the immunized mouse,

producing hybridoma cells,

screening the hybridoma cell supernatants for an increase in the procoagulant activity of Factor IXa, isolating and purifying the antibody from a supernatant from the

104

hybridoma cells which exhibit an increase in the procoagulant activity of Factor IXa.

18. The antibody or antibody fragment according to claim **4**, wherein the antibody fragment is a single chain antibody.

19. The antibody or antibody fragment according to claim **4**, wherein the antibody is a humanized antibody.

20. The antibody or antibody fragment according to claim **2** wherein the antibody is selected from the group consisting of an IgG, IgM, IgA or IgE antibody.

21. The antibody or antibody fragment of claim **1**, wherein the antibody fragment comprises a CDR3 peptide.

22. The antibody or antibody fragment of claim **1**, wherein the antibody fragment is a CDR3 peptide.

* * * * *